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Introduction: Coronary arteries are at differing vertical heights in a supine patient relative to the 
aortic root. Pressure within an artery varies based on distance from the aorta due to hydrostatic 
effect. This could impact pressure-based indices of stenosis severity, as the vertical distance 
between distal and proximal pressure sensors creates a baseline pressure difference. This is 
neglected in clinical practice, as distal and proximal sensors are considered at the same vertical 
level. 
Methods: Pd/Pa, instantaneous wave free ratio (iFR), fractional flow reserve FFR and doppler 
flow velocity were recorded in 23 coronary stenoses in the standard supine patient position, and in 
the prone position. Measurements between positions were compared using a Student’s t test for 
matched pairs.  
Results: There were significant differences in mean Pd/Pa (0.05), iFR (0.06) and FFR (0.06) when 
comparing prone and supine positioning (p<0.05). When inferior to the aorta, mean Pd/Pa, iFR 
and FFR were 0.96±0.05, 0.93±0.11 and 0.84±0.10 respectively. When superior, mean Pd/Pa, iFR 
and FFR were 0.91±0.07, 0.87±0.11 and 0.78±0 respectively. Resting and hyperaemic doppler 
flow measurements did not change significantly when comparing prone and supine patient 
position. 26% of all FFR and 36% of all iFR values were re-classified across a treatment threshold 
when hydrostatic effect was corrected. 
Conclusion. Patient position alters physiological stenosis severity as quantified by invasive 
coronary pressure measurements. Coronary stenoses positioned inferiorly to the aorta, produce 
significantly higher Pd/Pa, iFR and FFR values when compared to a superior position. Conversely, 
patient position did not influence coronary doppler flow velocity. This is the first study to quantify 
the effect of hydrostatic pressure on invasive measures of coronary stenosis. The data supports 
hydrostatic effect as a potential confounding factor leading to inaccurate lesion assessment. 
Keywords: Hydrostatic pressure, prone, supine, FFR, iFR, doppler 
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Chapter I – Introduction 
 
Having only two years to contribute new scientific knowledge in a subject area studied for decades, 
by incredibly gifted scientists and clinicians, appears initially a rather daunting task. As often 
occurs similarly in the entrepreneurial world, when faced with a potentially new or novel idea, 
someone has almost certainly thought of it first. Which leaves a scientific researcher with two 
choices. Firstly, delve into exceedingly niche areas which are yet to be explored, risking the 
possibility that they hold little potential for new discovery. Or go back to basic principles and aim 
to find something relevant, simple and unexplored. The latter options seem rather more appealing, 
however, the possibility of finding such a research topic within the basic concepts of a scientific 
method studied for decades, seems rather small. By chance, and rather by accident, I feel the 
second scenario applies to my research work and I will briefly try to explain why in this preface. 
Coronary artery disease is the most common cause of death in the UK after cancer (Avoidable 
mortality in England and Wales - Office for National Statistics, 2018). Working in a heart attack 
centre, and observing the positive outcomes for some patients, and the negative for others, one 
finds themselves asking; why did Mrs X do better than Mr Y? The initial idea for my research 
came from Dr John Davies, an interventional cardiologist at the Essex Cardiothoracic Centre, who 
has spent his consultant and training years treating emergency heart attacks. It is clear that the most 
important step in managing acute coronary syndrome (ACS), is reducing the size of the heart attack 
(or infarct size) (Stone et al., 2016). His initial idea was simple; could we increase blood flow to 
areas of heart muscle, simply by changing the position of the patient (e.g. lying them on their front 
during a heart attack)? This in turn would reduce the infarct size, and potentially improve the 
prognosis of the patient. The initial idea was met with scepticism by colleagues, and also initially 
by myself for a simple reason. There was a potential physiological explanation for the theory, but 
there was no relevant scientific literature in the area, no previous studies, and not even a mention 
of such a concept in academic literature. It may have been possible that a relatively simple idea, 
had just not been explored. As I started my research journey, this was the question I initially set 
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out to answer; does physiology and blood flow within a coronary artery change when comparing 
supine (standard) measurements, with prone (experimental) measurements.  
It became clear early into my research that this was an evidence free zone. Another realisation 
from a medical and ethical standpoint was that to understand what when a patient changes position 
during a heart attack, we needed to understand the science in stable (and relatively normal) 
coronary arteries first. In stable patients, we expect physiological mechanisms to be preserved 
(autoregulation intact), whereas during an acute heart attack, these mechanisms may be disrupted 
(autoregulation not intact). We set out to understand what 'normal' was before attempting to do the 
same for 'abnormal'. Elective patients who were referred for pressure wire assessment of a coronary 
artery lesion became the obvious starting point for a study cohort. Standard measurements occur 
when the patient is supine, but repeating the measurements when prone, in the same artery, for the 
same lesion, would provide a direct comparison, with position change being the only variable. 
Comparing measurements in coronary arteries with a focus on the difference in patient position 
change, had never been done and hence became the true starting point for my thesis, and research. 
One case report of a prone diagnostic coronary angiogram existed at the time of study conception 
(Kwon, Cha and Rhee, 2012), but no reported cases of prone invasive coronary physiological 
measurements did, and certainly no literature was available comparing prone measurements to 
supine. 
The next milestone was to understand which measurements I needed to obtain within the coronary 
artery. Blood flow was the key endpoint which we hypothesised may reduce infarct size during a 
heart attack. Several methods existed to measure this. The most widely used and validated, are 
pressure-based systems (FFR - fractional flow reserve), which use coronary artery pressure across 
a stenosis, as a surrogate measurement for flow, and contribute to decisions made regarding 
treatment. The principle revolves around a ratio of distal vessel pressure versus proximal pressure 
(aortic / origin of artery). Another less commonly used method (but arguably more accurate), due 
to the difficulty in acquiring measurements and time constraints, are velocity or flow-based 
measurements.  
The use of pressure-based measurements is widespread and forms a cornerstone of interventional 
cardiology. However, from basic physical principles, it is known that blood pressure at varying 
vertical heights from a fixed point (usually the heart, or aorta) will change. Coronary arteries in 
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their natural state lie in different vertical planes, yet we assume they are vertically level and use a 
standardised cut-off point across all arteries to indicate a significant stenosis, rather than vessel 
specific ones. Some coronary arteries take a superior path, and others an inferior one. Their path 
inherently alters the pressure within them compared to the aorta. This realisation was a major 
milestone, in that rather by chance, it appeared such a widely used and trusted coronary 
measurement system, based on pressure, would be altered by changing the patient's position even 
when all other variables remain constant. Changing position (supine to prone) may give a different 
measurement result for the same artery, due to a change in vertical height between a fixed proximal 
(aorta) and a changing distal pressure sensor (physiology wire) 
There may be potential clinical implications of this, as measurements in some arteries may be over 
or underestimated due to their position in a vertical plane and hydrostatic pressure effect. The 
change in pressure due to vertical height variations in a closed fluid loop is explained by Pascal's 
Law and is well documented in principles of fluid dynamics. The effect of hydrostatic pressure on 
physiological measurements is documented in medical textbooks, but disregarded clinically as a 
minor variable. 
Realising that the change in position alone may alter pressure-based measurements, independent 
of the stenosis itself, it was clear I also had to measure flow (doppler velocity, and not pressure 
based) which should not be affected by position. Coronary arteries regulate flow to the heart 
muscle over a wide blood pressure range. This phenomenon is known as autoregulation 
(Ramanathan and Skinner, 2005). Therefore, despite pressure alterations when changing position, 
coronary arteries react to keep flow to the muscle constant. My hypothesis is therefore in two parts. 
Firstly, I expect pressure derived indices to change between prone and supine measurements in the 
same artery, across the same stenosis, as they are reliant on pressure readings. The pressure change 
is due to the vertical shift in an artery, when a patient moves from supine to prone. Secondly, in 
stable and preserved coronary physiology, with functional autoregulation, I expect flow (velocity 
readings) not to be altered by position change and hydrostatic effect. The study aimed at answering 
these questions was called GRAVITY, and was designed, written and implemented by myself. The 
magnitude of effect between position change was not known at study conception, with limited 
clinical literature. Height measurements from CT coronary angiography, obtained before invasive 
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research, helped gauge the size of effect, and whether its clinical impact would be relevant, and 
measurable in an achievable sample size. 
If proven true, hydrostatic effect would affect the diagnostic tool that we use in aiding our 
treatment decisions, and not necessarily reflect a true change in physiology when changing 
position. Due to vertical variations between the coronary arteries, pressure-based indices could be 
confounded. This phenomenon exists in daily practice yet is widely ignored. This has the potential 
for misguiding treatment of coronary lesions in our patients. 
 
The treatment of coronary artery disease is separated into acute presentations (i.e acute coronary 
syndrome) and stable coronary artery disease. The treatment of stable coronary artery disease is a 
contentious issue, re-ignited by recent evidence (ORBITA and ISCHEMIA trials). 
The identification of stable coronary lesions which are ischaemic is a complex area. This has led 
to the development of invasive and non-invasive coronary physiology as a diagnostic aid in 
stenosis assessment. Both are covered in brief. 
The basic concepts of pressure based coronary physiology and angiography are introduced, 
highlighting the underlying physical principles. A wealth of data exists for the use of pressure-
based indices, and the most well-known landmark papers are described. Newer resting indices 
have gained clinical popularity over the past few years and form a part of the clinical methodology 
in the GRAVITY study. Pressure based indices have limitations and pitfalls, which are addressed. 
The most significant one in relation to this thesis is hydrostatic pressure. 
Hydrostatic pressure theory is described, comparing the coronary circulation to a closed fluid loop 
system. This is a theoretical model of fluid dynamics in physical science which mirrors the 
coronary circulation. There is a significant lack of published literature on the subject. 
The last section introduces CT coronary angiography in daily clinical practice and the specific 
relevance to this research. It will be preliminarily used to measure coronary height differences 
which produce hydrostatic effect in vivo. This was critical in vitro data, as the potential magnitude 
of effect in real patients was poorly understood. In turn, it was utilised to understand sample size 
5 
 
calculation, and whether hydrostatic theory could be effectively measured and demonstrated in 
vivo. 
 
Chapter II - Methods, Results and Interpretation from CT Coronary Angiography 
 
Data from this chapter has since been published in a peer reviewed journal (Al-Janabi et al., 2019) 
- see appendix G for the full paper. 100 selected CT coronary angiograms were analysed to assess 
the height differences between the ostium of the relative vessel, and the most distal point (where 
the physiology wire would be placed in a patient). 
In summary, the results showed significant variation from the ostial vessel to the distal vessel in 
all main coronary arteries (LAD, Cx, RCA-PLV and RCA -PDA). The vertical distance data was 
then used to calculate an estimated hydrostatic pressure effect using a pre-defined equation. The 
effect of this was translated into a computer model of 100 pressure wire recordings ranging from 
0.75 to 0.85. Up to 47% of these recordings were found to cross a physiological threshold of 
significance if corrected for hydrostatic pressure. 
The data from these CT scans provided an estimation of the magnitude of effect, meaning sample 
size could be estimated from a power calculation. Interestingly, during the study period, similar 
data was published by a German group in substantially different cohort of patients (Härle et al., 
2017a). Their data is compared with ours.  
 
A pre-study case example illustrates the potential hydrostatic effect in a real-life scenario, adding 
further indication that a difference would exist in vivo. The stenosis shown is at a branch point, 
where one branch travels superiorly and another inferiorly. Each branch produces different 
pressure-based results, which was a re-assuring finding so early on in the study's conception. 
 
 




The physical process of conducting this study was a significant obstacle in itself. Prone 
angiography is certainly not routine, and prone angiography with invasive coronary physiology 
had never been done before. This was new territory for everybody involved in the catheter 
laboratory. 
This chapter outlines some of the hurdles the team had to overcome to acquire the necessary data 
efficiently, safely and correctly. Several trial runs were conducted in a simulated patient scenario 
between team members. The act of turning the patient itself is described, along with the other 
challenges of prone angiography (the reversal of imaging views, altered positional anatomy of the 
coronary arteries and comfort of the patient). There was a substantial amount of forward planning 
required in the case of procedural complications or events (such as cardiac arrest) 
The study protocol is shown, focusing on inclusion and exclusion criteria, sample size calculation, 
and the physical steps taken to acquire all data. Sample traces and a description of the required 
equipment is also shown. 
When positioned supine (standard position), the circumflex and RCA-PLV are inferior, whereas 
the LAD and RCA-PDA are superior. This is reversed when prone. Due to hydrostatic pressure, 
inferior artery position should produce higher pressure-based indices across the same stenosis 
when compared to superior position. It was the logical choice to therefore compare superior and 
inferior artery position. 
The mean delta change across all values for Pd/Pa was 0.05, for iFR 0.06 and FFR 0.06. These are 
all statistically significant (p <0.05).  
In a subset of patients, FFR measurement were taken in a more 'clinical' position, i.e. less distal 
than outlined in the study protocol. The clinician placed the wire where they would normally 
during a routine case. There was a mean delta change of 0.06 in a subset of LAD stenoses which 
was statistically significant (p<0.05). The aim of this was to show that even when the wire was 
less distal and under lesser hydrostatic effect, the magnitude of effect was still significant. 
There was no change in doppler flow velocity at rest or during hyperaemia across all territories. 
The findings correlate with the initial hypothesis that the change in pressure-based indices do not 
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necessarily reflect a true change in coronary physiology, but rather the tool that is used in the 
assessment of a coronary stenosis. There is an inherent flaw in current pressure-based technology 
which makes it susceptible to hydrostatic pressure effect in the coronary circulation. This may over 
or underestimate stenosis severity. Doppler flow, which is a surrogate for coronary flow did not 
change, meaning this is not a true physiological change between prone and supine positioning. 
Correlation graphs shown at the end of the chapter show a trend but no significant correlation 
between guide to wire distance and delta change in FFR, Pd/Pa and iFR. From combined data, it 
appears that predicted changes in hydrostatic pressure from CT data, correlate closely with actual 

















Chapter IV highlights differences in demographic and angiographic data. The rationale behind 
significant changes in pressure-based indices and non-significant doppler flow measurements are 
discussed. Potential explanations are offered for the lack of correlation between guide to wire 
distance and delta change in Pd/Pa, iFR and FFR.  
The clinical implications of the data are discussed. This includes the lack of a 'level playing field'. 
There will be a resting gradient before the introduction of any stenosis, due to hydrostatic pressure 
alone. This confounds measurements using pressure-based indices.  
If the already existent pressure gradient is corrected, up to 36% of pressure-based indices will re-
classify across a significance threshold. The changes may appear small (0.05-0.06), but clinically 
appear to be important. Hydrostatic pressure effect may also be important in other clinical 
situations, such as in diffuse coronary disease, and in the measurement of IMR. 
Suggestions are made in how clinical practice could be changed to correct for hydrostatic effect. 
Adding or subtracting from measured FFR results could produce a more accurate result. The 
addition of a single correction factor per vessel is unlikely to be adequate on its own, and more 
data is required to 'map' hydrostatic effect at multiple points in each vessel. In vivo, this would 
require pressure wire measurements in normal coronary arteries, which is ethically unfavourable. 
Retrospective CT coronary angiograms may be useful in providing raw height data at multiple 
points in a single artery, which could then be converted to pressure change at proximal, mid and 
distal vessel. Limitations with the current study are discussed. Topics surrounding anatomical FFR 
(CT and Angio FFR) are discussed. These methods are not confounded by hydrostatic effect but 
have their own flaws. 
Study limitations and counter arguments are highlighted. Very recent evidence has emerged during 
the study period, with studies similar to the current research adding to the data pool. Data between 
studies are compared. 
Finally, future plans are suggested, leading back to the initial research question proposed three 
years ago. STEMI patients and CTO patients are possible next steps. Vessel mapping with further 
CT scanning could allow provide further information on hydrostatic correction per section of 
artery. The advent of newer pressure wires which are immune to hydrostatic pressure is an exciting 
























Chapter I - Introduction 
 
Percutaneous coronary intervention (PCI) is the mainstay of treatment for acute coronary 
syndromes (ACS), specifically ST elevation myocardial infarction (STEMI). The treatment of 
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chronic coronary syndromes (CCS - ESC Guidelines on Chronic Coronary Syndromes (Previously 
titled Stable Coronary Artery Disease), 2020) is more complex and requires expert clinical 
decision making. Diagnostic aids such as fractional flow reserve (FFR) have been used for over 
two decades as diagnostic tools, to guide this decision-making process. The impact of hydrostatic 
effect on these measuring tools is unknown. 
A general overview of coronary artery disease pathology, prevention, medical treatment and future 
implications is described in Appendix A. Below is a brief introduction to ACS, CCS, diagnosis 
and invasive treatment of coronary artery disease. Ischaemia testing, invasive and non-invasive, 
are critical in lesion selection for treatment. Invasive testing (Pd/Pa, iFR and FFR) and the potential 
confounding factor of hydrostatic pressure are the focus of this research. 
 
1.1 - Acute Coronary Syndrome 
 
Three presentations are classed as acute coronary syndromes (ACS). They are; ST elevation 
myocardial infarction (STEMI), Non-ST elevation myocardial infarction (NSTEMI) and unstable 
angina (UA). 
 
1.1.1 - ST Elevation Myocardial Infarction 
 
In ST elevation myocardial infarction, occlusion of a coronary artery causes ST segment elevation 




Figure 1 - STEMI ECG - an ECG of a patient attending the Essex Cardiothoracic Centre with an 
anterior STEMI (ST elevation myocardial infarction). Notice the raised ST segments in leads V1-
V5 (consent obtained for image use). 
 
The treatment for this presentation is immediate restoration of blood flow in the infarct related 
artery (IRA). The initial treatment for this was administration of a thrombolytic drug, but this has 
since been surpassed by primary percutaneous coronary intervention (PPCI) (Schömig et al., 2000; 
Le May et al., 2001; Busk et al., 2008). The main aim of treatment is reduction in infarct size, 
which has profound impacts on mortality and morbidity (Sobel et al., 1972; Stone et al., 2016). 
The most serious presentation is with cardiac arrest, caused by ventricular arrhythmia as a 
consequence of myocardial ischaemia. These patients are at higher risk of mortality (Siudak et al., 
2012; Demirel et al., 2015; Kvakkestad et al., 2018), should they reach hospital, of which a high 
proportion (approximately 75%) unfortunately do not (Perkins and Cooke, 2012). Survival to 
discharge is 5-8% from out of hospital cardiac arrests (Nichol et al., 2008; Perkins and Cooke, 
2012) 
The time to reperfusion holds prognostic value, with data showing reperfusion within two hours is 
important for left ventricular recovery and survival (Brodie et al., 1998). Before primary 
angioplasty, thrombolysis was shown to provide a clear survival advantage for patient suffering 
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with STEMI (Indications for fibrinolytic therapy in suspected acute myocardial infarction: 
collaborative overview of early mortality and major morbidity results from all randomised trials 
of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group, 1994). 
There was an early hazard associated with thrombolysis use within the first 24 hours, which was 
vastly outweighed by the survival benefit thereafter. 
Currently, the preferred method of reperfusion is Primary PCI (PPCI) and this has replaced 
thrombolysis in areas where tertiary cardiac centres are accessible within 30 minutes to an hour. 
Early trials showed improved outcomes when using PPCI compared to thrombolysis, leading to a 
reduction in mortality and re-infarction, as well as intracranial haemorrhage (Grines et al., 1993). 
Similar trials at the time demonstrated improved vessel patency at follow-up and higher left 
ventricular (LV) ejection fractions (EF) (Zijlstra et al., 1993). 
Two randomised controlled trials comparing PCI and thrombolysis followed in 1997 with Gusto 
IIb (Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes 
(GUSTO IIb) Angioplasty Substudy Investigators, 1997) and 2003 with DANAMI-2 (Andersen et 
al., 2003). Gusto IIb demonstrated a significant difference favouring PCI in the composite endpoint 
of death, non-fatal myocardial infarction and non-fatal stroke in 1138 patients presenting within 
12 hours for treatment. DANAMI-2 further supported the use of PCI in STEMI with a reduction 
in the composite endpoint of death, stroke and re-infarction. The composite endpoint was largely 
driven by much lower re-infarction rates in the PCI group, with no significant difference in 
mortality or stroke. The benefit was still seen after 8 years of with regards to the primary endpoint, 
however subsequent analysis showed mortality was also reduced in the PCI arm (Andersen et al., 
2003).  
A review of 23 trials comparing thrombolysis to angioplasty, totalling 7739 patients showed again 
superiority favouring angioplasty with lower mortality, re-infarction and stroke, independent of 
the thrombolytic agent used, which was maintained over long term follow-up (Keeley, Boura and 
Grines, 2003). 
 




NSTEMI represent a group with vulnerable coronary plaques which have caused partial or total 
vessel occlusion. Blood has usually spontaneously been restored by the time of presentation 
(Kumar and Cannon, 2009). Re-occlusion could occur at any time, meaning prompt treatment 
within 48 hours is usually recommended. Biomarkers are raised, indicating myocyte damage or 
stress. An important differentiation which has clinical implications is the formation of clot in both 
STEMI and NSTEMI. In NSTEMI, clot is usually white, and formed predominantly of platelet 
rich aggregates. This is in contrast to STEMI, where clot is usually red, and formed predominantly 
of red blood cells (DeWood et al., 1980; Quadros et al., 2012).This alters clinical management, as 
medical therapy in NSTEMI is centred around platelet inhibition, which allows endogenous 
fibrinolysis to break down the thrombus (Platelet Receptor Inhibition in Ischemic Syndrome 
Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study 
Investigators, 1998).  
Lastly, unstable angina is only differentiated against NSTEMI by the lack of raised biomarkers. 
The most commonly used biomarker is troponin, although other biomarkers can be used with 
different properties, including time to peak concentration. Figure 2 demonstrates this. 
Since the arrival or coronary stents, randomised control trials have compared optimal medical 
therapy, with coronary stenting (usually within 48 hours) and the effect on patient prognosis. A 
large trial of over two thousand patients published in 2001 demonstrated benefit in using early 
invasive coronary stenting for NSTEMI and UA over optimal medical therapy, with a reduction in 
mortality, myocardial infarction and re-hospitalisation for acute coronary syndrome (Cannon et 
al., 2001). The results were mirrored one year later, in a similarly sized trial, but the composite 
endpoint was significant mainly due to the reduction in on-going angina. Death and myocardial 
infarction rates were similar in both groups at 1 year follow-up (Fox et al., 2002). The same group 
of patients underwent follow-up at 5 years, and revealed significant benefits for the stent treatment 
group in relation to death and myocardial infarction (Fox et al., 2005). The benefit appears to be 
in the medium and long term, and maybe counter-acted in the first year by the increased risk of an 
invasive procedure. 
The FRISC-II study followed patients for 15 years, who either underwent and invasive or non-
invasive strategy for NSTEMI. At 15 years, patients who had invasive treatment postponed the 
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occurrence of death or myocardial infarction by 17 months, and re-admission by 17 months 
(Wallentin et al., 2016).  
A meta-analysis of invasive versus non-invasive treatment in the stenting era was conducted by 
Hoenig et al. in 2006 (Hoenig et al., 2006) consisting of nearly eight thousand pooled participants. 
The results showed that during hospital admission, there was a trend towards hazard with an 
invasive strategy, but it was not statistically significant. There was a peri-procedural two-fold 
increase in risk of myocardial infarction and 1.7-fold increase in bleeding. When comparing long 
term outcomes (> 1 year) there was a significant reduction in death, non-fatal myocardial infarction 
and rehospitalisation in the invasive group (Hoenig et al., 2006). 
 
 
Figure 2 - Cardiac Biomarkers - Biomarker peaks and troughs shown against time. CK-MB 
(Creatine Kinase Muscle/Brain) peaks and falls earlier than troponin. (J. Heuser JHeuser 





1.2 - Chronic Coronary Syndrome 
 
Stable angina by definition is the presence of cardiac chest pain on exertion or with emotional 
stress, which is relieved by rest or administration of nitroglycerin (Ohman, 2016). 
The assessment and treatment of stable coronary artery disease has been a fierce topic of debate 
for decades. The role of coronary stenting as opposed to medical therapy in stable coronary artery 
disease remains controversial. This controversy has driven technological expansion, leading to 
huge interest in the assessment of stenosis severity, which is the basis of this study and thesis.  
Coronary stenting has been compared with optimal medical therapy (OMT) in multiple 
randomised controlled trials. Results have been mixed, but no single trial has shown a reduction 
in mortality or rate of myocardial infarction, from the use of coronary stents (Al-Lamee, Davies 
and Malik, 2016). 
The COURAGE trial, published in the New England Journal of Medicine in 2007, was one of the 
first landmark trials comparing OMT to PCI over a five-year follow-up period. There was no 
reduction in death or non-fatal myocardial infarction when comparing PCI to OMT. There was 
however a significant difference in the need for revascularisation, favouring the PCI group. There 
was also a numerical difference in the amount of patients who were angina free, again favouring 
PCI, although this did not reach statistical significance (Boden et al., 2007). 
MASS II was a triple armed trial comparing OMT, coronary artery bypass grafting and PCI. PCI 
was found to be superior to medical therapy over a 10-year follow-up period, with regards to 
incidence of angina. Myocardial infarction rate favoured the use of PCI but was not statistically 
significant (Hueb et al., 2010). 
BARI-2D was a trial in diabetic patients, randomised to OMT or PCI. PCI showed demonstrable 
benefit with regards to reduction in angina, and rate of revascularisation. There was no difference 
in death or myocardial infarction (BARI 2D Study Group et al., 2009). 
From the three trials above, two showed a significant reduction in rates of angina, and two the need 
for repeat revascularisation. None showed a mortality difference, with one showing a reduction in 
myocardial infarction rate in diabetic patients. It is worth considering the limitations of these 
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randomised control trials, including the use of older PCI techniques, high rates of crossover from 
OMT to PCI groups, and the possibility of bias, due to the un-blinded nature of the trials. It has 
also been proposed that study power was not enough to meet the endpoint of mortality and softer 
endpoints such as symptom severity are subjective. More recent studies have attempted to use 
exercise time as a more reliable end-point for symptomatic relief after PCI, but showed no 
statistical improvement over OMT (Al-Lamee et al., 2018). 
Meta-analyses have supported the use of PCI in the relief of anginal symptoms, with a significant 
reduction in angina with the use of PCI. Again, mortality and myocardial infarction rates did not 
differ between the two groups and the limitations outlined above were highlighted (Pursnani et al., 
2012).It is also worth noting that other meta-analyses have shown no difference between PCI and 
OMT across all end-points, including mortality and rates of angina, myocardial infarction and need 
for revascularisation (Stergiopoulos et al., 2014).  
Symptomatic relief is the main clinical indication for PCI in the context of stable angina. UK and 
European guidelines suggest PCI for anginal symptoms only after a trial of medical therapy (Stable 
angina: management | Guidance and guidelines | NICE, 2018; Montalescot et al., 2013). Medical 
therapy is often under prescribed however, with some studies showing up to 50% of patients are 
only taking one anti-anginal medication, with a third taking none (Borden et al., 2013). There is 
also the issue of medication compliance, which is difficult to accurately measure. ORBITA, a 
recent trial conducted in the UK with strict enforcement of medical therapy demonstrated no 
increase in exercise time with PCI compared to medical therapy (Al-Lamee et al., 2018). There 
was strict medical optimisation over a 6-week period, which is difficult to replicate in NHS 
patients. There was however a reduction in ischaemia assessed by stress echocardiography after 
PCI. 
Very recently, the ISCHEMIA trial randomised patients to medical therapy or invasive treatment 
(stenting or surgery), based on demonstrable non-invasive ischaemia testing only (ISCHEMIA 
Trial Research Group et al., 2018). Provisional results were presented at the American Heart 
Association (AHA) conference, in November 2019. Interestingly, the invasive arm did not provide 
benefit with regards to reducing mortality, reducing the rates of myocardial infarction, improving 
anginal symptoms or quality of life. It has shown for the first time that medical therapy alone for 
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ischaemia may be a suitable alternative, without knowing coronary anatomy. Patients were 
permitted to have revascularisation for refractory symptoms, of which 23% did at 4 years. 
ISCHEMIA has divided opinions. Ischaemia on an appropriate testing modality plus refractory 
angina probably favours invasive treatment, unless there is a significant contraindication. 
However, treatment decisions in patients with ischaemia or symptoms only, is less clear. There is 
still substantial debate on how to interpret the trial results (Murthy and Eagle, 2018).  
 
1.3 - Assessing the Coronary Circulation 
 
 
1.3.1 - Diagnostic Coronary Angiography 
 
 
The focus of this thesis is the change in physiological measurements when comparing prone and 
supine patient positioning during angiography. To position the wire and conduct the procedure, a 
baseline coronary angiogram is needed. 
Coronary catheterisation was first conducted in man by Werner Fossman in 1928, who passed a 
65cm urinary catheter into his own cubital vein, until he felt it reach the right atrium (Meyer, 
1990). With the catheter hanging from his arm, he walked to the hospital basement to take an X-
ray and confirm its position (Figure 3). The first selective coronary angiogram, however was 
described by Dr. Mason Sones in 1958. Hand injected contrast media was passed into the right 





 Figure 3 - Original X-ray of a urinary catheter in Werner Forssman's right atrium (Meyer, 
1990) 
 
1.3.2 - Basic Concept 
 
 
The aim of a coronary angiogram is to identify luminal obstruction or narrowing of a coronary 
artery. This is done by injecting iodinated contrast media directly into an artery, under X-ray 
supervision to create an 'outline' of the vessel and identify stenosis. Access is usually gained via 
the right radial artery (85-90% at our institution but left can also be used). Initially femoral access 
was the method of choice but has been steadily replaced with radial access unless larger catheters 




Three main coronary arteries exist. The left anterior descending artery (LAD), circumflex artery 
(Cx) and right coronary artery (RCA). The LAD and Cx normally originate from the left coronary 
ostium, and the RCA from the right coronary ostium. Both of these ostia originate from the aorta 
as it leaves the left ventricle and lie above the aortic valve. Figure 4 demonstrates this. The anatomy 
and position of these arteries is important with relevance to this research, as they are in different 
vertical planes in a supine patient. 
 
Figure 4 - coronary anatomy showing coronary arteries and major cardiac venous and arterial 
vessels 
(Coronary.pdf: Patrick J. Lynch, medical illustrator derivative work [1]: 








Iodinated contrast media is necessary for acquisition of X-ray pictures, as the contrast fluid is x-
ray dense (Figure 5). The main concern regarding contrast use is the potential nephrotoxic effects, 
the most serious of which is contrast induced nephropathy (CIN). In turn, development of CIN has 
short and long term impacts on morbidity and mortality (Wi et al., 2011), (James et al., 2013). This 
was of importance with regards to the study protocol due to the extra measurements compared 
with standard care. The extra measurements inevitably meant higher contrast use for wire 
positioning and lesion visualisation. The incidence of CIN in elective patients is <3.5% (Rihal et 
al., 2002). For this reason, patients with significant baseline kidney dysfunction were excluded, as 
this is the most important risk factor for the development of CIN (Nash, Hafeez and Hou, 2002).  
Many contrast agents exist, but all are iodine based. The pathophysiology of CIN is complex and 
not completely understood, but culminates in hypoxia in the renal medulla, and eventually cell 
death (Wong et al., 2012). The osmolality (measure of the number of dissolved particles in a fluid) 
of contrast media, appears to have an impact on the risk of developing CIN. Contrast agents are 
divided into high, low or iso-osmolar (highest to lowest osmolality respectively). Meta-analyses 
have shown a risk reduction in the development of CIN when using low osmolar versus high 
osmolar agents (Barrett and Carlisle, 1993), and iso-osmolar versus low osmolar agents 
(McCullough et al., 2006). In our study patients, all received Visipaque™ which is classed as iso-
osmolar, and from current evidence, the safest agent available for use. There is clear evidence that 




Figure 5 - A right coronary artery injection, from a patient attending the Essex Cardiothoracic 
Centre. Contrast injection is shown in black, filling the coronary catheter, and the coronary artery. 




1.3.4 - Fluoroscopy 
 
The X-ray equipment can rotate 180 degrees in an anterior/posterior and lateral fashion, giving 
different views of the coronary arteries. Radiation injury is a known risk of exposed x-ray use. 
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This is more commonly seen in complex interventions, and we did not expect to see such 
complications during the study protocol. Injury can range from skin damage to necrosis of 
underlying structures (Wagner, 2007). Radiation doses are carefully monitored for staff and 
patients, any high dose procedures are reported to a central regulatory body. 
 
1.4 - Percutaneous Coronary Intervention 
 
 
With advances in coronary angiography, the focus of early pioneers turned to whether stenoses 
could be treated percutaneously, rather than with open heart surgery. The first coronary artery 
bypass graft was conducted in 1960, with the procedures becoming more widespread in the late 
1960's (Head et al., 2013). The first percutaneous coronary intervention was conducted much 
later, by Andreas Gruentzig, hailed as the 'father' of coronary angioplasty (Grech, 2003) in 1977, 
who treated a left anterior descending artery lesion in a 38 year old male with simple balloon 
angioplasty. 
Since then, advances in coronary intervention have meant more selective coronary catheters, 
coronary guidewires, balloon technology with higher pressure tolerance and lower profiles, as 
well as huge leaps in coronary stent technology. 
 
 
1.4.4 - Balloon Angioplasty and Bare Metal Stents 
 
 
Coronary stents revolutionised the treatment of coronary artery disease. The first coronary 
lesions were treated with plain old balloon angioplasty. While this was a landmark step is 
angioplasty as a whole, balloon angioplasty was compromised by acute vessel closure and re-
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stenosis (Bauters et al., 1996). Coronary stents were introduced to prevent elastic recoil in the 
vessel, and seal dissection flaps cause by POBA, with the aim of counter acting these issues. 
The very first stents to be used in man were stainless steel (BMS - Bare Metal Stent) and balloon 
expandable, being used predominantly in the early 1990's (Iqbal, Gunn and Serruys, 2013). As 
hoped, they did reduce early elastic recoil (and hence acute vessel closure), as well as restenosis 
(de Feyter, de Jaegere and Serruys, 1994). The early stents were not without flaws. There was a 
risk of stent thrombosis due to the high metallic density, and being large and technically difficult 
to deliver had a frequent failure rate by today's standards (de Feyter, de Jaegere and Serruys, 
1994). Furthermore, even though the restenosis rate was less than POBA, it was still seen in a 
third of patients in early studies (de Feyter, de Jaegere and Serruys, 1994). The initial use of 
stents was therefore limited to acute closure or restenosis after POBA. 
Two landmark trials published in 1993 BENESTENT (Serruys et al., 1994) and STRESS 
(Fischman et al., 1994) established BMS to be superior to POBA, driven mostly by reduced rates 
of revascularisation in the stenting group. This led to an exponential increase in stent use, 
meaning 80-90% of angioplasty cases utilised stents by the late 1990's (Serruys, Kutryk and 
Ong, 2006). 
In these landmark trials, there still remained a significant rate of restenosis, despite BMS' 
superiority over POBA. The issue of elastic recoil had largely been addressed, but smooth 
muscle cell proliferation causing restenosis had to be addressed for medium and long term 
prognosis. 
 
1.4.2 - Drug Eluting Stents 
 
 
Pharmacological agents were used in an attempt to limit smooth muscle proliferation and local 
inflammation. Early attempts to cover stents in gold, carbon and heparin did not confer any 
benefits (Iqbal, Gunn and Serruys, 2013). The breakthrough came when stents were coated with 
the anti-proliferative agents sirolimus and paclitaxel, which were both shown to reduce smooth 
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muscle cell proliferation and migration (Poon et al., 1996; Axel et al., 1997). The addition of 
these drugs to a polymer allowed drug release over several weeks, and in turn, the first sirolimus 
eluting stent (CYPHER™, Cordis Medical, Milpitas, California, United States) was implanted in 
1999. It became available for clinical use in 2002, followed closely by a paclitaxel eluting stent 
(TAXUS™, Boston Scientific, Marlborough, Massachusetts, United States). Both stents 
underwent numerous randomised controlled trials and proved superior to BMS in reducing rates 
of restenosis (Morice et al., 2002; Moses et al., 2003; Stone et al., 2004). 
 
Since the first generation of drug eluting stents (DES), adaptations have been implemented 
aiming to make them more deliverable, with some incorporating differing pharmacological 
agents (e.g. zotarolimus, everolimus, biolimus), improved drug polymers, and thinner stent struts 
(Serruys et al., 2010). Evidence from meta-analyses demonstrate a benefit of second generation 
DES over first generation DES with regards to stent thrombosis, and repeat revascularisation 
rates, but not death or myocardial infarction (Park et al., 2013).  
 
1.4.3 - Drug Eluting Stents vs. Bare Metal Stents 
 
 
Drug eluting stents generally require a longer duration of antiplatelet treatment, due to the 
extended period of exposed stent struts. Recent data however has shown the safety in reducing 
antiplatelet duration in current generation DES (Windecker et al., 2020), providing an apparent 
safe alternative. In some clinical situations, bleeding is a potential issue, or more urgent cessation 
of antiplatelet medication is required. Here, a risk benefit decision needs to be made, individual 
to the patient and clinical situation. Shorter lesions (<20mm) with a larger vessel diameter 
(>3mm), appear to have similar outcomes when comparing BMS to DES in some studies. 
Patients with diabetes mellitus are at risk of accelerated restenosis, and data supports the use of 
DES in this subgroup. The use of DES was associated with lower rates of mortality, myocardial 
infarction and revascularisation when compared to BMS (Garg et al., 2008). This stance has been 
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supported by large meta-analyses (Bangalore et al., 2012), regardless of vessel size or lesion 
length.  
 
1.5 - Risks of Percutaneous Coronary Intervention 
 
 
Percutaneous coronary intervention, by necessity requires a diagnostic coronary angiogram to 
visualise the lesion for treatment. Therefore, the baseline risks of coronary angiography are 
inherent in the procedure (approximately 1 in 1000). Instrumentation of an artery with coronary 
guidewires and balloons plus subsequent stent implantation brings about additional risks (quoted 
1 in 100 during patient consenting process). The risks are described in detail in Appendix B. 
Mentioning risk is important, as it forms a critical part of the decision making process regarding 
the treatment of a coronary lesion. This in turn has led to the use of tools to assess the 
significance of a stenosis and whether there is a need to put patients at risk of a PCI procedure. 
 
1.6 - Identifying Significant Lesions in Stable Coronary Artery Disease 
 
 
The focus of onward discussion will be the patient demographic for this study - chronic coronary 
syndrome. The decision to treat a lesion is based on two questions: 
 
1. Does the patient have an indication for invasive treatment of their coronary artery 
disease? 
 




The severity of a stenosis on coronary angiogram correlates poorly with coronary physiology 
(Adjedj et al., 2017). This is known as angiographic ambiguity. Physiological evidence of 
ischaemia is usually necessary in the decision making process. Even with evidence of ischaemia 
however, decisions are not binary.   
 
Data from recent trials, ISCHEMIA (ISCHEMIA Trial Research Group et al., 2018) and 
ORBITA (Al-Lamee et al., 2018) suggest no significant difference in optimal medical therapy 
plus invasive treatment for proven ischaemia or angina symptoms over optimal medical therapy 
alone. This is still not widely accepted, as earlier trials outlined below demonstrate benefit. 
Treatment is tailored to the individual, taking into account multiple factors. To complicate 
matters further, there are multiple modalities of ischaemia assessment (invasive and non-
invasive). 
 
1.7 - Non-Invasive Ischaemia Assessment 
 
 
Although not the focus of this research, non-invasive ischaemia tests are clinically relevant. 
These tests should not be affected by hydrostatic effect as they do assess stenosis within a closed 
fluid system. This has important implications if hydrostatic effect is found to be a true 
confounding factor during this research, as such tests may be a viable alternative.  
In the United Kingdom, non-invasive ischaemia assessment is still widely used. Exercise 
treadmill ECG was widely used but has largely been phased out. In recent times, stress 
echocardiography, myocardial perfusion scanning, and stress cardiac MRI (CMR) have gained 
popularity. A negative test for either of these modalities is a good prognostic indicator of future 
cardiac events (Smulders et al., 2017) whilst being extremely safe. 
The above modalities look for ischaemia during cardiac stress. CT coronary angiography 
(CTCA) is a well-known imaging modality that provides anatomical data instead. It has a strong 
negative predictive value of 97-99% (Budoff et al., 2008). Although CTCA is not strictly an 
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ischaemia test, algorithms have been recently implemented to use the anatomical images CT 
provides to produce a measure of ischaemia non-invasively, known as CT FFR. 
 
1.7.1 - CT FFR 
 
Previous studies have shown that CT FFR correlates well with invasive FFR (r = 0.82) 
(Nørgaard et al., 2014) although discordance is still approximately 15%. Such studies use 
computer generated fluid dynamic models to generate a non-invasive FFR value. Such models 
aim to factor in the effects of hyperaemia, microvascular resistance and cardiac output. 
Inevitably, CT FFR uses generic parameters of heart, systemic and microcirculation, 
superimposed onto patient specific coronary CT images to produce a CT FFR (Taylor, Fonte and 
Min, 2013). This assumes patients 'fit' into these generic parameters, and ignore other variables 
such as LVEDP, wedge pressure, hyperaemic response and hydrostatic effect. 
The PROMISE trial (Lu et al., 2017) took patients who proceeded to invasive coronary 
angiography from a standard CT coronary angiogram, and correlated a CT FFR <0.8 with 
coronary revascularisation or major adverse cardiac events (MACE). Patients with a CT FFR of 
<0.8 were more likely to have revascularisation or MACE compared with CT FFR >0.8. Also 
those with CT FFR <0.8 were significantly more likely to receive revascularisation when 
compared to severe stenosis on CTA alone. Lastly, it was suggested that CT FFR may reduce the 
number of referrals for invasive angiography nearly half, using <0.8 as a threshold. It is 
noteworthy that of all patients screened for PROMISE, approximately half had to be excluded 
for multiple reasons, including inadequate imaging. 
 
1.8 - Invasive Ischaemia Assessment 
 
 
Fractional flow reserve (FFR) is the most widely used invasive physiology tool in clinical 
cardiology. Newer resting indices such as instantaneous wave free ratio (iFR) have gained 
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popularity over recent years. In acute presentations of coronary artery disease (ACS), the risk of 
revascularisation is often outweighed by the risk of leaving a vulnerable plaque untreated. In 
chronic coronary syndromes, ischaemia assessment forms a vital part of the decision to treat. 
 
1.8.1 - History of Invasive Coronary Physiology 
 
Many types of intracoronary indices exist, and have been studied, dating back to 1974 when 
Gould proposed a measurement known as coronary flow reserve (CFR), using velocity 
measurements. The term coronary flow reserve, can be found dating further back, to 1963 
(Johnson, Kirkeeide and Gould, 2015). The term gained interest in 1974 as it linked CFR to 
anatomical stenosis in canine studies, and demonstrated the heart's ability to increase blood flow, 
versus several different severities of coronary stenosis (Gould and Lipscomb, 1974). CFR is 
calculated by measuring coronary flow during hyperaemia and dividing by flow at baseline. This 
gives a ratio above one, describing how much flow can be augmented, when there is myocardial 
demand. The first study in 1974 even hinted that a CFR of less than 1.5 may be an indication for 
bypass surgery, suggesting a clinical use in decision making. CFR was studied in 1997, in the 
DEBATE trial, showing CFR had a modest predictive value for patients who would benefit from 
coronary angioplasty based on a CFR of less than 2.5 (Serruys et al., 1997). 
CFR use fell in the late 90's when pressure-based systems such as FFR became more available. 
Even with advances in doppler technology, pressure-based systems are quicker and more robust 
to use compared to doppler based systems, leading to a significant rise in their popularity. 
Fractional flow reserve, a pressure-based measurement, was first described experimentally in 
1993 by Pijls and De Bruyne (Pijls et al., 1993). Pressure based indices before FFR often used 
resting conditions and measured pressure gradients across a stenosis. The concept was simple; a 
stenosis creates a pressure difference between the proximal section of the artery, and the section 
distal to the stenosis. The difference is known as the gradient and indicates the severity of the 
stenosis. Pd / Pa is often described as a ratio between 0 and 1.Grüntzig applied this concept in 
1979 on 32 patients who underwent percutaneous balloon angioplasty (Grüntzig, Senning and 
Siegenthaler, 1979). Wijns also conducted similar research in 1985 (Wijns et al., 1985). Resting 
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indices have been superseded by FFR, but have made a re-appearance in recent research, and 
will be described separately. Figure 6 demonstrates a resting stenosis measurement, known as Pd 
(distal pressure) over Pa (aortic / proximal pressure). 
 
Figure 6 - demonstration of Pa and Pd. Pd / Pa gives a ratio which is used to assess stenosis 
severity 
 
A major breakthrough came with the introduction of coronary vasodilators, culminating in the 
use of adenosine in 1990 (Wilson et al., 1990) and in turn FFR. These agents induce hyperaemia, 
which is critical for lesion assessment. Adenosine and hyperaemia, induce a closer physiological 
state to exercise, than a resting state. Furthermore, coronary autoregulation maintains coronary 
flow over a wide blood pressure range by adjustment of coronary resistance (mostly from the 
microcirculation). Using vasodilatory agents, reduces resistance to a steady minimal state, 
allowing us to isolate the stenosis and assess a change in pressure gradients, once autoregulation 
is inhibited (Johnson, Kirkeeide and Gould, 2015; Blows and Redwood, 2007). This is the 







1.8.2 - The Theory of Fractional Flow Reserve 
 
 
FFR was first reported in the literature in 1993, building on previous work of coronary flow 
reserve (Pijls et al., 1993). The model was initially validated in dogs, and later validated in 
human coronary arteries in 1994 (De Bruyne et al., 1994). 
The aim of FFR is to ascertain whether a stenosis is flow limiting, using pressure-based 
measurements (instead of flow). CFR had been well validated at this point and the underlying 
concept of both is similar. They both use maximal flow as an indication of stenosis severity. CFR 
uses flow-based measurements to provide information on how much an artery can augment flow 
compared to baseline, in the presence of a coronary stenosis. Less flow, suggests a more 
significant stenosis. FFR on the other hand uses pressure-based measurements during maximal 
flow or hyperaemia, distal to a stenosis, and compares it to a pre-stenotic measurement. It is Pd 
over Pa, as demonstrated in figure 6, during the administration of a vasodilator (adenosine) to 
produce maximal and steady state hyperaemia. 
FFR is thought to have advantages over CFR in multiple ways. Velocity based measurements are 
less robust, and take longer to acquire than pressure based measurements (Pijls et al., 1993). 
Furthermore, CFR utilises two different states of physiology (baseline and hyperaemia) as a ratio 
against each other. This means a CFR result could be due to alterations in either state, not 
necessarily just one. Furthermore, the overall physiological state of the patient has an effect on 
CFR calculations, with variable factors including blood pressure and heart rate (Gould, Kirkeeide 
and Buchi, 1990). FFR is thought to be more reproducible with these issues and provide a more 
isolated measurement for the stenosis in question. 
 
1.8.3 - Pressure and Flow 
 
 
The coronary circulation has a strict autoregulatory system. A reduction in pressure, is not 
proportional to a reduction in myocardial blood flow, due to changes in vascular resistance in the 
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coronary bed (Ramanathan and Skinner, 2005). This concept is described in physical principles 
and follows the same concept as Ohm's law (Figure 7). 
 
 
Figure 7 - Ohm's law. Voltage is the product of current, multiplied by resistance. 
 
Ohm's law can be applied to the cardiovascular system. Voltage is replaced by pressure and 
current by flow. The result is shown in Figure 8. 
 
Figure 8 - Ohm's law, applied to the cardiovascular system. This forms the basis of 
autoregulation. 
 
Autoregulation can be explained using the equation in Figure 8. If pressure drops, and flow is to 
remain constant, resistance must decrease, and vice versa. However, when maximal hyperaemia 
is applied, resistance is assumed to me minimal and constant, inhibiting autoregulation. In turn, a 




Figure 9 - at maximal hyperaemia, when resistance is minimal and constant, a change in 
pressure can be said to be proportional to a change in flow. Triangles represent the sum of 
change 
 
In the coronary circulation therefore, FFR measures 'flow' (actually measuring mean pressure) 
beyond a stenosis (Pd), and compares it to flow before a stenosis (Pa). The proximal pressure is 
recorded either in the aorta or ostial left main stem (Pijls et al., 1996). This gives the FFRmyo 
which provides information regarding flow to the myocardium beyond the stenosis (Figure 10). 
In the originally described formula, venous pressure is factored into the pressure reading (taken 





Figure 10 - Calculation of FFR- diagrammatic representation of FFR measurement beyond a 
stenosis. Pd = distal mean pressure, Pa = distal aortic/proximal pressure, Pv = venous pressure 
from right atrium. FFR = fractional flow reserve. 
 
In current clinical practice, with the majority of cases being carried out radially, and right atrial 
pressure requiring femoral vein puncture, venous readings are rarely recorded. Recently, the 
effect of right atrial pressure on FFR calculation has been shown to be minimal (Toth et al., 
2016). In Pijls original paper in 1993, he described a method to calculate FFRcor . This FFR at 
coronary level, which factors collateral pressure into the equation, and removes it. This involves 
measuring wedge pressure, which is not routine practice. A wedge pressure is the measured 
pressure within a coronary artery when a coronary balloon is inflated to stop antegrade flow 
(Figure 11). The resulting pressure comes solely from collateral vessels. Calculating FFRmyo is 
then truly the sum of pressure anterogradely through the stenosis, and collaterals from other 




Figure 11 - Original FFR Model - Representation of wedge pressure with a balloon (marked) 
inflated to impede antegrade flow. The resulting pressure distal to the stenosis, measured by a 
pressure wire positioned there, is now solely from collaterals. Pa = proximal pressure, Pd = 




FFR is a number between 0 and 1.0. The proximal pressure is assumed to be the maximal flow 
obtainable in the artery if stenosis free, and is the denominator in the equation. The value in 
theory, should not be above 1, which indicates the same flow beyond the stenosis, as before it, 
and the best achievable flow. A cut off value of 0.8 is routinely used in clinical practice, to 
denote a negative FFR, and a lesion which does not need treatment. Simply, one can interpret 
this as 80% of maximal achievable flow. Values above 1.0 are not uncommon however, which 
relates to several potential confounding factors in FFR measurement, the most important of 
which for this thesis, is hydrostatic pressure. This and other confounding factors are discussed 
separately.  
The practicalities of measuring FFR are outlined in the chapter III. In brief, the operator must 
pass a physiology wire, with a pressure sensor, beyond a coronary stenosis and obtain 
measurements while the patient is in hyperaemia. This is usually accomplished by a continuous 
infusion of intravenous adenosine for 1-2 minutes. Physiology / pressure wire technology has 
improved through the years, encouraging widespread use in most interventional cardiology 
laboratories. 
 
1.9 - Clinical Evidence Supporting FFR 
 
 
Several randomised control trials have supported the use of FFR in a clinical context. Studies 
were conducted to test the safety of deferring lesions which had a negative FFR, and the 
accuracy of FFR versus conventional angiography only in lesion assessment. 
 
1.9.1 - DEFER Study 
 
 
The defer study was the first widely recognised RCT involving FFR (Bech et al., 2001) 
published in 2001. The unique study design used FFR to assess coronary stenosis in elective 
patients presenting with stable angina. Patients with negative FFR values (>0.75) were 
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randomised to either optimal medical therapy (OMT) (defer group), or PCI (perform group). 
Follow-up has recently been completed over a 15 year period (Zimmermann et al., 2015a). There 
was a significant reduction in the rate of myocardial infarction in the defer group, compared to 
the perform group (2.2% vs.10%). The rate of death was not statistically different between the 
two groups. This not only demonstrates that the rate of myocardial infarction is low with a 
negative FFR, but that treating a negative FFR lesion did not improve outcome, and may indeed 
worsen prognosis. This is especially relevant at 15 year follow-up, where no 'catch-up' 
phenomena was seen, potentially relating to restenosis of the stent. 
 
1.9.2 - FAME Study 
 
 
The FAME study, published in 2009 (Tonino et al., 2009) aimed to compare angiography guided 
PCI with physiology guide PCI for the first time. Coronary angiography was the standard 
method to which decisions regarding coronary stenting was made. 1005 patients were 
randomised to either angiographically guided stenting, or FFR guided stenting based on a 
positive result (FFR <0.8). The study population had multi-vessel coronary artery disease with an 
average of 2.7 lesions per patient. The composite endpoint was of death, myocardial infarction 
and urgent revascularisation at 1 year follow-up. The FFR guided group has significantly less 
events compared to the angiography guided group (13.2% vs. 18.3%). 
 
1.9.3 - FAME II Study 
 
 
FAME II, build upon results in FAME by posing a slightly different question. Published in 2012 
(De Bruyne et al., 2012), one can liken the design to DEFER, but with FFR values of <0.8. 
Initially, 1220 patients were assessed and of those 888 had a coronary stenosis with an FFR of 
<0.8. These were randomised in a 1:1 fashion to OMT or OMT+PCI and followed up for two 
years. The composite endpoint of death, myocardial infarction and urgent revascularisation, had 
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less events in the PCI group (8.1% vs. 19.5%) (De Bruyne et al., 2014), driven mostly by the 
need for urgent revascularisation. The rate of death and myocardial infarction was also lower in 
the PCI group in a landmark analysis from 8 days to 2 years. 
Five year outcome data for the FAME II trial was recently published (Xaplanteris et al., 2018a). 
The composite endpoint of death, myocardial infarction and urgent revascularisation, showed 
significant benefit favouring the PCI group, again driven by a large difference in urgent 
revascularisation rates  (6.3% vs. 21.1%). The individual rates of death and myocardial infarction 
was not different between the two groups. 
This demonstrates a benefit in stenting to lesions with and FFR <0.8 compared with medical 
therapy alone. DEFER showed no benefit in treating lesions with an FFR of >0.75. Table 1 
summarised these three randomised control trials. Another study published in 2011 further 
demonstrated the safety of medical therapy with FFR >0.8 lesions in the proximal LAD. Survival 
rates were statistically similar to patients in a reference group without known coronary artery 
disease at 5 years (Muller et al., 2011). This adds to the compelling evidence to treat such lesions 















DEFER FAME FAME II 
Population Stable angina Stable angina Stable angina 
Treatment at 
Randomisation 
Angiogram Angiogram Angiogram 
Arm 1 FFR >0.75 
PCI 
FFR guided PCI FFR <0.8, PCI + 
OMT 




FFR <0.8, OMT 
Standard Care When 
Study Conducted 




Outcome Stenting FFR 
>0.75 - No 
benefit 
FFR guided PCI better 
than angiography 
guided PCI 
PCI + OMT better 
 
Table 1 - summary of DEFER, FAME and FAME II. FFR -fractional flow reserve, PCI - 
percutaneous coronary intervention, OMT - optimal medical therapy. 
 
1.9.4 - Registry Data 
 
 
The Mayo registry, comprising of 7358 patients compared two groups of patients; those 
undergoing PCI without FFR guidance, and those undergoing PCI with FFR guidance (Li et al., 
2013). Patients treated with FFR guidance had a significantly reduced rate of major adverse 




The ISIR-FFR registry comprised 5846 patients and over 8000 coronary lesions (Ahn et al., 
2017). In this data set, lesions with FFR <0.75 showed significantly improved outcomes if 
treated with PCI compared with medical therapy. This re-iterates the findings from FAME II. 
Lesions above this cut off had similar outcomes if treated medically or revascularised. This is a 
slightly different finding to DEFER, however one appreciates this is comparing registry data to a 
randomised trial. Furthermore, in untreated lesions, the FFR showed an inverse linear 
relationship with adverse events. 
 
1.9.5 - FFR in Current Clinical Guidelines 
 
 
European Society of Cardiology guidelines were published in 2014 and give the following 
guidance on FFR use (Authors/Task Force members et al., 2014); 
• FFR assessment for moderate coronary stenoses are indicated to measure functional 
consequences 
• Deferral of revascularisation with an FFR >0.8 appears safe 
• FFR guided PCI and OMT is superior to OMT alone with regards to need for urgent 
revascularisation 
 
American guidelines, updated in 2017 (Patel et al., 2017) suggest; 
• FFR may be helpful in defining the need for revascularisation 
• FFR <0.8 is consistent with ischaemia 





1.9.6 - FFR Use in Acute Coronary Syndrome 
 
 
Early data was predominantly in stable presentations of chest pain. FFR measurement at the time 
of acute myocardial infarction, is invalid, due to microvascular dysfunction, and falsely raised 
FFR values (Claeys et al., 2001). Microvascular dysfunction causes a reduction in flow through 
the culprit artery, and in turn reduces the pressure gradient across a stenosis. This leads to an 
underestimation in FFR, and hence invalidates its use. 
Use of FFR in non-culprit arteries during STEMI is still an area of fierce debate. DANAMI-3-
PRIMULTI was a study conducted in the context of non-culprit coronary artery disease, treated 
based on FFR guidance at the index admission of a STEMI, versus treatment of the culprit only 
(Engstrøm et al., 2015). Patients who had complete revascularisation based on FFR had a 
significant reduction in the need for repeat revascularisation. 
The Compare-Acute study (Chin et al., 2017), had a very similar study design to DANAMI-3-
PRIMULTI, and showed similar results with a reduction in MACE, driven mostly by reduced 
revascularisation in the FFR guided PCI group. Interestingly, investigators also found that nearly 
half of lesions deemed significant on angiography, were physiologically negative when assessed 
by FFR. This supports the concept that FFR reduces unnecessary revascularisation when used to 
aid treatment decision. 
 
1.10 - Resting Indices 
 
 
Recently, novel resting measures of stenosis severity have gained increasing popularity. They 
can provide an assessment of ischaemia quickly and without the need for adenosine. 
Instantaneous wave free ratio (iFR) was the first of the novel resting indices and used coronary 
pressure distal to the stenosis with proximal coronary pressure in the wave free period of the 
cardiac cycle, located in diastole (Figure 12). It has been compared to FFR in a randomised 
control trial DEFINE-FLAIR (Davies et al., 2017). With regards to major adverse cardiac events 
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at 1 year, it was shown to be non-inferior to FFR in guiding treatment strategy, with fewer 
adverse procedural symptoms and shorter procedural time.  
 
Figure 12 - The Wave Free Period- in which iFR is calculated (Pd/Pa). 
(IFR calculation.pdf: Sukhjinder.nijjer (https://commons.wikimedia.org/wiki/FileIiFR 
calculation.pdf, https://creativecommons.org/licenses/by-sa/3.0/legalcode) 
 
The discovery of iFR led to expansion in scientific investigation. The wave free period was 
specifically of interest, as it was believed to be physiologically identical to hyperaemia, without  
needing adenosine. Resistance in the wave free period was thought to be minimal and constant, 
to the same magnitude as with central infusion of adenosine. The VERIFY study (Berry et al., 
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2013) however showed that iFR was significantly influenced by introduction of hyperaemia, and 
correlated weakly with FFR casting doubt upon its clinical validity. 
Using data from the VERIFY-2 study (Hennigan et al., 2016), a further study questioned the 
specific timing of the wave free period. Pd/Pa measurements were taken during the whole of 
diastole, the middle 50% of diastole and the midpoint of diastole, with readings compared to iFR. 
All of these resting indices (known as varying diastolic pressure ratios (DPR) produced almost 
identical results to iFR with correlation values above 0.99. It appeared therefore that the wave 
free period did not differ significantly from other periods of diastole, as the results were 
essentially identical. 
Furthermore, recent data has shown that taking the lowest Pd/Pa value across the whole cardiac 
cycle (systole and diastole) would again produce almost identical results to iFR. The 
VALIDATE-RFR study (Svanerud et al., 2018) produced a new index, RFR, with correlation 
values above 0.99 when compared to iFR. Furthermore, the lowest Pd/Pa value was outside of 
diastole in 12.2% of all cardiac cycles, and 32.4% of cardiac cycles in the right coronary artery. 
This means physiologically significant stenoses may be missed by focusing purely on the 
diastolic portion of the cardiac cycle. 
 
1.11 - Pitfalls of Pressure Derived Indices 
 
 
Venous pressure was factored into the original FFR equation. In routine clinical practice with the 
increasing popularity of radial access, venous puncture to acquire right atrial pressure, has 
become increasingly uncommon. Recent studies have shown that even in the presence of 
significantly raised right atrial pressure, the impact on FFR is negligible (Toth et al., 2016). This 
holds true even in the context of a CTO (Karamasis et al., 2018). 
In current clinical practice, wedge pressure is not factored into FFR calculation to produce 
FFRcor . In patients with extensive collaterals, FFR may be inaccurate. 
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Gender has been linked to a difference in FFR values, dating back as far as FAME and it's sub-
studies (Kim et al., 2012).The general explanation is thought to be due to microvascular 
dysfunction. Another theory is that the female heart is smaller with less myocardial mass to 
subtend. This in turn leads to a higher FFR on average in females when compared with males. 
The current haemodynamic state of the patient can alter pressure derived indices. Tachycardia, 
and raised left ventricular end diastolic pressure (LVEDP) may increase microvascular resistance 
and in turn FFR (Spaan et al., 2006). Furthermore patient's with microvascular dysfunction may 
not respond to pharmacological vasodilatation, leading to falsely elevated FFR measurements 
(van de Hoef et al., 2013). 
The amount of mass subtended by a coronary artery is linked to fractional flow reserve, with 
higher myocardial mass being more likely to produce a positive pressure derived value (Leone et 
al., 2013b). This is due to increased flow, due to more myocardium, and in turn a reduction in 
pressure.  
Finally, one must not forget the technical and practical issues in measuring pressure derived 
indices. There is a distinct learning curve when first introduced to a new catheter laboratory and 
various human or technical errors, may alter recordings. One hopes these will be minimised with 
time and experience, but good clinical practice is paramount. Technical points include: 
• Adequate administration of vasodilators 
• Flushing of the guide catheter and coronary artery with saline to clear contrast 
• Correct normalisation of the pressure wire in the proximal vessel 
• Selection of an appropriate guide catheter for the artery in question, to avoid wedging and 
pressure drop. 
• Recognition of submaximal hyperaemia. 
 
Lastly, the effect of hydrostatic pressure is negated in clinical practice. Hydrostatic pressure is 
present due to the vertical distance between the pressure wire in the coronary artery, and the 
guide catheter in the aorta/ostial vessel. The pressure at these points is not the same if vertically 
they lie at different levels, producing a potentially important confounding factor. 
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1.12 - Hydrostatic Pressure 
 
 
Hydrostatic pressure is the pressure exerted by fluid in a confined space. In relation to coronary 
physiology, coronary arteries are a close fluid system, with the fluid being blood. Hydrostatic 
pressure in coronary vessels is therefore blood pressure. 
This pressure forms the basis of invasive physiology measurements used so frequently in the 
catheterisation laboratory. Measurements are taken in the distal vessel, across a stenosis, and 
compared with pressure at the origin of the vessel or aorta. This, as described, forms the basis of 
FFR calculation, the gold standard technique for stenosis assessment for decades. 
According to the physical laws of fluid dynamics, hydrostatic pressure changes due to the 
vertical point of measurement in a cylindrical tube, due to the force of gravity (Härle et al., 







Figure 13 - Close Fluid Model of the Coronary Circulation- A cylindrical tube, demonstrating 
aortic level and the position of superior or inferior coronary arteries, with the effect on pressure. 
Pa - proximal pressure, Pd - distal pressure. 
 
If an artery takes a superior course from the aorta, pressure measured in a superior position will 
be lower than it is at the aorta, purely due to gravitational effect. The opposite is true for an 
inferior artery, with pressure being higher. Therefore, in a completely disease free vessel lying 
superiorly to the aorta, with the distal pressure sensor above aortic level, Pd/Pa will be less than 
1.0.  The physiology assessment is already skewed, before a stenosis is introduced. With 
inferiorly positioned vessels compared to the aorta, Pd will be higher than Pa, and Pd/Pa will be 
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greater than 1.0. Only when the measuring point is at aortic level, will hydrostatic pressure not 
affect measurement. This is seldom the case in clinical medicine. 
If one now considers the same stenosis in a coronary artery, the final Pd/Pa measurement will be 
lower in a superior artery, due to a lower starting value, and therefore more likely to be 
abnormal. It is possible that we are therefore over-estimating some lesions (superior lying 
arteries) and underestimating others (inferior lying arteries) 
Although this concept has been acknowledged as a potential confounding factor in FFR 
measurement, it has largely been dismissed, as the magnitude of effect is thought to be too small 
to be of clinical relevance. 
 
1.12.1 - Magnitude of Effect 
 
 
Pascal's law dictates hydrostatic effect with the following equation; 
 
Hydrostatic pressure =  Fluid Density x Gravity x Height Difference 
  (Pascal's)   (kg/m3)    (9.8ms/2)  (m) 
 
An elegant paper recently published by Härle et al (Härle et al., 2017a) used a pressure simulator 
to calculate the effect in a coronary model. The calculated effect was 0.77mmHg per cm of 
height variation. An important consideration is that this coronary model used 0.9% saline 
solution as the fluid. Blood has higher density, and an anticipated change would be closer to 
0.8mmHg per cm. 
From the equation, fluid density and gravity are constant, the sole variable being height 
difference between two measurement points. To power the study adequately, I had to know the 
anticipated magnitude of effect. This meant calculating the potential height difference between 
distal coronaries artery and their origin. Data from CT coronary angiography was used to 
estimate this height difference in one hundred patients, and is expanded upon later in this 
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chapter, and in chapter II. One can accurately map the route of each coronary artery and measure 
the vertical height difference from the aorta using CT.  
1.12.2 - Hydrostatic Effect in Clinical Literature 
 
 
Relevant data in this area is sparse. Although the concept of hydrostatic pressure within coronary 
arteries is noted in medical text books, and even by the manufacturers of pressure wires, it is 
dismissed as a non-significant factor during clinical measurement. At the time of study 
conception, no study had explored this in vivo. 
Hydrostatic effects on blood pressure have been observed in peripheral, non-invasive studies. 
One such study measured the pressure needed to occlude the femoral artery using an external 
cuff placed on a patient's thigh (Sieljacks et al., 2018). This was measured supine and then in a 
seated position. When supine, the femoral artery is much closer to aortic level, compared to 
seated, where clearly it lies below. There was an observed increase in pressure needed to occlude 
the artery by 29 mmHg on average, when measured in a seated position.   
Further supporting evidence comes from physiology studies including normal or reference 
vessels. In one such studies, FFR results of above 1.0 were noticed, predominantly in reference 
vessels and circumflex arteries (Nijjer et al., 2016). This supports hydrostatic theory, as the 
circumflex artery lies predominantly inferior to the aorta leading to an FFR above 1.0. 
In a group of patients with moderate coronary artery stenoses, measurements in posterior arteries 
produced significantly higher FFR results than anterior vessels (0.87 vs. 0.79) (Härle et al., 
2017c). All compared vessels had very similar coronary stenosis severity (61.6% vs. 62.5%). 
This could be explained by the difference in height between distal and proximal sensors and 
hence hydrostatic effect. The results included iFR, which followed the same trend, as expected 
for a pressure-based index. 
Registry data follows this trend.  In nearly four thousand patients on a registry data set, there was 
a clear mismatch in angiographically moderate lesions in the LAD and correlation with invasive 
FFR (Nakamura et al., 2014). The CVIT-DEFER registry demonstrated LAD lesions were 
statistically more likely to yield a positive FFR result (<0.80). The opposite was true for Cx and 
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RCA lesions, which were more likely to yield a negative result. There was no difference in left 
main stem lesions. A further study of 643 patients yielded the same results (Cho et al., 2014). 
This further supports hydrostatic pressure theory. The authors of both studies however suggest 
that the mismatch seen was related to the amount of myocardium supplied by the LAD compared 
to other vessels. Hydrostatic effect was not mentioned. 
A study from 2017 in moderate coronary stenoses correlated IMR values to mismatch in invasive 
FFR and angiography. Lower IMR values were linked to lower FFR values and vice versa 
(Yonetsu et al., 2017). As in previous studies, mismatch was also seen in LAD lesions, yielding 
more positive results in angiographically less severe lesions. The authors again suggested 
subtended myocardium and microcirculatory dysfunction as the explanation. 
The current leading figure in coronary hydrostatic pressure is Tobias Härle, a German 
cardiologist. His elegant study on potential effects of hydrostatic pressure in coronary vessels 
demonstrated two things (Härle et al., 2017a). Firstly, CT data quantified the vertical height 
differences between distal coronary vessels and their ostia, when supine. It is worthwhile noting 
that this study group consisted of predominantly elderly patients with aortic stenosis and may not 
be a true representation of the general cardiac patient base. Following this, a novel dynamic 
pressure simulator was used to predict the effect of coronary anatomy on FFR measurements. 
Indeed, this model confirmed that when the distal pressure sensor was placed at a different height 
to the proximal sensor, in a completely normal vessel (saline filled tube) with no stenosis, FFR 
measurements diverged from 1.0. FFR was >1.0 when the distal sensor was moved below the 
proximal sensor, and <1.0 when raised above.  
No in vivo trials at study conception have been conducted. 
 
1.13 - Research Hypotheses and Pre-Work 
 
 
To test and build on hydrostatic pressure theory in vivo, I would alter the position of the patient 
on the angiography table from supine, to prone. Turning the patient on the angiography table 
would be an ideal way to prove hydrostatic pressure in vivo. Manoeuvring from prone to supine 
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keeps the aorta at an almost identical vertical level, but reverses distal coronary vessel position 
completely (Figure 14). This had never been done previously. Superior vessels become inferior 
and vice versa. The delta change one would see in vivo is therefore equal to the vertical height 
difference between superior, and inferior position, not solely the height change to the aorta. The 
aorta becomes the 'axis' around which superior and inferior measurements are taken. 
 
Figure 14 - Superior vs. Inferior Coronary Arteries- Illustration of superior and inferior distal 
pressure points versus aortic pressure. The effect size is dictated via vertical height shown with 
the arrows.  
 
In clinical practice, the hydrostatic effect on wire measurement in a superior or inferior artery 
will be approximately half of the observed change between prone and supine measurement. 
If the wire position is kept constant by strict study protocol, the only variable becomes the 
vertical height of the artery we are interrogating. Furthermore, the patient acts as their own 
control, meaning measurements are matched to their specific physiology and directly 
comparable. 
 
The study hypothesis is then divided into two separate points: 
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• Pressure based measurements (FFR, iFR, Pd/Pa) will significantly differ between supine 
and prone measurements. 
• Velocity based measurements will not change between supine and prone measurements 
(due to autoregulation). 
 
To elaborate on the latter point, the observed change in pressure I aim to see, should not convert 
into an increase or decrease in flow through the stenosis. The study group of patients will have 
an intact autoregulatory system, meaning the change in pressure is compensated for by the 
physiological mechanisms mediated by the coronary microcirculation. The focus is on the 
physiological tools that use pressure as their primary measure, and how hydrostatic pressure can 
impact their results. 
 
1.13.1 - CT Coronary Angiogram Pre-work 
 
 
The data from CT coronary angiography is critical to preliminary study work. It was of great 
importance that I understood the anatomy of each coronary artery, and the vertical pathways they 
took. There are inevitably differences in individual patient's anatomy. However, the knowledge 
of the most common position in the vertical plane was essential for correct placement of the 
pressure sensor during angiography.  
Quantitative data was needed to accurately calculate the height difference between the distal 
vessel and the proximal vessel and in turn the expected effect on FFR. This would guide study 






1.14 - CT Coronary Angiography (CTCA) 
 
 
CT coronary angiography builds upon conventional CT scanning to produce a non-invasive 
method of imaging the coronary arteries. The first CT scanner was invented by Godfrey 
Hounsfield, with the first patient scanned in 1971, visualising the brain (Rubin, 2014). CT 
scanning uses x-ray to take multiple images from differing angles, which are then reconstructed 
by computer software, to give a final set of images.  
Imaging of the coronary arteries became technically feasible in the late 90's (Donnelly, 
Higginson and Hanley, 2005). In current medical practice, cardiac CT can aid diagnosis in 
multiple clinical scenarios. An example of a cardiac CT scan is shown in figure 15.  
 
Figure 15 - Cardiac CT Showing Coronary Anatomy. LAD = left anterior descending artery. 




In current NICE (National Institute for Health and Care Excellence) guidelines, coronary CT is 
the first line diagnostic test for typical and atypical angina (Chest pain of recent onset: 
assessment and diagnosis | Guidance and guidelines | NICE, 2018). CTCA has a high negative 
predictive value for the exclusion of significant coronary stenosis in stable coronary artery 
disease (Budoff et al., 2008, Meijboom et al., 2008). Studies have also supported the use of 
CTCA in ACS in lower risk patients, potentially reducing length of stay (Hoffmann et al., 
2012).There is also some evidence that CTCA can identify 'vulnerable' plaques, at risk of rupture 
and causing acute coronary syndrome (Sun and Xu, 2014). There is still some variability in 
reporting of these plaques, which can make diagnosis challenging. 
Although invasive angiography is still regarded as the gold standard for coronary imaging, 
CTCA may have some subtle advantages. Angiography provides detailed luminal assessment, 
whereas CTCA highlights coronary anatomy and extra luminal details. This can include non-
atherosclerotic abnormalities and incidental findings,  occurring in up to 4.4% of scans in some 
studies (Knickelbine et al., 2009). Abnormalities detected can include anomalous coronary artery 
origins, coronary artery fistulas, coronary artery aneurysms, coronary dissection, coronary 
vasculitis.  
Finally, extra-coronary diagnosis can be made, including aortic stenosis, hypertrophic 
cardiomyopathy, and pericarditis (Kanaganayagam et al., 2014). Overall CTCA can also identify 
extra-cardiac abnormalities, such as aortic disease, pulmonary emboli and lung disease. 
 
1.14.1 - Limitations of CT Coronary Angiography 
 
 
A major limitation of CTCA is the image disruption caused by calcification. Whilst CTCA has a 
high negative predictive value, calcium deposits within the artery can lead to over estimation of 
coronary atheroma, in turn reducing positive predictive value (Sun, Choo and Ng, 2012). Patients 
with high calcium score are particularly at risk of such issues, as demonstrated by clinical trials 
(Budoff et al., 2008)  
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CT images need to be acquired in a short time frame with minimal motion artefact, meaning 
adequate heart rate control (<70bpm) for a satisfactory diastolic period, and adequate breath 
holding from the patient. Obtaining such conditions is sometimes not possible, and can be further 
compounded by arrhythmias such as atrial fibrillation (Clayton, Roobottom and Morgan-Hughes, 
2015). 
 Radiation dose has steadily been falling with advances in technology. It is however still a 
consideration. The average dose can rage widely but a recent study of 1341 CTCA, found an 
average dose of 5.9mSv (Castellano et al., 2017).  This is higher than the standard coronary 
angiography, which is thought to be approximately 3mSV (Einstein et al., 2007). 
Intravenous contrast medium is injected during CTCA and there are associated risks with 
introduction of these agents. The volume of contrast used is less than coronary angiography, but 
may pose a problem in patients with significant renal impairment. 
 
1.15 - Feasibility of in Vivo Research 
 
 
The function of cardiac CT imaging with relation to this research, was to understand the height 
differences between certain points within the coronary vasculature and the aorta or ostial vessel. 
This provides information on the magnitude of hydrostatic pressure, whether an in vivo study is 
feasible, and the sample size needed to support it.  
 
1.15.1 - Current Relevant Literature 
 
 
During the data collection period, a paper by Härle et al was published focusing on the same 
subject matter (Härle et al., 2017a). This elegant paper used CT coronary angiography to map 
coronary anatomy, in a group of patients predominantly suffering from severe aortic stenosis, 
and awaiting TAVI (transcatheter aortic valve implantation). The vertical height variations 
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between various points in the coronary tree were calculated. A dynamic pressure simulator was 
also used separately, to demonstrate how height variations could alter FFR using 0.9 % saline as 
the fluid in the circuit. 
Data from Härle is compared with my own in chapter II. 
 
1.15.2 - Calculating Hydrostatic Effect from Vertical Measurements 
 
 
The hydrostatic effect has been demonstrated by Härle to be 0.77 mmHg/cm. This was using 
0.9% saline solution in a hydrostatic simulator. 0.9% saline is less dense that blood, and the 
effect is thought to be closer to 0.8 mmHg/cm. This will be the conversion rate used herein. 
Figure 16 demonstrates how a calculation for hydrostatic pressure effect on a single point in an 
artery will take place. 
 
Figure 16 - Estimated Hydrostatic Effect - example of a superiorly positioned artery and the 
calculated effect on hydrostatic pressure. Distal red dot shows where the pressure wire will be 




Figure 16 demonstrates a scenario where a superiorly positioned artery has a distal point of 
measurement 4 cm higher than the proximal point (in a supine patient). One can assume this is 
the LAD. The pressure difference due to height alone between the ostium of the artery, and the 
distal portion of the artery is 3.2 mmHg. As the artery is superior, the effect is a reduction in 
pressure at the distal point in the artery. 
Therefore, if the proximal pressure is 100 mmHg, the distal artery will have a pressure of 96.8 
mmHg. If this was under hyperaemic conditions, the FFR would be 96.8 / 100, or 0.97 to two 
decimal places. If this whole scenario is reversed in the case of an inferiorly positioned artery, 
the resulting FFR would be 1.03. 
 
1.15.3 - The Clinical Effect on FFR 
 
 
We anticipated the effect on distal pressure (4-6 cm between origin and distal artery from 
literature and data in Chapter II) to be 3-5 mmHg, depending on the vessel. This is the change in 
Pd. However, it is appreciated that FFR is Pd/Pa at maximal hyperaemia, and that Pa can also 
change for a multitude of reasons. As Pa is the denominator in the FFR equation, a lower Pa may 
exaggerate the effect Pd has on Pa and vice versa. A table showing this effect is shown in Table 










Pa Pressure Pd Pressure Pd/Pa Corrected Pd/Pa 







0.88 0.81 0.07 
90 0.78 0.72 0.06 
100 0.70 0.65 0.05 
110 0.64 0.59 0.05 
120 0.58 0.54 0.04 
 
Table 2 - the effect of a change in Pd of -0.05 on Pd/Pa with various systemic/Pa. As Pa pressure 
rises, the effect a change in Pd has (and in turn hydrostatic pressure), lessens. 
 
This is of clinical relevance when calculating FFR due to the use of adenosine. Adenosine is a 
necessary step in FFR calculation, as it induces stable state hyperaemia. A side effect however is 
inevitably a drop in Pa pressure, which may lead to an amplification in the effect of hydrostatic 
pressure change measured in the distal vessel.  
 
1.15.4 - The Effect on Resting Indices 
 
 
The transtenotic gradient for hyperaemic indices, must reach 20 mmHg (assuming a Pa of 100) 
to be classed as significant (FFR <0.8). A change of 5mmHg is therefore 25% of the transtenotic 
gradient required to class a lesion as significant. The resting indices however (Pd/Pa and iFR), 
require a transtenotic gradient of less than half of this, with a negative iFR being classed as >0.92 
for example. A 5mmHg change here is therefore relatively much larger, accounting for over 50% 
of the transtenotic gradient.  
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In clinical terms therefore, the hydrostatic effect may have a much larger effect on the 
classification of resting indices, due to the smaller magnitude of transtenotic gradient used in 
their measurement. 
 
1.15.5 - Clinical Relevance and Mathematical Model 
 
 
FFR uses a threshold (0.8) to determine the significance of a coronary lesion. The potential 
changes that hydrostatic pressure has on FFR may cause some values to 'cross' the threshold once 
corrected. To demonstrate this phenomenon, we aim to use data from CT coronary angiography 
to provide a correction factor for hydrostatic pressure. This will be applied to a mathematical 
model of 200 randomly generated FFR values ranging from 0.75 - 0.85. One may then determine 
how many of these values cross the threshold of 0.8 and change classification from positive to 
negative or vice versa due to hydrostatic effect. 
 
1.15.6 – Research Questions, Aims and Objectives 
 
The main research question is whether hydrostatic effect is significant confounder when using 
invasive pressure-based measures of stenosis assessment 
The aim of this research is to quantify the magnitude of effect hydrostatic pressure exerts on the 
coronary circulation in each coronary artery. Once magnitude is known, one can quantify the 
extent of clinical inaccuracy when using pressure-based indices to assess the severity of a 
stenosis. 
The research objectives are; 
1) To map coronary anatomy using CT coronary angiogram and predict hydrostatic effect 
using coronary height data 
2) To see if CT data is accurate in vivo, using a new research protocol comparing prone and 
supine measures of coronary physiology across the same stenosis 
3) To measure coronary flow in prone and supine patient position and compare it to pressure 
measurements across the same stenosis 
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Data from this chapter has been published in a peer reviewed journal (Al-Janabi et al., 2019). 
For the full manuscript, please see appendix G.  
 
This chapter describes the methodology and corresponding results of data collected from CT 
coronary angiograms retrospectively. The data was used to inform the research team if the 
clinical magnitude of hydrostatic effect is measureable and demonstrable in vivo  
 
Data was retrospectively collected from 100 CT coronary angiograms conducted at the Essex 
Cardiothoracic Centre from August 2016 to April 2017.  
 









• Previous coronary artery bypass grafting 
• Left dominant coronary circulation 
• Poor image acquisition or visualisation of the coronary arteries 
• Upper rim of the CT table not visible (reference point for measurement) 
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2.2 - CT Coronary Angiogram 
 
 
The CT coronary angiogram was conducted by trained radiographers at the Essex Cardiothoracic 
Centre using a 64 slice CT scanner. All patients had adequate breath holding, with a heart rate of 
less than 80 beats per minute. Intravenous metoprolol was used to achieve adequate heart rate 
control if necessary. 
 
Vertical Height Measurement 
 
 




1. Left coronary ostium 
2. Ostial left anterior descending (LAD) 
3. Distal LAD - at its highest point 




1. Right coronary ostium 
2. Right coronary artery bifurcation 
3. Distal posterior descending artery (PDA) - at its highest point 
4. Distal posterior left ventricular artery (PLV) - at its lowest point 
 
The upper rim of the CT table was used as a fixed position, by which the vertical height of these 
points were measured. Figure 17 demonstrates a measurement taken from the left main stem. The 
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CT table is curved, so the lowest point is the reference point.  
 
 
Figure 17 - Height Measurement Using Coronary CT - demonstration of a vertical measurement 
between the rim of the CT table, and the left main, stem using an electronic measuring calliper. 
The image is a transverse section. 
 
Agfa IMPAX™ was used to view and measure distance on a hospital workstation. 
Measurements were taken using a contrast enhanced transverse view of the heart. The furthest 
point where contrast penetrated was the measurement point for distal recordings. Subtracting 
height values would then give the height difference two desired points.  





The height in centimetres multiplied by 0.8 provided hydrostatic effect in mmHg. This change 
for each measurement point will be factored into 100 randomly generated FFR values between 
0.75 and 0.85 using Microsoft Excel ™. The resulting corrected FFR (cFFR) will be compared to 
the original FFR. The percentage of these values above and below the threshold of 0.8 will be 
compared between FFR and cFFR to determine percentage discordance. 
 
2.4 - Statistical Analysis 
 
 
Continuous variables are expressed as mean values plus or minus standard deviation. Categorical 
variables are described as numbers and percentages. Statistical significance of coronary height 
variations was calculated using the Student t test. 
 
 
2.5 - Results 
 
 
2.5.1 - Patient Demographics 
 
 


































Table 3 - CT Data Patient Demographics. 
 
 
Two circumflex measurements and five PLV measurements were un-recordable. 15% of 
measurements in the PDA were un-recordable due to poor contrast visualisation. 
 
2.5.2 - Vertical Height Measurements 
 
 
Table 4 summarises the distance from the upper rim of the CT table to the specific point in the 
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artery. After the LCA and RCA ostium, each subsequent measurement in the left or right system 
is compared to the respective ostium for statistical significance. The only non significant 




Mean height from Upper Rim of CT 





   
LCA Ostium 170.0  ±19.6 N/A 
LAD Ostium 167.9    (±19.6) 0.06 
Distal LAD 222.5    (± 28.3) <0.0001 
Distal Cx 136.4    (± 20.4) <0.0001 
   
RCA Ostium 193.8    (± 21.1) N/A 
RCA bifurcation 175.6    (± 28.3) <0.0001 
Distal PDA 212.1    (±-30.7) <0.0001 
Distal PLV 136.4    (±-26.1) <0.0001 
 
Table 4 - CT Height Data. Multiple measurement points referenced from the upper rim of the CT 
table in millimetres. LCA - Left coronary artery, LAD - left anterior descending artery, Cx - 
Circumflex artery, RCA - right coronary artery, PDA - posterior descending artery, PLV - 
posterior left ventricular artery. The results are presented as mean ± standard deviation in mm. 
Figure 18 demonstrates the height from the respective ostium, to the measurement point. For LAD 
ostium, distal LAD and distal Cx, this is the left coronary artery ostium or left main stem. For RCA 






Figure 18 - Coronary Height Data - Graphical presentation of specific measurement points to 
their respective ostium. LAD = left anterior descending artery, Cx = circumflex, RCA = right 
coronary artery, PDA = posterior descending artery, PLV = posterior left ventricular. 
 
2.5.3 - Effect on FFR 
 
 
Table 5 below shows the height variation converted into pressure difference using a 
0.8mmHg/cm conversion factor for each measurement point. The resulting change in FFR or 

















LAD Ostium Distal LAD Distal Cx RCA
Bifurcation
Distal PDA Distal PLV
Distance  in mm from respective LCA/RCA Ostium



































      






+52.5 -4.2 +0.04 1.0 1.04 
Distal Cx 
 
-33.6 +2.7 -0.3 1.0 0.97 
      
RCA bifurcation 
 
-18.2 +1.5 -0.02 1.0 0.98 
Distal PDA 
 
+18.3 -1.5 +0.02 1.0 1.02 
Distal PLV -57.4 +4.6 -0.05 1.0 0.95 
 
Table 5 - CT Heights to Ostium and Effect On Pressure - The height of measurement points 
within a coronary artery, in relation to their respective coronary ostium and in turn the 
hydrostatic pressure effect. The two columns on the right dictates from physical principles, the 
effect of this height difference on the Pd pressure sensor and FFR given a Pa of 100. The 
resulting is the corrected FFR (cFFR). 
2.5.4 - FFR and cFFR Discordance 
 





% FFR below 
0.8  



























6 94 42.5% 
Distal Cx 
(-0.03) 
72 28 26.5% 
Distal PLV 
(-0.05) 
92 8 46.5% 
Distal PDA 
(+0.02) 
30.5 69.5 15% 
 
Table 6 - cFFR Values Crossing Ischaemic Threshold. The percentage of patients with 'negative' 
or 'positive' FFR results before and after hydrostatic correction in 100 random FFR values 
between 0.75 and 0.85. Substantial change occurs when hydrostatic pressure is corrected for. 
The furthest column on the right shows the percentage of FFR values that cross from positive to 
negative, or vice versa. 
 
 
2.6 - Discussion and Interpretation  
 
 
The findings can be summarised into three points; 





2. Depending on the point of measurement, there is a potential change in FFR of 0.02-0.05, 
when hydrostatic pressure is corrected for. 
 
3. 15% to 46.5% of FFR values between 0.75 and 0.85 re-classified across a treatment threshold 
of 0.8 when correcting for hydrostatic pressure effect. 
 
 
Our patient demographic consisted of younger female patients. 33% of patients had an 
echocardiogram at the time of scanning, with preserved ejection fractions on average (54.8%). 
Before the introduction of updated NICE guidelines in stable chest pain (Chest pain of recent 
onset: assessment and diagnosis | Guidance and guidelines | NICE, 2018), CT coronary 
angiography was used in patients with low to intermediate risk of having coronary artery disease. 
This may explain the trend in demographic toward younger female patients. 
 
 
2.6.1 - Height Variations 
 
 
All measured points were statistically significant when compared to their respective ostium, 
except for the ostial LAD. 
The vertical course of arteries followed expected patterns from known coronary anatomy in all 
cases. No patient was found to have anomalous coronary anatomy. The LCA ostium was 
23.8mm lower than the RCA ostium. The average height measurements from the CT table to the 
distal PLV and distal Cx were equal. Compared to the respective ostium however, the PLV had a 
greater distance, due to the more superior position of the RCA ostium. 
It is important to note that the most distal point in the artery is not always the most superior or 
inferior. An example of this would be in patients who have a 'wrap around' LAD. Here, the LAD 
reaches the left ventricular apex, and the most superior point in its course, before wrapping 
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around the apex and travelling inferiorly for a distance. This has been described in medical 
literature and can occur in up to half of patients (Kobayashi et al., 2015a). 
Although not measured specifically, side branches tended to follow the same vertical course as 
the main vessel they branched from. An example would be the obtuse marginal branches of the 
circumflex (OM). These would bifurcate and often became as inferior as the main branch, albeit 
in a more medial horizontal plane. This is demonstrated in Figure 19. The same applies to the 
diagonal branches of the LAD. 
 
 
Figure 19 - Coronary Branch Points - Illustration of branching points of the circumflex (Cx) and 
left anterior descending artery (LAD). The obtuse marginal (OM) branches of the circumflex 
would often end as inferiorly as the circumflex AV (atrioventricular) branch, meaning equal 
distal measurements in each branch, and potentially hydrostatic effect. The diagonal branches of 
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the LAD would take a more horizontal course, and not reach the same vertical distance as the 
LAD itself.   
 
2.6.2 - Al-Janabi  vs.Härle Data 
 
 
Härle et al published similar CT data recently in an older cohort of patient awaiting TAVI. A 
































































Table 7 - Al-Janabi vs. Härle CT data. Height difference between various coronary points 
calculated using CT coronary angiography. 
 
The measurements between LMS and RCA ostium, LMS to distal LAD and LMS to distal Cx 
were largely similar. There were however more pronounced differences in measurements 
between ostial RCA and distal PLV, and ostial RCA to distal PDA. There could be several 
reasons for this. 
 Firstly, inter-observer measurement variation could play a role in part of the difference seen. 
Secondly, contrast penetration to the distal PDA was not clearly seen in 15% of our CT scans, 
meaning an underestimation of the height variation in our data for this artery. Finally, our study 
demographic consisted of predominantly young female patients with normal aortic valves. The 
demographic of Härle's group, consisted predominantly of elderly patients with severe aortic 
stenosis. The calcification of the aortic valve may alter coronary position in these patients. One 
may also take into consideration other factors such as patient height, which may have varied 
between the two groups. Unfortunately, this was not available for me to collect retrospectively. 
Data from the dynamic pressure simulator in Härle's study also supported the predicted effect of 
changing Pa pressures. As Pa pressure fell below 100mmHg, there was a greater effect on Pd/Pa 
when altering Pd pressure (by changing vertical height in the simulator). The opposite was true 
when Pa pressure was above 100mmHg, with the same change in vertical height resulting in a 
lesser effect (Härle et al., 2017a). The authors state that the effect of hydrostatic pressure on FFR 
or Pd/Pa is inversely proportional to aortic pressure.  
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The mathematical model assumes a Pa pressure of 100, essentially meaning a change in Pd 
pressure cause the FFR to change by the same amount. A drop in distal pressure by 4mmHg, 
equates to a drop in FFR by 0.04, a drop in pressure by 2mmHg equates to a drop in FFR by 
0.02. 
Table 2 from section 1.15.3 highlighted the importance of Pa pressure variation. The lower the 
Pa, the greater the change in Pd will affect FFR.  
This has relevance to the study protocol, as resting measurements will also be collected. There 
may indeed be a difference between hydrostatic pressure effect in resting indices (i.e. resting 
Pd/Pa/iFR) and FFR, as resting indices will not have the effect of adenosine reducing blood 
pressure and therefore a higher Pa value. 
2.6.3 - FFR Magnitude of Effect 
 
 
The magnitude of change (0.02-0.05) may seem small in relation to a possible FFR reading of 0-
1.0. However, lesions can frequently circle the threshold of treatment (currently accepted as 0.8 
for FFR), meaning slight variations may impact clinical decision making (Montalescot et al., 
2013). If one accepts a binary cut-off point, applying correction factors for height seen a 
substantial number of values change their classification from positive FFR values (<0.8) to 
negative, and vice versa. This alone could lead to a significant change in treatment for patients. 
Many operators agree that treatment of a coronary stenosis is not a binary decision and takes into 
account other clinical factors. The effect of hydrostatic effect on an artery, may need to be one of 
these identifiable factors. 
 
2.6.4 - Potential Impact on Clinical Practice 
 
 
A Pd/Pa above 1.0 has anecdotally been noticed at our institution by multiple operators, usually 
in the circumflex artery. This observation is also described in the medical literature, especially in 
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mildly diseased or normal arteries (Nijjer et al., 2016). This is the result of the pressure sensor on 
the wire, lying inferiorly to the proximal pressure sensor. Pd is therefore greater than Pa, and the 
resulting value is greater than 1.0. 
Furthermore, the effect of hydrostatic pressure is seen when comparing similar stenoses in 
superior and inferior arteries. Arteries that are positioned inferiorly had higher average FFR and 
iFR values than those positioned superiorly, despite similar stenosis severities between the two 
groups (Härle et al., 2017a; Davies et al., 2017) . This is shown below (Table 8).   
 
 
Artery Position When 
Supine 




















Table 8 - Superior vs. Inferior Stenosis Position - effect on iFR and FFR. Superior vs. Inferior 
anatomically positioned arteries in a group of 214 coronary stenoses. The % stenoses were very 
similar but FFR and iFR measurements were significantly higher in those arteries positioned 




In daily practice therefore, the position of the wire in the distal coronary artery may have clinical 
importance, and potentially affect the FFR by up to 0.05, assuming a Pa pressure of 100.  
 
2.6.5 - PDA vs. PLV Wire Placement - A Clinical Case Example 
 
 
PDA to PLV distance was shown to be relatively large in both Härle's data and my own (65mm 
and 75.7mm respectively). These branches bifurcate from the main RCA at the crux. Wire 
position in either branch is usually an arbitrary decision in a stenosis at or proximal to the crux. 
Pressure recordings may therefore differ based on the branch chosen due to hydrostatic pressure 
effect across the same stenosis.  A procedure that follows was conducted at the Essex 
Cardiothoracic Centre, and demonstrates such a scenario. 




Figure 20 - Case Study - mid RCA lesion in a 73 year old male with exertional angina. The 
stenosis, PLV (posterior left ventricular artery) and PDA (posterior descending artery) are 
marked with arrows. 
 
The stenosis is situated approximately 30 mm from the crux/bifurcation. The pressure wire could 
be placed in either PLV or PDA. For clinical clarification, FFR and doppler velocity 
measurements were taken in the distal PLV, and distal PDA and subsequently compared. Table 9 













Table 9 - Pressure and Flow Case Study Data. FFR (fractional flow reserve) and doppler flow 
measurements across the right coronary artery stenosis, with the physiology wire placed in the 
PDA (posterior descending artery) and PLV (posterior left ventricular artery). 
 
FFR was technically negative when the wire is positioned in the PLV (0.8). When moved to the 
PDA, the FFR is positive (0.75) suggesting the need for treatment. The PDA is superior to the 
PLV, giving a lower distal pressure and in turn a lower FFR value. Doppler flow did not change 
significantly and falls within the error rate of the doppler measuring technology (Davies et al., 
2006). 
 
2.7 - Limitations 
 
 
2.7.1 - Patient Demographic 
 
 
The patient demographics were clearly of a specific group. The average age was 56 with 68% 
being female. This represents selection bias regarding those patients put forward for a CT 
coronary angiogram in the first instance. Before the update from NICE (Stable angina: 
management | Guidance and guidelines | NICE, 2018), CT coronary angiography was used in 
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predominantly low to intermediate risk patients, as shown in Figure 21 below (BrJCardiol, 
2018). 
 
Figure 21- 2018 NICE Guidelines for Stable Angina - the likelihood of CAD versus investigation 
modality. As show, patients scoring low for coronary artery disease risk, were often investigated 
with CT coronary angiography (from NICE guidelines CG95). 
 
It is expected the group of patients in the study will be a different demographic with more 
coronary artery disease, and predominantly male. This may have an effect on coronary height 
variations, as Härle et al showed sex was a predictor of distance between maximal height 
measurements in the coronary tree (Härle et al., 2017a). The maximum measured height 
difference was greater in men, and interestingly also in those with reduced ejection fractions. 
This may be associated with ventricular dilation, although this was not specifically commented 
upon. In our demographic, composed predominantly of women, the average height variations 




2.7.2 - Coronary Visualisation 
 
 
A proportion of CT scans in the data acquisition period could not be analysed due to poor 
coronary visualisation. The predominant reason for this was inadequate contrast penetration to 
all distal vessels. This may lead to underestimation of the maximal height difference. It must be 
noted that in clinical practice, the distal vessel seen on CT scan may be too distal for wire 
placement, and therefore is less important. 
Coronary calcification did not affect measurement of distal vessel height in this study population. 
 
2.7.3 - Measurement Point 
 
 
Measurements were taken at the most distally visualised point in the artery. In clinical practice, 
the wire may not be placed as distally due to operator preference. 
Human error may also lead to variations in the maximal height measurements. Despite the 
greatest care, it is not unreasonable that two separate researchers may have obtained slightly 
different results, using the same scans. The CT table is also slightly curved, meaning great care 
had to be taken to use the correct reference point each time when measuring the coronary 
arteries. Furthermore, the measurement point in the coronary artery was the central point in the 
lumen, which may lead to small reproducibility errors. 
Whilst the vertical height deviation of a coronary artery from its ostium are gradual, it would 
have been useful to map the rate of change in height, with the horizontal distance from the 




2.7.4 - Mathematical Model 
 
 
Microsoft Excel™ was used to generate 200 random numbers between 0.75 and 0.85. 45.5% 
were below 0.8, and 55.5% were above. The distribution was not equal purely due to chance. 
The model only factors in a single variable to a change in FFR, when in reality, hydrostatic 
pressure is a single potential variable. Whilst independent of stenosis severity, and position in the 
artery, hydrostatic pressure effects may be affected by patient factors such as heart rate and 
systemic blood pressure. This is also the case for FFR measurements in general. 
Hydrostatic pressure calculation uses a conversion factor of 0.8 mmHg/cm of vertical height. 
This is extrapolated from Härle's paper where a dynamic pressure simulator found the conversion 
rate to be 0.77 mmHg/cm using 0.9% saline. In vivo, where blood is the fluid, the assumed 
conversion rate will be higher, owing to blood's higher density, hence 0.8 mmHg is used in the 
model. This is the best estimate known at this time, and hence could be subject to change, 
potentially affecting the calculations within the model. 
Finally, the Pa pressure for all calculations is assumed to be 100 mmHg. At maximal 
hyperaemia, Pa pressure will undoubtedly fall, possibly below 100 mmHg, meaning a greater 
effect when Pd is altered or corrected for due to hydrostatic pressure. The opposite is true if Pa 
pressure is above 100 mmHg, with a lesser effect from hydrostatic pressure altering Pd. 
 
2.8 - Conclusions 
 
 
The distal point in all coronary arteries vary significantly in vertical height from their ostium, yet 
in clinical practice they are assumed to be 'level'. The effect of this height variation is a 
difference in intracoronary pressure between the ostium and distal vessel due to hydrostatic 
forces. Alterations in distal pressure lead to a change in FFR of 0.02 - 0.05 (assuming a Pa 
pressure of 100mmHg). Using a mathematical model and correcting for hydrostatic effect  46.5% 
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of  FFR measurements between 0.75 and 0.85 re-classify (from positive to negative, or vice 
versa) across a given treatment threshold of 0.8. 
Chapter III - Methods and Results from Invasive Physiology 
 
 
3.1 - Method Overview 
 
 
GRAVITY is a prospective observational study conducted at the Essex Cardiothoracic Centre, 
Basildon and Thurrock University Hospitals NHS Foundation Trust comparing supine and prone 
invasive coronary physiology.  
Prone patient position during invasive coronary angiography is a novel concept, with no previous 
guidance in the medical literature. At the time of writing, no evidence existed of instrumentation 
of an artery in a prone patient. I designed the study and wrote the protocol and supporting 
documents, obtained ethical permission and screened and recruited all patients. I collected all 
physiological data during angiography and performed subsequent analysis. The first patient was 
successfully studied at the Essex Cardiothoracic Centre in July 2017. 
There were many technical, safety and ethical considerations which were addressed with careful 
planning and multiple trial runs using staff as practice patients. 
 
3.2 - Primary and Secondary Endpoints 
 
 











• The delta change in velocity recordings, between supine and prone measurements 
 
 
3.3 - Ethical Approval and Study Population 
 
 
3.3.1 - Ethical Approval 
 
 
The study protocol was given a favourable opinion by the East of England - Cambridge South 
Research Ethics Committee on 16th of March 2017. 
 
3.3.2 - Clinical Study Registration 
 
 









The study population consisted of patients with coronary artery disease of 'moderate severity' 
referred to our institution for further assessment of coronary artery severity in the form of a 
'pressure wire'. All were elective day case patients loaded with aspirin and clopidogrel in 
preparation for possible stent implantation. All patients were provided with written study 
information and the chance to ask any questions before giving written consent. They were also 
involved of their right to withdraw at any time, without affecting their medical care. 
Inclusion and exclusion criteria are given below (Table 10), as well as a flowchart summarising 





1. Age > 18 years of age 
 
1. Previous CABG with any 
patent grafts 
 
2. Anginal symptoms or 
evidence of myocardial 
ischaemia 
 
2. Significant left main stem 
stenosis 
 
3. Stenosis >50% on coronary 
angiogram or CT coronary 
angiogram 
3. Haemodynamic Instability 
 
4. Participant is willing and able 
to give informed consent 
4. Unable to consent 
5. Eligible for PCI 
 




 6. Contraindication to adenosine 
 
 7. Recent acute coronary 
syndrome (ACS) (<48 hours) 
 8. Pregnancy 
 
 9. Unable to lie prone 
 




11.  Severe renal dysfunction 
(eGFR <30mls/min) 
 
Table 10 - Inclusion and exclusion criteria. PCI = percutaneous coronary intervention, CABG = 









Recruitment based on finding of stenosis >50% and symptoms 
of ischaemia 
Inclusion and exclusion criteria 
satisfied 




For continuing care as 
per Essex CTC 
***Patient starts Prone*** 
 
Measure physiology 
Turn patient supine and measure 
physiology. 
Complete procedure as per 
operator ± PCI 
GRAVITY Study 
Physiology Data Collection Pathway 
 




3.4 - Sample Size Calculation and Statistical Analysis 
 
 
Sample size was calculated for 80% power, and for a p value of <0.05, using a paired T-test to 
meet the primary endpoint. GPower3™ statistical software calculator was used for the power 
calculation (Faul et al., 2007).  
In our study, a standard deviation of the difference in the mean of 0.04 is used for FFR, as has 
been for previous studies assessing change in coronary artery physiology (Ladwiniec et al., 
2015). The minimum difference we expect to see between prone and supine physiology 
measurements using the mean is 0.06. This calculated minimum difference is extrapolated from 
CT coronary data (See Data from Chapter II), where the smallest height difference (Circumflex 
artery) equates to a 0.03 change in one position. When the patient is turned from prone to supine, 
this number will in theory double, meaning a total change of 0.06. 
UsingGPower3™, for a two tailed, matched T-test, with 80% power and a 5% error rate, the 
minimum sample size required is 6. As three coronary arteries are being included, 6 
measurements per artery, equates to 18 patients overall as a minimum. Ethical approval was 
obtained for 30 patients in total, with regular data review during recruitment. The calculation 
from GPower3™ is shown below in Figure 23. 
 
 
Figure 23 - Power Calculation - using GPower3™. Effect size was calculated using difference 
between the means of matches pairs (0.06) and standard deviation (0.04). 
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Continuous variables are presented as means with standard deviation. Categorical variables are 
presented as numbers and percentages. Delta change in measurements between prone and supine 
position are given a positive delta if the direction of change is as expected based on physical 
principles. A negative value is given if against. Correlation between height differences and delta 
change in pressure-based indices was assessed by Spearman's correlation/ 
All statistics were calculated using IBM SPSS® statistics software. 
 
3.5 - Study Challenges 
 
 
Supine standard measurements are a daily occurrence at our institution. Prone position is 
completely novel, and as such was carefully planned. 
 
3.5.1 - Vascular access 
 
 
Safe femoral access is not possible when prone. Left radial access was chosen as the most simple 
and safe site. 
|The sheath is inserted with the patient prone and wrist pronated at the standard right side of the 





Figure 24 - Prone Positioning - The left arm is being draped and readied for arterial puncture. 





Figure 25 - Prone Positioning 2- Patient being positioned prone, with two members of the team 
on each side for safety.  
 
3.5.2 - Turning Manoeuvre 
 
 
Prone positioning has been used for ventilated patients suffering from acute respiratory distress 
syndrome (ARDS) (Kallet, 2015). Intensive care staff kindly offered training to catheter 
laboratory staff.  
 The patient was treated as a 'sedated' patient and prompted not to assist or move the left arm 
(holding the radial sheath). When the study protocol required turning from prone to supine, two 
slide sheets are inserted under the patient and pulled in the correct direction. Two members of 
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staff are situated on each side of the table to ensure the patient cannot fall off the table and a 
central position is maintained. Before turning, all coronary catheters, physiology wires and other 
equipment attached are removed from the patient. Cannulae could be temporarily disconnected 
and reconnected once turned. ECG leads were not removed but could be adjusted if displaced 
during repositioning.  
Displacement of the sheath was a possibility during turning, and the team had to be observant 
regarding this issue. A checklist of events is given in Appendix D. 
 
3.5.3 - Procedural Considerations 
 
 
Once the patient is in a prone position, the procedure is largely the same as in a supine position. 
Puncturing the left radial artery in a prone patient, with a pronated hand, is anatomically different 
to standard procedure. Operators had to adjust their puncture technique to compensate for this.  
Secondly, the image and position of the coronary arteries were reversed. For example, the right 
coronary artery originated on the right side of the screen (as opposed to the left side in standard 




Figure 26 - Prone Angiographic Projection - Standard angiographic appearance of the right 
coronary artery in a supine patient on the left. On the right, the right coronary artery is seen in a 
prone patient with the origin appearing from the opposite side of the screen.  
 
Cranial and caudal views were also reversed. Therefore, the operators and radiographer had to 
reverse normal projection positions to visualise specific arteries (Appendix E).  
There were other technical considerations. Firstly, accessory equipment such as ECG's and 
cannulae had to be tested to make sure their length was adequate when a patient was prone. 
Oxygen nasal cannula and masks were also tested to ensure oxygen delivery was safe and 
uncompromised in the prone position. 
 
 
3.5.4 - Safety and Practical Considerations 
 
 
Our utmost consideration was for the safety and comfort of our patients. Pillows and hand gel 
cushions were placed to ensure optimal comfort during the procedure. As part of the pre-
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screening, patients were asked of any difficulties lying prone and any measures that could be 
taken to ease this. In some cases, the patient was asked to lie themselves prone outside in 
recovery before the procedure, to try and anticipate any issues with lying in this position.  
Nausea is sometimes experienced during angiography. Being prone actually reduced the risk of 
aspiration and made management of vomiting somewhat easier. 
Defibrillation pads could be placed anterior and posterior or posterior and lateral or (instead of 
anterior and lateral) when the patient was prone. If defibrillation did not restore spontaneous 
circulation, chest compressions would be inefficient when prone. The team would therefore 
perform a turning manoeuvre in the event of a cardiac arrest requiring CPR. The estimated delay 
in turning is 10-20 seconds at maximum. 
Asystole or severe bradycardia is a transient phenomenon occurring in approximately 5% of 
cases (Landau et al., 1994). Causes include contrast injection, medication or temporary occlusion 
of a coronary artery. If this occurred, the patient would be positioned supine immediately. 
 
 
3.6 - Study Protocol 
 
 
3.6.1 - Prone Component 
 
 
Once arterial access is gained via the left radial artery (and verapamil or nitrate has been given 
intra-arterially to avoid vasospasm), a standard guidewire with overlying 6 French catheter of the 
operators choice, is passed into the aortic root. Once the stenosis was adequately visualised, 




3.6.2 - Physiology Wire 
 
 
Pressure and velocity measurements were recorded in the coronary artery of interest. A 
Combowire™ made by Volcano Corporation (San Diego, California, United States) was used in 
all cases. This was connected to a Combomap© device, to capture the outputs from the wire. 
 Pressure sensors on the wire are placed at 1.5cm from the wire tip, while flow sensors are at the 




Figure 27- ComboWire - Illustration of the Combowire (Image from Volcano Corporation, San 





3.6.3 - Combomap System 
 
 
Unfortunately, our integrated physiology system in the laboratory, even though manufactured by 
Volcano Corporation, was only compatible with a pressure wire, not a pressure and velocity 
wire. Therefore, a standalone unit was used, capable of measuring pressure and velocity outputs 




Figure 28 - Combomap System - used for physiology output data. (Image from Volcano 
Corporation, San Diego, California, USA). 
 
3.6.4 - Physiology Measurements 
 
 
70-100 units per kg of unfractionated Heparin is given prior to physiology wire insertion. 
Measurements were taken on a Combomap™ system (Volcano Corp, San Diego, California, 
United States) connected via a pressure and flow plug, as illustrated above. The Combomap™ 
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system was zeroed at the same time as the laboratory invasive pressure monitoring, at the 
beginning of the case. Pressure is normalised at the coronary ostium. Intra coronary 
gylcerlytrinitrate at a dose of 250-500 micrograms is then administered followed by a saline 
flush of 10ml. This process has remained largely unchanged from its initial experimental 
publication in medical literature (Pijls et al., 1993). Figure 29 shows data collected from a patient 
on the Combomap™ system. 
 
Figure 29 - Invasive Pressure Normalisation - in a GRAVITY patient. Top strip showing the 
patient's ECG, with some minor interference. Bottom strip showing invasive blood pressure (red 
line) normalised with the Combowire™ pressure readings (yellow line). 
 
Once adequately normalised, the wire was passed beyond the stenosis, into the distal vessel. 
Initially the wire was placed as distally as possible. Once in position, slight adjustments in torque 
of the wire were made to give the clearest velocity doppler trace. Resting Pd/Pa and resting flow 
were measured. In some cases, it was necessary to move the wire slightly back or forward to 
achieve a clear velocity trace. The position was noted and fluoroscopically stored for the 
upcoming supine physiology measurements.  
Hyperaemic measurements were taken with the intravenous infusion of 140/mcg/kg of 
adenosine. During hyperaemia, FFR and hyperaemic velocity measurements were obtained. 
Finally, a 'drift check' was conducted to ensure there was no pressure deviation from the original 
normalisation, ensuring the Pd/Pa was 1.0 (±0.02).  Figure 30 shows a hyperaemic trace 
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measured on the Combomap™ system. This is the same patient as Figure 29 previously. This 
concludes the prone aspect of the study protocol. The patient is now turned supine. 
 
Figure 30 - Hyperaemic Pressure and Flow Measurements - from the Combomap™ system. The 
top strip demonstrates the ECG, middle strip shows aortic pressure (blue) versus wire pressure 
(yellow) in the distal vessel. The bottom strip is an outline of the hyperaemic flow in the distal 
vessel measured by the wire. The FFR in this vessel was 0.85 in the prone position. 
 
3.6.5 - Supine Component 
 
 
Supine protocol is identical to prone. The wire was placed as identical a position as it was during 
prone angiography. Side branches and anatomical landmarks were used as a guide.  
The operator is given supine FFR measurements as a diagnostic aid. No input or guidance was 





3.6.6 - Post Procedure and Recovery 
 
 
No extra precautions were taken post procedure or during recovery. The patient was observed in 
recovery on a cardiac monitor over the next 4 to 6 hours. Once reviewed by clinical staff 
(including a post procedure ECG), the patients were allowed home the same day. Contact details 
were left to allow patients to liaise with the research team if there were any further issues. No 
follow-up procedures or investigations were organised as part of the study. Patients exited the 
study once angiography was complete. 
 
3.7 - Midpoint Protocol Changes 
 
 
After the tenth patient, the study team reviewed all results and implemented slight changes to the 
protocol, within ethical limits. 
 
3.7.1 - Clinical Measurement Point 
 
 
A second FFR measurement point was added during hyperaemia. The operator was asked to 
choose a point in the artery where they would clinically place the wire. For one artery therefore, 
a distal FFR and clinical FFR were measured. The reason for this change is to assess whether a 
more proximal wire position would still be significant, given the expected lesser effect of 
hydrostatic pressure. 
In some cases, where the coronary stenosis was very distal, the distal wire position was the same 




3.7.2 - Left Lateral View and Vertical Height Measurement 
 
 
A ninety-degree left lateral X-ray picture was taken in a subset of patients to assess vertical 
height from wire to aorta. This is the similar to the pre-study coronary CT height data, but 
directly from angiography. This change was implemented to try and identify a correlation 
between vertical height and the change in Pd/Pa, iFR and FFR. Figure 31 is an example of a 
measurement acquisition. 
 
Figure 31 - Guide to Wire Measurement - in the left lateral x-ray view between the guide 





3.8 - Data Analysis 
 
 
Data was analysed using a software program called Study Manager™ (Volcano Corporation). 
Optimal tracings for resting and hyperaemic indices were used to obtain: 
1. Resting distal pressure over aortic pressure (Pd/Pa) 
2. iFR 
3. Resting velocity 
4. Hyperaemic Pd/Pa (also known as fractional flow reserve) 
5. Hyperaemic velocity 
 
Five cardiac cycles were averaged to give the above values (apart from iFR which required ten 
cycles), which were imported into an Microsoft Excel™  for further statistical analysis. Flow and 
pressure measurements were taken, whenever possible from the same five beat sample, as long 
as quality was adequate for both.  Mean values were used for pressure and velocity recordings 




QCA (Quantitative Coronary Analysis) was used to measure lesion length and stenosis 
percentage on a laboratory work-station. It was also used to measure aorta to wire distance. 
 
3.9 - Statistical Analysis 
 
Normally distributed continuous variables are presented as means with standard deviation. 
Categorical variables are presented as numbers and percentages. Data was compared for 
statistical significance using a Student’s t test for matched pairs. Significance was calculated for 
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a p value of <0.05. Statistics were calculated using IBM SPSS® statistics software. SPSS was 
also used to calculate a Spearman correlation between two sets of data. 
 
3.10 - Outcome Measures 
 
 




1. Change in pressure-based measurements (Pd/Pa, iFR and FFR) when prone and supine. 
 




1. Correlation in vertical height (wire to aorta on QCA) and change in pressure-based 
measurements (protocol change during recruitment). 
 
2. Change in pressure-based measurements (Pd/Pa, iFR and FFR) when the wire is position 






3.11 - Results Overview 
 
 
The results in this chapter will be divided into the following sections: 
 
1. Patient Demographics 
 
2. Angiographic data 
 
3. Resting Indices (Pd/Pa, iFR) 
 
4. Hyperaemic Indices (FFR) 
 
5. Velocity / Flow measurements 
 
 
3.12 - The First Patient 
 
 
The first patient was recruited on the 14th of July 2017. 
 
3.13 - Patient Demographics 
 
 
Twenty-one patients were recruited with twenty three coronary lesions, between July 2017 and 
August 2018. Ten LAD, seven Cx and six RCA lesions were included in analysis.  
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Patient demographics are summarised in table 11 below. All patients were male. Three female 
patients declined study participation. Two patients had two lesions assessed as part of one 
procedure. One with a lesion in the LAD and PDA, a second with PLV and Cx. All right 
coronary lesions were in a dominant vessel. 
One patient suffered a physiology wire related dissection in side branch of a main vessel. This 
was treated conservatively with no clinical sequelae. The patient was discharged home the same 




Total (%) LAD (%) Cx (%) RCA (%) 
Total Number 
 
23 (100) 10 7 6 
Age 
 
63 65 61 63 
Male 
 
23 (100) 10(100) 7 (100) 6 (100) 
Height (cm) 
 
174 174 176 170 
Smoking 
 
1 (4) 0 (0) 1 (14) 0 (0) 
Diabetes 
 





10 (43) 5 (50) 1 (14) 4 (66) 
Hypercholesterolaemia 
 
11 (48) 4 (40) 3 (43) 4 (66) 
Family History 
 
2 (9) 1 (10) 0 (0) 1 (17) 
Ejection Fraction 
 
52 52 51 54 
% Stenosis* 
 
50 43** 50 63** 
Complications 
 
1 (4) 1 (10) 0 0 
Adverse Events (re-
admission, MI, stroke, 
death) 
 
0 0 0 0 
 
Table 11 - Patient Demographics - In Vivo Data. Divided per artery. *Right coronary artery 
stenosis was significantly higher on angiographic QCA compared to the LAD. 
 
On average, LAD lesions were less angiographically severe compared to the overall average 
(58% vs. 63%) and RCA lesions were more stenosed (78% vs. 63%). The LAD was significantly 
less stenosed on QCA when compared to the RCA (p<0.05). 
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3.14 - Lesion Characteristics 
 
 
Specific lesion data is summarised below per artery studied (Table 12). Stenosis percentage was 
calculated using QCA (quantitative coronary analysis). 
 
Case Number % Stenosis Length (mm) Position of Lesion 
LAD 
1 48 17.9 Proximal 
4 52 10.5 Proximal 
7 51 13 Proximal 
9 43 21.2 Proximal 
10 41 6.6 Proximal 
11 10 4.1 Mid 
15 43 4.5 Proximal 
16 38 10.7 Mid 
17 60 6.8 Proximal 
18 43 8.6 Mid 






% Stenosis Length of Lesion 
(mm) 
Position of Lesion 
2 44 13.2 Mid 
3 57 14 Distal 
6 44 22.8 Mid 
8 61 4.9 Proximal 
21 46 10.5 Proximal 
22 55 22.3 Mid 
23 46 5.0 Mid 
Mean (± SD) 50.0 (± 7.0) 13.2± 7.3) - 
Right Coronary Artery 
Case Number 
 
% Stenosis Length of Lesion 
(mm) 
Position of Lesion 
5 52 19.6 Mid 
12 47 5.3 Distal 
13 70 11.9 Mid 
14 70 11.9 Proximal 
19 55 12.0 Distal 
20 84 5.2 Distal 




Table 12 - Stenosis Data for All Cases 
Overall five patients of twenty three were treated with coronary stents following measurement of 




Artery FFR Treatment 
4 
 
LAD 0.72 3.0 x 16 Synergy DES 
5 
 
RCA 0.62 3.5 x 20 Synergy DES 
7 
 
LAD 0.64 3.0 x 24 Synergy DES 
17 LAD 0.54 2.75 x 38 Xience DES and 3x 8 
Xience DES overlapping 
20 
 
RCA 0.7 2 x 18 Xience DES 
 







3.15 - Guide to Wire Measurement 
 
 
Guide to wire measurement for all arteries are shown in table 14 below. Using the collected 
height data, the estimated pressure change is estimated. Assuming a Pa pressure of 100, the mean 
predicted change in FFR is 0.09 in the LAD, 0.05 in the Cx and 0.05 in the RCA (figure 32). 
 







LAD 66 10.6 
11 
 
LAD 52 8.4 
12 
 
PLV 33.4 5.4 
13 
 
PLV 50 8 
14 
 
PDA 11.1 1.8 
15 
 
LAD 53.5 8.6 






LAD 68.1 10.8 
18 
 
LAD 65.3 10.4 
19 
 
PLV 46.5 7.4 
20 
 
PLV 20.4 3.2 
21 
 
CX 35.9 5.8 
22 
 
CX 29.3 4.6 
23 
 
CX 27.7 4.4 
 
Table 14 - Guide to Wire Data. Measurements in mm, and the estimated hydrostatic effect. The 
vertical distance should double (x 2) when the patient changes position from supine to prone, as 





Figure 32 - Estimated Hydrostatic Effect - calculated from mean guide to wire measurement in 
mmHg across all coronary arteries ± standard deviation. Mean LAD = 9.3 mmHg, Cx = 4.9 
mmHg, RCA = 5.2 mmHg.  
 




3.16.1 - Delta Change 
 
 
Prone and supine pressure-based indices are compared to produce a delta change. For each 
artery, there is a predicted direction of change. For example, an LAD is situated inferiorly in a 

















Estimated Hydrostatic Effect (mmHg)
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therefore expect the pressure measurement to drop when moving from prone to supine and vice 
versa. This is the expected direction of change. 
 If the change seen is in the predicted direction, the calculated delta change will be allocated a 
positive value. A change in the opposite direction of expected change will be allocated a negative 
delta. This is for all pressure-based indices. A summary of the expected direction of change in all 









Higher Lower Decrease 
Cx 
 
Lower Higher Increase 
PDA 
 
Higher Lower Decrease 
PLV 
 
Lower Higher Increase 
 
Table 15 - Anticipated Direction of Change. This is the expected direction of change and is 





3.16.2 - Pd/Pa 
 
Prone versus supine data from all Pd/Pa measurements is presented table 16. The mean delta 
change between positions was 0.05 (p < 0.0001). Figure 33 shows superior versus inferior artery 
position Pd/Pa across all vessels. One cannot compare prone and supine positions across all 
vessels simultaneously, as some are inferior when prone and some superior when prone (and vice 
versa). Superior position is expected to produce lower pressure-based values.   
Mean superior vs. inferior Pd/Pa was 0.91 vs. 0.96 respectively (p < 0.001). Each group of 













0.96 (0.07) 0.88 (0.09) 0.08 (0.04) 0.0006 
Circumflex (7) 
 
0.93 (0.03) 0.98 (0.02) 0.05 (0.04) 0.009 
RCA-PDA(2) 
 
0.93 (0.03) 0.91(0.06) 0.02 (0.02)  
0.032 
 RCA-PLV (4) 
 
0.91 (0.07) 0.98 (0.02) 0.07 (0.05) 
All (± SD) (23) 
 




Table 16 - Prone vs. Supine Pd/Pa. Prone mean Pd/Pa and supine mean Pd/Pa with delta 
change and standard deviation.  
 
Figure 33 - Pd/Pa of Superior vs. Inferior artery position. Mean values are in red. The results 
are statistically significant. (p<0.05). 
 




































Superior Position Inferior Position
Pd/Pa - superior vs. inferior artery position
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Left Anterior Descending Artery Measurements 
 
Table 17 and figure 34 show Pd/Pa in all cases of LAD stenosis. Prone Pd/Pa was 0.96 vs. 0.88 


















P = 0.0006 
4 
 
0.97 0.87 0.10 
7 
 
0.95 0.86 0.09 
9 
 
1.02 0.92 0.10 
10 
 
1.03 0.93 0.09 
11 
 
1.02 0.97 0.05 
15 
 





0.97 0.95 0.02 
17 
 
0.78 0.67 0.11 
18 
 
0.95 0.84 0.11 
Mean (±SD) 0.96 (0.07) 0.88 (0.09) 0.08 (0.04)  
 
Table 17 - LAD Pd/Pa. Delta change in Pd/Pa between prone and supine positioning in the left 




Figure 34 - LAD Pd/Pa - between prone and supine positioning. Mean values are in red. The 
results are statistically significant. (p<0.05). 
 
Circumflex Artery Measurements 
 
Table 18 and figure 35 compare Pd/Pa in all cases of Cx stenosis. Prone Pd/Pa was 0.93 




































Prone Pd/Pa Supine Pd/Pa Delta Change  
2 
 












0.96 0.99 0.03 
6 
 
0.95 0.97 0.02 
8 
 
0.92 0.99 0.07 
21 
 
0.86 0.98 0.12 
22 
 
0.94 0.96 0.02 
23 
 
0.94 1.0 0.06 
Mean (±-SD) 
 
0.93 (0.03) 0.98 (0.02) 0.05 (0.04) 
 
Table 18 - Cx Pd/Pa. Delta change in Pd/Pa between prone and supine positioning in the 







Figure 35 - Cx Pd/Pa Delta Change - between prone and supine positioning. Mean values are in 
red. The results are statistically significant. (p<0.05). 
 
Right Coronary Artery Measurements 
 
Table 19 and Figure 36 summarise all RCA data. The mean delta change of 0.05 was statistically 




















Circumflex Artery - Pd/Pa
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Case Number Prone Pd/Pa Supine Pd/Pa Delta Change  
5 (PDA) 
 







P = 0.032 
14  (PDA) 
 
0.95 0.95 0.00 
PDA Mean (+SD) 
 
0.93 (0.03) 0.91 (0.06) 0.02 (0.02) 
12 (PLV) 
 
0.96 0.99 0.03 
13 (PLV) 
 
0.86 0.96 0.10 
19 (PLV) 
 
0.9 0.93 0.03 
20 (PLV) 
 
0.89 0.97 0.09 
PLV Mean (±SD) 
 
0.91 (0.07) 0.98 (0.02) 0.07 (0.05) 
PLV and PDA 
Mean (± SD) 
  0.05 (0.04)  
 
Table 19 - RCA Pd/Pa. Delta change in Pd/Pa between prone and supine positioning in the right 








3.16.3 - Instantaneous Wave Free Ratio (iFR) 
 
 
iFR data across all arteries is shown in Table 20. All iFR data is shown in figure 37, which 
compares superior to inferior artery position. The mean delta change in iFR was 0.06 (p < 























Right Coronary Artery Pd/Pa
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remaining 22 measurements. Mean superior vs. inferior iFR was 0.87 and 0.93 respectively. 




Prone iFR Mean 
(±SD) 







0.91 (0.16) 0.85 (0.14) 0.06 (0.07) 0.02* 
Circumflex (7) 
 
0.90 (0.05) 0.97 (0.03) 0.07 (0.04) 0.01* 
RCA-PDA(2) 
 




0.87 (0.10) 0.94 (0.04) 0.07 (0.07) 
All (±SD) (22)** 
 
- - 0.06 (0.05) <0.0001* 
 
Table 20 - Prone vs. Supine iFR. Prone mean iFR  and supine mean iFR with delta change and 
standard deviation. * represents statistical significance. **It was not possible to calculate iFR 





Figure 37 - Superior vs. Inferior iFR. Mean values are in red.  The results are statistically 
significant. 
 
Data grouped per artery is shown below. 
 































Superior Position Inferior Position
iFR - superior vs. inferior artery position
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In the left anterior descending artery, prone vs. supine iFR was 0.91 vs. 0.85 respectively. The 



















P = 0.02 
4 
 
0.91 0.83 0.08 
7 
 
0.92 0.84 0.08 
9 
 
1.02 0.89 0.13 
10 
 
1.07 0.89 0.18 
11 
 
1.01 0.97 0.04 
15 
 
0.94  0.92 0.02 






0.5 0.5 0 
18 
 
0.86 0.73 0.13 
Mean (±SD) 0.91 (0.15) 0.85 (0.14) 0.06 (0.06) 
 
Table 21 - LAD iFR. Delta change in iFR between prone and supine positioning in the left 






Figure 38 - LAD iFR Delta Change - between prone and supine positioning. Mean values are in 




In the circumflex artery, prone vs. supine iFR was 0.90 vs. 0.97 respectively, with the mean 































Left Anterior Descending Atery - iFR
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P = 0.01 
3 
 
0.97 0.98 0.01 
6 
 
0.92 0.95 0.03 
8 
 
0.89 0.99 0.10 
21 
 
0.80 0.96 0.16 
22 
 
0.90 0.92 0.02 
23 
 
0.92 1.0 0.08 
Mean (±SD) 
 
0.90 (0.05) 0.97 (0.03) 0.07 (0.05) 
 
Table 22 - Cx iFR. Delta change in iFR between prone and supine positioning in the circumflex 





Figure 39 - Cx iFR Delta Change between prone and supine positions. Mean values are in red. 
Results are statistically significant (p=0.01). 
 
Right Coronary Artery 
 
The mean delta change of 0.04 for both PLV and PDA was not statistically significant. Table 23 




























Prone Pd/Pa Supine Pd/Pa Delta Change  
5 (PDA) 
 








P = 0.19 
14  (PDA) 
 
0.92 0.93 -0.01 
PDA Mean (+SD) 
 
0.85 (0.10) 0.85 (0.11) 0.00 (0.02) 
12 (PLV) 
 
0.97 0.99 0.02 
13 (PLV) 
 
0.77 0.92 0.15 
19 (PLV) 
 
0.87 0.91 0.04 
20 (PLV) 
 
N/A N/A N/A 
PLV Mean (±SD) 0.87 (0.10) 0.94 (0.04) 0.07 (0.07) 
 
PLV and PDA 
Mean (±SD) 






Table 23 - RCA iFR. Delta change in iFR between prone and supine positioning in the right 
coronary artery. The results are not statistically significant (p>0.05).  
 
 
Figure 40 - RCA iFR Delta Change between prone and supine positioning. Mean difference is 
not statistically significant (p>0.05). 
 
3.16.4 - Fractional Flow Reserve 
 
 
Fractional flow reserve across all arteries is summarised in table 24 and figure 41. The mean 
change in FFR was 0.06 (p <0.0001). Superior vs. inferior FFR was 0.78 vs. 0.84 respectively. 























Prone FFR Mean 
(±SD) 







0.86 (0.11) 0.77 (0.14) 0.09 (0.07) 0.003* 
Circumflex (7) 
 
0.82 (0.06) 0.87 (0.07) 0.05 (0.03) 0.006* 
RCA-PDA(2) 
 




0.82 (0.10) 0.86 (0.08) 0.04 (0.03) 
All (± SD) (23) 
 
- - 0.06 (0.04) <0.0001* 
 
Table 24 - Prone vs. Supine FFR. Prone mean FFR and supine mean FFR with the delta change 






Figure 41 -FFR Delta Change - Superior vs. Inferior. Mean values are in red. Results were 
statistically significant - p=<0.0001.  
 
 
Left Anterior Descending Artery 
 
In the LAD,  mean prone versus supine FFR was 0.86 vs. 0.77 respectively. The delta change of 




















































Prone FFR Supine FFR Delta Change  
1 
 










P = 0.0027 
4 
 
0.86 0.72 0.10 
7 
 
0.82 0.64 0.18 
9 
 
0.97 0.84 0.13 
10 
 
0.95 0.85 0.10 
11 
 
0.97 0.91 0.06 
15 
 
0.72 0.75 -0.03 
16 
 
0.97 0.89 0.08 
17 
 
0.66 0.54 0.12 




Mean (± SD) 
 




Table 25 - LAD FFR. Delta change in FFR between prone and supine positioning in the left 
anterior descending artery. The results are statistically significant (p<0.05) 
 
 
Figure 42- LAD FFR Delta Change between prone and supine positioning. Mean values are in 






































FFR in the circumflex artery, prone vs. supine was 0.82 vs. 0.87 respectively. This delta change 
was statistically significant. Table 26 and figure 43 summarise the results. 
 
 
Case Number Prone FFR Supine FFR Delta Change  
2 
 








P = 0.0056 
3 
 
0.85 0.84 -0.01 
6 
 
0.87 0.91 0.04 
8 
 
0.86 0.91 0.05 
21 
 
0.77 0.83 0.06 
22 
 
0.73 0.76 0.03 
23 
 
0.90 0.96 0.06 




Table 26 - Cx FFR. delta change in FFR between prone and supine positioning in the Circumflex 
artery. One delta changed the opposite direction as anticipated. Results are statistically 
significant (p <0.05). 
 
 
Figure 43- Cx FFR Delta Change between prone and supine positioning. Mean values are in 





























Circumflex Artery - FFR
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Right Coronary Artery 
 
Delta change between positions in the RCA was 0.04 (p < 0.05). Table 27 and figure 44 





Prone FFR Supine FFR Delta Change  
5 (PDA) 
 
0.68 0.62 0.06  
14  (PDA) 
 
0.82 0.75 0.07  
PDA Mean (±SD(+) 
 
0.75 (0.10) 0.69 (0.10) 0.07 (0.01)  
12 (PLV) 
 
0.89 0.91 0.02 P = 0.004 
13 (PLV) 
 
0.74 0.80 0.06  
19 (PLV) 
 
0.73 0.77 0.04  
20 (PLV) 
 
0.68 0.70 0.02  
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PLV Mean (± SD) 0.82 (0.10) 0.86 (0.08) 0.04 (0.03)  
 
Table 27 - RCA FFR. Delta change in FFR between prone and supine positioning in the right 





Figure 44 - RCA FFR Delta Change between prone and supine position. The results are 



























3.16.5 - FFR Clinical Measurement Point 
 
 
Left Anterior Descending Artery 
 
Measurements at the clinical point in the LAD are shown below. Prone FFR vs. supine FFR was 
0.91 vs. 0.85 respectively, giving a mean change of 0.06. These values were statistically 
















Case Number Prone FFR Supine FFR Delta Change  
9 
 
1.0 0.93 0.07  
10 
 
0.98 0.93 0.05  
11 
 
0.95 0.91 0.04  
15 
 
0.89 0.86 0.03 P = 0.0028 
16* 
 
0.97 0.89 0.08  
17 
 
0.66 0.54 0.12  
18* 
 
0.92 0.89 0.03  
Mean (± SD) 0.91 (0.12) 0.85 (0.14) 0.06 (0.03)  
 
Table 28 - LAD Clinical Measurement Point. Clinical measurement points for FFR. All values 
changed in the appropriate direction. The clinical values are statistically significant (p <0.05). 












Only three cases were recorded at the clinical point which is insufficient for adequate statistical 
























Left Anterior Descending Artery - Clinical Measurement Point FFR
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Case Number Prone FFR 
 
Supine FFR Delta Change  
21 
 




P = 0.37 
22 
 
0.89 0.91 0.02 
23 
 
0.94 0.99 0.05 
Mean (± SD) 
 
0.91 (0.03) 0.93 (0.05) 0.02  (0.03) 
 
Table 29 - Cx Clinical Measurement Point 
  
 
Posterior Descending Artery 
 
Only one result was obtained for the PDA.  The clinical FFR did not change and remained at 0.8 
in both positions. 
 
Posterior Left Ventricular Artery 
 
Four cases are available for comparison of clinical measurement points in the PLV, which is 
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insufficient for adequate statistical power (Table 30). The results were not significant statistically 
(p<0.05). 
  
Case Number Prone FFR 
 




0.91 0.99 0.08  
13 
 
0.79 0.79 0.00  
19 
 
0.76 0.75 -0.01 P = 0.35 
20 
 
0.68 0.70 0.02  
Mean (± SD) 
 
0.79 (0.10) 0.81 (0.13) 0.02 (0.04)  
 
Table 30 - RCA Clinical Measurement Point 
 
 
3.17 - Summary of Pressure Based Measurements 
 
 





1. There is a statistically significant difference in prone versus supine position for Pd/Pa 
(delta change 0.05) across all arteries and also when grouped per artery (p<0.05).  
 
2. There is a statistically significant difference in prone versus supine FFR (delta change 
0.06) across all arteries and also when grouped per artery (p<0.05) 
 
3. There is a statistically significant difference in prone versus supine iFR (delta change 
0.06) (p <0.05) across all arteries. 
 
4. All 23 measurements for Pd/Pa changed in the expected direction, apart from two 
measurements, which did not change. 
 
5. All but two iFR measurements changed in the anticipated direction 
 
6. All but three FFR measurements changed in the anticipated direction. 
 
7. There is a statistically significant difference in prone versus supine clinical FFR 




3.18 - Stenosis Re-classification 
 
 
When correcting iFR and FFR by a magnitude of 0.06 (the mean delta change across all 
measurements), 36% of iFR and 26% of FFR measurements re-classify from positive to 










22 8 36% 
FFR (<0.80) 
 
23 6 26% 
 
Table 31 - Stenosis Re-classification. Percentage of values crossing iFR and FFR threshold, 
once corrected for hydrostatic pressure effects. 
 
3.19 - Doppler Measurements 
 
 
Combined and grouped mean doppler velocity between prone and supine positions at rest and 
hyperaemia were not statistically significant (Table 32 and 33). Resting doppler flow superior vs. 
inferior was 17cm/s vs. 15cm/s and 29cm/s vs. 28cm/s at hyperaemia. At rest, the mean delta 













Mean (±SD) - 
cm/s 
Supine Velocity 








15.8 (4.2) 15.4 (3.8) 0.4 (2.9) 0.71 
Circumflex (7) 
 
16.8 (5.4) 21.3 (6.7) 4.5 (7.0) 0.15 
RCA -PDA(2) 
 




11.8 (2.9) 11.5 (2.7) -0.3 (3.1) 
All (23) 
 
- - 1.6 0.31 
 
Table 32- Prone vs. Supine Resting Doppler Flow. There were no statistical differences across 















Mean (±SD) - 
cm/s 
Supine Velocity 








30.6 (9.7) 30.4 (14.1) 0.2 (12.1) 0.96 
Circumflex (7) 
 
31.5 (7.3) 33.5 (11.4) -2 (10.9) 0.64 
RCA -PDA(2) 
 




18.9 (5.5) 19.4 (3.7) 0.5 (3.1) 
All (23) 
 
- - -0.9 0.85 
 
Table 33 - Prone vs. Supine Hyperaemic Doppler Flow. As for resting flow, there were no 






Figure 46 -Doppler Flow Data -  superior versus inferior artery position, at rest and 
hyperaemia. There was no statistical difference between superior and inferior artery position, at 
rest or hyperaemia. Red lines and data labels represent mean values. 
 




















Doppler flow in all Coronary Arteries
p = 0.31 






















9.0 2.0 46.7 20.5 -26.2 
2 15.0 
 
16.0 1.0 39.0 41.3 2.3 
3 22.6 
 
13.2 -9.4 35.3 35.8 0.5 
4 16.7 
 
16.2 -0.5 29.7 26.9 -2.8 
5 16.2 
 
13.8 -2.4 24.8 23.9 -0.9 
6 18.3 
 
15.8 -2.5 29.9 31.3 1.4 
7 16.2 
 
14.0 -2.2 19.1 18.5 -0.6 
8 31.6 
 
17.4 -14.2 41.7 33.8 -7.9 
9 15.4 
 
12.1 -3.3 25.0 24.8 -0.2 
10 17.7 
 
17.4 -0.3 37.8 56.4 18.6 
11 21.2 
 
18.3 -2.9 34.4 48.3 13.9 
12 10.4 
 
14.1 +3.7 22.2 26.5 4.3 
13 15.4 
 
12.6 -2.8 22.6 19.1 -3.5 
14 11.4 
 
11.4 0 17.8 17.1 -0.7 
15 11.7 
 
11.0 -0.7 27.0 22.2 -4.8 
16 19.5 
 
20.5 1.0 42.1 46.0 3.9 
17 13.1 
 
19.3 6.2 16.2 19.0 2.8 
18 19.0 
 





12.8 2.0 17.7 13.9 -3.8 
20 9.4 
 
7.6 -1.8 15.0 16.2 1.2 
21 13.2 
 
9.4 -3.8 13.0 20.6 7.6 
22 28.0 
 
19.0 -9.0 47.2 23 -24.2 
23 20.4 
 






15.0 (4.3) -1.5 (4.7) 
 
28.7 (10.3) 27.9 (11.3) -0.8 (9.8) 
 
  





Figure 47 -Resting and Hyperaemic Doppler flow per artery - prone versus supine ± SD. Delta 







































3.20 - Summary of Doppler Based Measurements 
 
 
In summary, the doppler based measurements demonstrated the following; 
 
1. There was no statistical difference between prone and supine doppler measurements in 
the resting state, in all coronary arteries (in combination and individually). 
 
2. There was no statistical difference between prone and supine doppler measurements 
during steady state hyperaemia in all coronary arteries (in combination and individually). 
 
Results were non-significant for resting and hyperaemic measurements (p= 0.12 and 0.68 
respectively). 
 
3.21 - Guide to Wire Correlation Data 
 
 
3.21.1 - Pd/Pa 
 
 
Each guide to wire measurement has been correlated with the delta change in Pd/Pa for that 
specific stenosis. A scatter plot below is shown in figure 48. Spearman's correlation calculation 







Figure 48 - Height Versus Delta Change in Pd/Pa. Spearman correlation was not significant. 
 
 
3.21.2 - iFR 
 
 
A Spearman's correlation value of 0.402 was obtained for iFR versus guide to wire distance. This 





Figure 49 - Height Versus Delta Chaneg in iFR. Spearman's correlation was not significant. 
 
 
3.21.3 - FFR 
 
 
For FFR versus guide to wire distance resulted in a Spearman's correlation value of 0.528. This 




Figure 50 -Height Versus Delta Change in FFR. Spearman's correlation was not significant. 
 
 
3.22 - Estimated Hydrostatic Effect versus in Vivo Effect 
 
 
Guide to wire measurements from angiography were used to predict a mean hydrostatic effect as 
previously shown in Figure 32. Now table 35 compares the predicted mean change, to the actual 







Change Based on 
Anatomy (mmHg) 
Predicted Change 
in Pd/Pa, iFR and 
FFR 
Actual Change in 
Pd/Pa, iFR and FFR 
LAD 
 
9.3 0.09 0.09 
Cx 
 
4.9 0.05 0.05 
RCA 
 
5.2 0.05 0.04 
 
Table 35 - Predicted vs. Actual Hydrostatic Effect in Vivo 
 
 
3.33 - Summary of All Results 
 
 
1. For all lesions referred for pressure wire, stenosis severity assessed by QCA varied 
significantly between the LAD and RCA. 
 
2. There was a statistically significant difference between mean prone and supine Pd/Pa 
across all arteries  
 
3. There is a statistically significant difference between mean prone and supine iFR across 
all arteries. 
 
4. There was a statistically significant difference between mean prone and supine FFR 




5. There was no statistical change in mean resting or hyperaemic doppler flow between 
prone and supine positions across all arteries. 
 
6. Guide catheter to wire measurements did not significantly correlate with delta change in 


























4.1 - Overview 
 
 
The study hypotheses consisted of two points. The results obtained from clinical data support 
these points in that; 
1. Pressure based  measurement did significantly differ between prone and supine positions 
 
2. Velocity based measurements did not significantly differ between prone and supine 
positions 
 
Discussion topics will follow the below order; 
 
1. Patient Demographics 
 
2. Angiographic Data 
 
3. Pressure-based indices 
 
4. Doppler-based indices 
 
5. Potential Clinical Implications 
 









4.2 - Patient Population / Demographic 
 
The average age for recruited patients was 63 years old, and was similar between artery groups. 
All patients were male, with two female patients declining invitation to participate in the study. 
Male sex is associated with greater vertical height variations between coronary artery and aorta 
(Härle et al., 2017a). 
 
Smoking and diabetes were uncommon overall, 4% and 13% of all patients, whereas 
hypertension and hypercholesterolaemia were more common, 43% and 48% respectively. 
 
All patients had preserved LV function >50%. LV dilation would have likely increased 
hydrostatic effect, as the coronary circulation sits atop an expanding ventricle. Although this is 
an evidence free area, (Härle et al., 2018) showed in a subset of patients with impaired LV 
function, hydrostatic effect was still prominent. 
No adverse events were recorded in the study population. One physiology wire related coronary 
dissection occurred in a side branch. The rate of  iatrogenic coronary artery dissection is very 
low (<0.2%), and can be due to guide catheter trauma, guidewire induced injury, balloon 
inflation or stent implantation (Eshtehardi et al., 2010).  The rate quoted during consent for wire 
related injury to the vessel is 1 in 500. However, data on incidence using specific physiology 
wires is scarce. In a study using the same physiology wire as the current research, the rate of 
dissection is reported to be 1 in 192 in the hands of experienced operators (Waard et al., 2018). 
Physiology wires with doppler measuring equipment have added weight and bulk, and almost 
certainly increase the risk of coronary injury. Along with time and cost implications, this adds to 
the reasons such measures of invasive coronary physiology have been phased out of clinical 
practice. There is now more than ever a reliance on pressure-based equipment due to its safety 
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and efficiency. This reliance and widespread use heighten the importance of recognising 
hydrostatic pressure effect as true confounder. 
 
 
4.3 - Angiographic Data 
 
 
A larger number of patients were referred for pressure wire assessments in LAD lesions. The 
referrer's reasons for this have not been recorded, but is likely due to the anatomical importance 
of the LAD and the myocardial mass supplied (Kim et al., 2016).  
 
4.3.1 - Stenosis Percentage 
 
 
Despite the increased number of referrals for LAD lesions, stenosis as measured by QCA was 
numerically less than the Cx artery and significantly less when compared to RCA lesions. The 
burden of myocardial ischaemia is linked to the benefit seen with revascularisation in that 
territory (Reynolds Harmony R., Picard Michael H. and Hochman Judith S., 2015). This in turn 
could lead to referrals for pressure wire assessment in lesions which are not as severe, but in 
clinically important arteries. Visual assessment however does not correspond strongly with QCA 
(Adjedj et al., 2017). QCA has reasonable diagnostic accuracy when compared to FFR as a gold 
standard but has less reliable outcome data (Budoff et al., 2016). 
Lesion length was similar in all artery groups. Previously, studies have shown a strong 
correlation with lesion length and FFR (López-Palop et al., 2013). Lesion length may be one of 




4.3.2 - Position of Stenosis 
 
 
Of all twenty three lesions, 10 were classified as proximal (first third of the vessel), 9 were 
classified as mid (middle third of vessel), and 4 as distal (final third of vessel). Vertical height 
variation from the ostial vessel generally increases in a gradual fashion along the length of the 
vessel (chapter II). Lesions in the proximal and mid vessel may not alter pressure-based indices 
substantially, as the hydrostatic effect is limited by the vertical height at the point of 
measurement. This concept led the research team to take more proximal measurements after a 
results review (clinical measurement point data). 
Looking at the seven clinical measurement points taken in the LAD specifically, four lesions 
were proximal and three were in the mid vessel. Two of the lesions in the mid vessel used the 
same point in the vessel for clinical (as per operator decision) and study measurement points. 
The mean delta change was 0.06 across these seven lesions. This is clinically very re-assuring, as 
in routine practice, physiological measurements may not be taken as distally as stipulated in the 
study protocol. This subset of results shows that even when the wire is positioned more 
proximally, hydrostatic effect is still relevant. 
 
4.3.3 - Guide to Wire Measurement Correlation 
 
 
Guide to wire measurements did not show a significant correlation with delta change in Pd/Pa, 
iFR or FFR per lesion, but did show a trend towards positive correlation. However, the overall 
mean guide to wire distance measured on QCA, almost exactly predicted mean FFR delta change 
in vivo per artery group (Table 35).  
Guide to wire measurements in this research had inaccuracy. A single LAO measurement, taken 
when prone, was multiplied by two to give an estimated additive hydrostatic effect from the 
supine component. In retrospect, a more accurate method would have been an additional LAO 
measurement when supine, in addition to the prone measurement QCA also has inherent error in 
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measurement (Wunderlich et al., 1998) which may have impacted subsequent correlation 
analysis. The fluoroscopic angle also varied and may not have been exactly 90 degrees LAO in 
each case. Lastly, purely based on patient position, the LAO 90 may not have captured a purely 
perpendicular view of the coronary tree. 
After study recruitment and during data analysis, a study by Härle et al investigated the effect of 
hydrostatic pressure in vivo (Härle et al., 2018), following on from the previous work on 
hydrostatic pressure models (Härle et al., 2017a). This was the first published study in vivo to 
focus on hydrostatic effect. His group measured FFR in the standard supine position, and 
compared FFR measurements with the patient positioned on the right and then left lateral 
position. This work was published after this study's data collection period. 
This is a similar clinical study to the current research, despite different patient positions, and 
pressure-based measurements only (no doppler flow).  Härle's study showed a significant 
correlation between height and FFR change in positions (with a Spearman's correlation value of 
0.694 versus our value of 0.528). With regards to Pd/Pa, Härle's data also showed a significant 
correlation with height (0.604 versus our data of 0.493. QCA was used to measure height 
between the guide catheter and the wire in each position, giving a more accurate correlation than 
the current study. 
Härle also demonstrated, in a similar way to the current research, that the differences seen in 
Pd/Pa, iFR and FFR between supine, left and right sided patient positions, could be abolished by 
adjusting for hydrostatic pressure via mean height measurements on angiography (Härle et al., 
2018). 
An interesting point is the moderate to good correlation per lesion, but an almost exact prediction 
on mean hydrostatic effect per artery group from mean height per artery group measured on 
QCA. This is difficult to explain, but height may not be the only confounding variable in 
pressure-based indices during patient position change. 
Prone positioning has been used as a strategy to treat ARDS for decades. Recently, prone 
positioning has been trailed in patients with COVID-19 (Sartini et al., 2020). When prone, the 
weight of the heart, lungs and abdominal viscera is lifted off the dorsal lung regions, aiding 
ventilation to these areas (Scholten et al., 2017). The weight of the heart itself is thought to add 
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3-5cm H2O (5.5 to 9.3mmHg) of pressure to the underlying tissue (Malbouisson et al., 2000). It 
is not known whether this adds to, and to what magnitude it affects, the hydrostatic pressure 
effect within coronary arteries. If we believe to moderate correlation of vertical height to delta 
change in pressure-based indices, the physical weight of the heart could be a substantial 
contributor. In turn, those with dilated ventricles, may have a greater mass effect as well as 
greater height deviation of coronary arteries from the aorta. Both may present as a significant 
change in hydrostatic pressure compared to supine positioning. 
 
 
4.4 - Pressure Results 
 
 
Pd/Pa, iFR and FFR measurements changed significantly when comparing prone and supine 
measurements. The direction of delta change supported physical principles, with inferior 
readings measuring higher than superior readings in the vast majority of cases. 
 
4.4.1 - Pressure Based Values > 1.0 
 
 
Across Pd/Pa, iFR and FFR readings, there were numerous instances of recordings above 1.0. If 
pressure is truly proportional to flow, as pressure-based indices imply, a value above 1.0 
suggests greater flow distal to a stenosis than at the ostial vessel. This is unlikely to be true and is 
a potential pitfall of using a pressure-based measurements as a surrogate for flow.  
In supine patients, this is phenomenon is normally seen in mildly disease vessels, and usually the 
circumflex artery. Observation of this phenomenon has been recognised by other authors in the 
medical literature (Nijjer et al., 2016), but the potential impact on day to day use of pressure 
based indices, has largely been overlooked. Readings above 1.0 suggest an inherent error in 
measurement before the addition of a stenosis, leading to inaccuracy. 
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The novel aspect of this research is that recordings over 1.0 were frequently seen in the LAD 
when prone. In this instance, the LAD has assumed the position of a circumflex artery (i.e. 
inferior to the aorta) in a standard supine patient. On the contrary, the LAD in a supine patient 
would have a resting value below 1.0, even in a completely disease-free vessel. Again, there is 
inherent error and resting inaccuracy of measurements, due to hydrostatic effect. This error is 
present in all pressure-based methods of assessing coronary stenoses. 
 
4.4.2 - Pd/Pa 
 
 
Resting Pd/Pa has been validated against FFR in large volume trials and has an overall accuracy 
of 80% when compared to FFR. This is comparable to newer resting indices such as iFR 
(Jeremias et al., 2014). The binary 'cut off' point for Pd/Pa is usually 0.9 - 0.92. A change of up 
to 0.11 as seen in some Pd/Pa measurements, could drastically alter decision making in a 
proportion of patients. It is noteworthy that resting Pd/Pa is not routinely used to guide treatment 
alone, especially with iFR and other novel resting indices readily available. 
All Pd/Pa recordings altered in the expected direction based on hydrostatic theory.  
 
4.4.3 - iFR 
 
 
iFR measurements were calculated retrospectively from raw data. One iFR result could not be 
retrospectively calculated, as the raw data trace was too short. Therefore 22 results in total were 
available for analysis. RCA iFR was the only subgroup in which statistical significance was not 
reached, as only five cases were available. All other subgroups of arteries amongst Pd/Pa, iFR 




4.4.4 - FFR and Hyperaemia 
 
 
Hyperaemia is a distinct variable between FFR and iFR or Pd/Pa. On average the Pa pressure did 
vary between resting measurements and hyperaemia. Furthermore, supine Pa pressure was lower 




Prone Pa (mmHg) Supine Pa (mmHg) 







Table 36 - Pa Pressure During Prone and Supine Pd/Pa, iFR and FFR. 
 
As described in section 1.15.3, the Pa pressure is directly related to the hydrostatic effect on 
Pd/Pa and FFR. A lower Pa pressure amplifies the effect of pressure change in the artery when 
calculating Pd/Pa for FFR by directly altering the denominator in the equation. For example, a 
change in Pd of 5mmHg leads to a change in Pd/Pa of 0.07 at a Pa pressure of 80 mmHg, but 
only 0.04 at 120 mmHg. This could be a potential explanation for the difference in FFR delta, 
and Pd/Pa delta.  
Adenosine infusion and hyperaemia is the cause for a drop in Pa when comparing resting indices 
and FFR. The cause of a lower supine Pa compared to prone Pa is uncertain and likely multi-
factorial. As per study protocol, prone measurements were performed first, followed by supine 
measurements after the turning manoeuvre. Therefore, supine measurements, would have 
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potentially had two doses of intravenous nitrates and adenosine. The patient would have also 
been exposed to an increasing length of time on the angiography table, potentially leading to 
greater intravascular depletion. 
One may expect a small variation due to inherent error rates in equipment. FFR has been shown 
to be a highly reproducible measure. Nevertheless, studies analysing paired tests in the same 
artery and stenosis demonstrate a standard deviation of 0.02 between measurements (Johnson et 
al., 2015) in 190 patients. This applies to the current research as the same artery was measured 
twice in differing patient positions.  
 
4.5 - Supporting Evidence in the Clinical Literature 
 
 
Härle and his group conducted the first published in vivo study with left and right lateral 
positioning (Härle et al., 2018). This has already been discussed with relation to guide to wire 
correlation with change in FFR in section 4.3.3. The study was published during this research's 
data collection period. 
In 30 coronary stenoses, there were statistically significant changes in Pd/Pa, iFR and FFR when 
comparing supine measurements, to left and right lateral patient position. No velocity of flow-
based measurements were conducted. Pressure based indices produced larger values when 
inferior to the aorta, compared to superior in the same artery, across the same stenosis. This was 
statistically significant for Pd/Pa, iFR and FFR. These findings mirror our own, despite different 























Table 37 - Delta Change Between Patient Position - Al-Janabi vs. Härle Data. 
 
The magnitude of change in Härle's data is less than the current research. This can be explained 
by the difference in positions between both studies. One may expect a lesser hydrostatic effect 
when positioned laterally, compared to prone. Compared to current research, Härle's group 
rotated partially around the 'axis' of the aorta by 90 degrees, whereas the current research rotated 
180 degrees. Intrathoracic physiology may also vary due to the varying angles of rotation. 
Pd/Pa shows less change than iFR and FFR in both data sets, with iFR and FFR delta change 
being very similar. In Härle's data set 26.7% of FFR lesions changed classification across a 
binary cut-off (0.8) based on the position showing maximum delta change. This is identical to 
the 26% seen in the current research. iFR re-classification in Härle's data was the same at 26.7%, 
but higher in the current research at 36%. The magnitude of change in some stenoses would have 
been amplified in the current research, given the greater effect of hydrostatic pressure when 
prone.  
Their conclusion was similar to ours. There is a clinically relevant change in pressure-based 
indices, affecting stenosis classification. This potentially leads to misclassification of lesions and 
mistreatment.  
Within the last 6 months, a Japanese research group have conducted an almost identical study to 
ours, measuring Pd/Pa and FFR in 27 lesions in the prone and supine positions (Kawaguchi et 
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al., 2019). Their study starting recruitment two months after ours (September 2017) and 
produced very similar results. A comparison with our results is shown below in Table 38. 
 



























Table 38 - Al-Janabi vs. Kawaguchi Data. Delta change (between prone and supine positions) in 
Pd/Pa and FFR in LAD, Cx and RCA. 
 
The only differing measurements were the RCA Pd/Pa and FFR delta change. LAD and Cx 
measurements were identical, which is extremely re-assuring. The differences in the RCA could 
be due to which specific distal branch was chosen (PLV or PDA). Kawaguchi et al did not 
specify this in their methods, however diagrammatically, it appears the wire was positioned at 
bifurcation of the RCA. 
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Their data set did not include iFR or doppler flow velocity. The current research adds to current 
data by adding novel data for these parameters. Pd/Pa, is now rarely used, and including the 
effect on a newer resting index such as iFR is clinically relevant. Furthermore, the current 
research confirms that coronary flow is unchanged, which no other study has to this point. This 
provides supporting evidence that hydrostatic effect exists and confounds the tool of pressure 
based indices we use routinely during PCI.  
However, the similarity between data sets shows reproducibility and a reassuringly constant 
confounding effect of hydrostatic pressure. 
 
4.6 - Doppler Measurements 
 
 
There was no significant change between prone and supine doppler flow across resting and 
hyperaemic measurements. The overall delta changes between the groups were almost zero, with 
a change of -1.5cm/s in resting measurements and -0.8 cm/s in hyperaemic measurements across 
all cases. The majority of cases had small delta changes in flow (less than 5cm/s in 16 of 23 
cases). This correlates with the original theory that coronary flow will be maintained even when 
the pressure changes in the artery. There were some large changes in individual cases however 
(case 1  - 46.7cm/s prone and 20.5cm/s supine) which is difficult to fully explain.  
A possible explanation is variation in the doppler signal strength. Whilst gaining experience as a 
research group, it was clear that small variations in rotation or horizontal movement of the wire, 
could lead to large doppler signal changes. Flexibility in wire positioning was limited, with the 
aim to match the same position in the artery between prone and supine measurements. Rotation 
was the major variable in gaining adequate signal. In general, the operator would attempt to get 
the strongest signal within 2-5 minutes of wire placement to minimise radiation and prolonged 
procedural times. Positional stability and the correct signal angle have been noted to be the main 
technical challenges with invasive doppler measurements (Newby and Fox, 2002). 
Bradycardia, coronary spasm and dissection are known to be rare complications (<1%) of 
doppler wire use (Qian et al., 2000). Coronary doppler flow velocity has good short term 
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reproducibility (de Bruyne et al., 1996). Long term reproducibility is modest, as measurements 
are affected by heart rate, aortic pressure and luminal area (Mario, Gil and Serruys, 1995). This 
shouldn't have been an issue in the current study where measurements were taken within a very 
close time frame. 
Until recently, our understanding of human coronary physiology came predominantly from 
animal models. In 2016, Nijjer et al, acquired extensive data from 567 coronary measurements, 
including trans-stenotic gradient, FFR, doppler flow, microvascular resistance and coronary flow 
reserve. Autoregulatory mechanisms, which maintain prone and supine doppler measurements in 
this research, were clearly demonstrated. As stenosis severity increases, microvascular resistance 
falls, caused by a vasodilatation of the microcirculation (Figure 51). Flow was kept stable and 
constant until a critical stenosis point is reached (85-90%). At this point, flow does fall, leading 




Figure 51 - Coronary Flow Versus Stenotic Gradient and Resistance. Flow is maintained even in 
the presence of worsening stenosis severity and gradient, at the expense of a gradually 
vasodilating microcirculation. From Nijjer et al., European Heart Journal, 2016. (Nijjer et al., 
2016) 
 
When hyperaemia is induced, flow augments based on the vasodilatory reserve left. In mild 
stenosis, the microcirculation is still not maximally vasodilated, so exogenous adenosine, 
produces a marked increase in flow. In severe stenoses, the microcirculation may be close to 
maximal vasodilatation, and hence the vasodilatory reserve is small. This leads to much smaller 
increase in flow, or possible no increase in flow at all, and potentially symptoms of angina on 
exertion. 
In the study population, mean hyperaemic flow was approximately twice resting flow, i.e. a CFR 
of 2. Studies have previously demonstrated the prognostic value of CFR, with CFR values less 
than 2, being associated with worsening cardiovascular outcomes (Rigo et al., 2007), (van de 
Hoef et al., 2014). There are also instances where CFR and FFR are discordant. In such 
situations, some studies have found CFR to be a more reliable predictor of outcome than FFR, 
when the two are compared (van de Hoef et al., 2014). A recent has also demonstrated that iFR 
may correlate with CFR more closely with FFR (Cook et al., 2017), providing flow as an 
explanation for iFR/FFR discordance. It is unfortunate that doppler or flow-based systems have 
been largely replaced by pressure based invasive physiological system, largely due to ease of 
use. 
A change of 5-10mmHg in the distal coronary vessel is therefore of no concern to coronary flow 
if the microcirculation autoregulates this change. If the microcirculation is unable to compensate 
(due to microvascular dysfunction or maximal vasodilatation), in theory hydrostatic pressure 





4.6.1 - Dysfunctional Microcirculation 
 
 
Myocardial oxygen uptake is almost maximal even at rest, meaning any increase in oxygen 
demand must be delivered by increased coronary flow. Coronary flow augmentation, as 
previously described, is controlled by the microcirculation. The coronary microcirculation and 
microvascular dysfunction is a vast topic and beyond the scope of this thesis. In general, 
microcirculatory disease is known to be associated with heart failure, arrhythmias and adverse 
cardiovascular events (Taqueti and Di Carli, 2018). It has consistently been linked to certain risk 
factors such as hypertension, diabetes, renal impairment and epicardial coronary artery disease 
(Suzuki et al., 1994). 
There is no literature on hydrostatic effect in the context of a dysfunctional microcirculation. 
However extrapolating from known principles, it is thought that below a coronary pressure of 
40-60mmHg, the coronary vasculature is dependent on driving pressure upstream (Goodwill et 
al., 2017). Pressure is flow outside the autoregulatory window of approx 40-120mmHg. In this 
situation hydrostatic effect could have a direct effect on coronary blood flow. Especially relevant 
in patient's presenting acutely with ACS, in which the microcirculation may be compromised. 
The magnitude of effect is unknown, and would have to be assess in vivo for accurate estimates. 
Interestingly, the right coronary artery appears to have less autoregulatory capacity than the left 
coronary system. Some studies have shown that blood flow can drop by 35% when reducing 
coronary pressure from 80 to 40mmHg, whereas flow in the left system remains constant (Canty 
and Smith, 1995). In turn, dysfunctional microcirculation in the right coronary artery could make 






4.7 - Potential Clinical Implications 
 
 
4.7.1 - Pressure Based Measurements : A 'Level' Playing Field 
 
 
In clinical cardiology, a treatment threshold exists for guiding clinical management in all 
coronary arteries based on the index used. There are no specified threshold based on the artery in 
question. Even in FAME (De Bruyne et al., 2014), FFR values were combined across all three 
coronary arteries. If analysed separately, one may find differing thresholds per artery for major 
cardiac events. 
 In almost all studies, the value for FFR is 0.75-0.80 (De Bruyne et al., 2012;  Johnson et al., 
2014), for iFR 0.89  and for Pd/Pa 0.92 (Hennigan et al., 2016). Resting indices are gaining 
scientific interest and popularity in recent months (Svanerud et al., 2018)  for their ease of use, 
and ability to take measurements without the need for adenosine use. This increases the scope of 
relevance for hydrostatic pressure. 
There is an assumption that each vessel's 'normal' reading will be 1.0 (distal and proximal 
pressure are equal). The data from this research suggests this is not the case, and the' playing 
field' is not level from the offset. Before the introduction of any stenosis, the value of 1.0 for a 
normal vessel has already been confounded. Whilst true that some lesions may be very proximal 
or ostial, where hydrostatic effect is less prominent, any vertical deviation from the ostial vessel 
will produce a hydrostatic effect, however small. 
There exists therefore, separate levels of 'normality' where distal height varies from aortic height, 
and the Pd/Pa or FFR is not 1.0. Figure 52 plots all measurement points from CT coronary 





Figure 52- Hydrostatic Pressure Effect Per Artery. Diagrammatic representation of the 'level' 
playing field. In reality, multiple levels of height variation exist between the ostial and distal 
vessel. A standardised threshold for all vessels is therefore impossible. The resting Pd/Pa values 
at each level is shown in brackets. 
 
In the LAD, with a wire positioned in the distal vessel, the value of 1.0 for normal is already 
abnormal at 0.96, in the absence of a stenosis. In turn, a lower transtenotic gradient is needed to 
reach the treatment threshold in the LAD. The LAD FFR must drop by 0.16 points to reach 0.8. 
Conversely, the PLV begins at a higher value (1.05), requiring 0.25 change to reach 0.8. 
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Extrapolating this further, a lesion which produces a transtenotic gradient of 20mmHg would be 
'abnormal' in the LAD (FFR 0.76) but 'normal' in the circumflex artery (0.85). This leads to over-
treatment of LAD lesions and under treatment of Cx lesions. In 214 coronary stenosis with equal 
severity, lesions in the circumflex and other inferiorly position arteries (also referred to as 
posterior) had significantly higher FFR values than superiorly positioned arteries (referred to as 
anterior) (Härle et al., 2017c).Unfortunately, this is overlooked in clinical medicine with a single 
oversimplified threshold for all vessels. 
This has important clinical implications. Lesions may be mistreated, but it may also lead to 
learned behaviour in those who utilise coronary physiology. Lesions in the LAD were less 
severely stenosed than in any other vessel, but still referred for pressure wire assessment. This 
could be due to operator experience, learning that previous lesions in the LAD were significant, 
even if angiographically milder than other vessels.  
Of the ten LAD cases where FFR measurements were taken, five were positive (i.e. FFR below 
0.8) when the patient was in the standard supine position. However, when prone, only two of ten 
were considered positive. Moreover, the doppler flow in these arteries did not significantly 
change between positions. This means that FFR that is confounded by hydrostatic pressure and 
does not convey a true change in coronary physiology according to doppler flow. 
The same is seen with circumflex artery measurements, but in reverse. In supine measurements, 
one lesion out of seven demonstrated an abnormal FFR, whereas three out of seven 
measurements were abnormal when prone. The circumflex artery has been positioned superiorly 
in an 'LAD position', when the patient is prone, in turn reducing FFR. Anecdotally, the phrase 
'the circumflex is always negative!' is often heard amongst interventional cardiologists. This 
research may provide an explanation. 
It is noted that the overall change is small (0.05 as a maximum) and that clinicians should use 
FFR as a diagnostic aid alongside clinical judgment. FFR alone should not be used to provide a 
binary decision on treatment strategy. Clinical judgement and decision making would be 
simplified however if FFR measurements across a given stenosis were as accurate as possible. 
Hydrostatic pressure is one of many potential confounding factors and eliminating these will 
provide the best clinical assessment possible.  
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4.7.2 - Clinical Measurement Point 
 
 
The LAD clinical measurement point group was the only artery subgroup to have adequate 
numbers for statistical power. The results were statistically significant with a delta change of 
0.06 between prone and supine measurements. Hydrostatic effects appear relevent even in more 
proximal portions of vessel. The clinical measurement data points in the LAD, all correlated 
correctly with the anticipated direction of change. 
Guide to wire height at the clinical measurement point would have been a useful addition to the 
data set. Acquiring this during hyperaemic pullback would need ethical re-approval, given the 
time taken to acquire an acceptable left lateral image during adenosine infusion. This would also 
expose the patient to a larger infusion of adenosine. Realistically, the study protocol would 
require two pressure wire measurements per artery, per position (clinical and distal, prone and 
supine), meaning four pressure wire measurements per lesion. Ethically, this was not covered in 
the initial approval. 
 
4.7.3 - Statistical Significance versus Clinical Significance 
 
 
Despite a change of 0.05-0.06 in pressure-based indices being statistically significant, clinical 
significance and impact is harder to justify. A change of this magnitude is 25% and 50% of the 
required trans-stenotic gradient to class a lesion as significant using FFR and iFR respectively. A 
change of 0.06 re-classified 36% and 26% of lesions based on iFR and FFR respectively. Data 
from chapter II suggests that this number could be up to 46.5% in 'grey-zone' cases, i.e. those 
surrounding the threshold (0.75-0.85).  
Härle recently a published a similar study with smaller changes to Pd/Pa, iFR and FFR,  in a peer 
reviewed journal (Härle et al., 2018). This is excellent news for the field of hydrostatic pressure 
effect and encouraging to see colleagues value such data.  
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Recently, our institution showed that donor vessels to chronic total occlusions (CTO) increased 
FFR and iFR by 0.03 to 0.04 respectively after treatment of the CTO. This was accepted as 
significant by the scientific community and recently published (Mohdnazri et al., 2018). One 
hopes that the larger change in the current study in less complex lesions than CTO, will also be 
viewed as relevant in current clinical practice. The invasive data from this research is currently 
under review for publication. 
 
4.7.4 - Wire Placement - PLV versus PDA 
 
 
In chapter II section 2.6.5, a case report highlights the trivial decision of wire placement in a 
terminal branch of the right coronary artery. The right coronary artery has two terminal 
bifurcating branches, the PLV travelling inferiorly, and the PDA taking a superior course in a 
supine patient. The average difference in height between the distal PDA and PLV from CT data 
is 75.7mm. A lesion before this bifurcation can then be at risk of differing pressure results, 
depending on where the wire is placed. 
Operators should remain mindful of wire position, especially if the lesion is close to or at the 
bifurcation of these vessels. PDA pressure indices are expected to be lower than in the PLV. As 
shown in the described case, the difference in FFR between each artery is 0.05, which is not 
clinically negligible. This may alter decision making or stenosis classification (as it did in the 
described case). Coronary doppler flow did not change significantly, demonstrating that 
hydrostatic effect is impacting the diagnostic tool of pressure-based measurement, rather than 






4.7.5 - Diffuse Disease and Serial Stenosis 
 
 
Regarding wire position, the initial FFR papers from Pijls and De Bruyne simply state the wire 
should be 'beyond the stenosis' (Pijls et al., 1996). In serial stenosis or diffuse coronary disease, 
the wire must be placed beyond the most distal stenosis (Pijls et al., 2000) meaning potentially a 
more distal wire position, and a greater hydrostatic pressure effect in such scenarios (Bruyne et 
al., 2000). 
 
4.7.6 - Other Physiological Indices 
 
 
Distal coronary pressure is also utilised in other physiological measurements within coronary 
arteries. The index of microvascular resistance (IMR) utilised distal coronary pressure in part of 
the equation for its calculation (Ng, Yeung and Fearon, 2006) as shown below. 
 
IMR = Distal Artery Pressure x Mean Transmit Time 
 
As distal pressure is affected by hydrostatic effects, there may also be an impact on IMR 
calculation. A vessel inferior to the aorta (such as the circumflex) with higher distal artery 
pressure will produce a higher IMR compared to the LAD for example. 
 
4.7.8 - Accounting for Hydrostatic Pressure Effect 
 
 
Some cardiologists may claim hydrostatic effect is another minor confounding factor, such as 
atrial pressure or the individual patient response to adenosine. A lettered response to Härle's CT 
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paper already summarises some of the communities' thoughts (Hydrostatic Forces: Don’t Let the 
Pressure Get to Your Head! - PubMed - NCBI, 2019). In summary, the response dampens the 
clinical importance of hydrostatic effect as just another minor confounding factor. The letter also 
highlights the wealth of data supporting pressure-based indices, and the fact that in reality, 
patients are standing upright in their daily lives, not lying prone or supine. 
One cannot however deny the basic physical principles that underpin this concept. Patients are 
upright in daily life, but we have always assessed coronary physiology when supine. This study 
also does not aim to discredit the wealth of data for pressure-based indices, rather highlight a 
potential unknown variable. A single cut-off point is an oversimplification of pressure based 
physiological assessment. Vessels are not in the same vertical plane. In some cases, hydrostatic 
effects may be negligible, however there are some key concepts that have arisen from this study: 
 
1. The more distal the wire is placed in the vessel, the larger the potential hydrostatic effect. 
 
2. The same lesion in a superiorly positioned artery, will not yield the same FFR result if 
positioned in an inferiorly positioned artery (PLV vs. PDA). 
 
3. There is potentially a greater effect in resting indices. 
 
4. Re-classification of ischaemia is common around treatment thresholds when correcting 
for hydrostatic pressure effects. 
 
The aim is to try and abolish or correct hydrostatic effect as a confounding variable. I feel there 
should be different treatment thresholds or cut-off points for each coronary artery. For example, 
the circumflex artery should have a raised FFR threshold (0.83-0.85) to account for the higher 
starting measurement, which is usually above 1.0 in mildly diseased or normal arteries. In turn 
the LAD should have a lowered threshold, to account for its lower starting point. Table 39 








Correction Factor New FFR Threshold 
LAD 
 
0.80 -0.04 0.76 
Cx 
 
0.80 +0.03 0.83 
PLV 
 
0.80 +0.05 0.85 
PDA 
 
0.80 -0.02 0.78 
 
Table 39 - Vessel Specific FFR 
 
Vessel specific FFR, iFR and even Pd/Pa, could give the operator a more balanced assessment of 
a coronary stenosis. There are some limitations with such a suggestion however. Firstly, the 
vessel specific values given in table 39 are suggestions from the data set obtained during the 
study. More numerous data measurement points across the length of the artery are required to 
produce a robust and complete data set, the data from coronary CT for this study was in a 
selective group of patients (young female patients, low risk of ischaemic heart disease), and does 
not mirror the general population. Furthermore, height variations are affected by multiple factors, 
such as sex and body height, as demonstrated previously be Härle et al (Härle et al., 2017a).  
Patients with certain disease processes such as cardiomyopathy or valvular heart disease, may 
have altered coronary anatomy. This means a single value given for all arteries, across all patient 




Secondly, the hydrostatic effect is not constant across the entire length of the vessel. A graded 
change in hydrostatic effect, where for example the proximal circumflex FFR is adjusted by 
0.01, mid vessel by 0.02 and distal vessel by 0.03 would be more accurate (more describe under 
Vessel Mapping below).  
In some situations, hydrostatic effect may not alter ischaemia classification. Using FFR as an 
example, the maximum hydrostatic effect in one position is thought to be 0.06 on average. If the 
FFR reading is below 0.74 or above 0.86, adjustment for hydrostatic effect is unlikely to change 
the clinical classification of the lesion from significant, to non-significant, and vice versa. If the 
FFR is between 0.74 and 0.86 however, the operator has several options. They may be mindful 
of the confounder of hydrostatic effect and make an informed decision. The operator may wish to 
correct for hydrostatic effect by using known correction factors. In the extreme, one could 
measure the guide to wire distance, in the catheter laboratory, using the left lateral position on 
the x-ray, and acquire the vertical distance between each. Using a correction factor of 
0.8mmHg/cm, one could calculate the corrected FFR. This can then be combined with clinical 
judgment to decide on the most appropriate treatment strategy. 
Each option has advantages and limitations, with the last adding extra radiation and time to the 
procedure, which operators would prefer to avoid. It would however provide a more accurate 
assessment of the lesion in question, especially in the FFR 'grey zone' of 0.75 to 0.85. 
 
4.8 - Anatomical FFR and Hydrostatic Pressure 
 
 
Anatomical measures such as CT FFR have been briefly discussed in Chapter I. CT FFR and 
similarly angiographic FFR are not confounded by hydrostatic pressure effects due to their very 
nature being non-invasive. There are other inherent flaws due to this, specifically the need for 
estimations of invasive haemodynamics required to produce an 'FFR value'. However, they may 




4.8.1 - CT FFR 
 
 
CT coronary angiography has been used to provide a non-invasive version of FFR, known as CT 
FFR (Davies and Cook, 2017). CT images, a mathematical model, and several assumptions 
(cardiac output, aortic pressure and microvascular resistance) are combined to create a CT FFR 
value via several different mathematical models. CT FFR is shown to correlate with invasive 
FFR relatively well. The DISCOVER-FLOW (Koo et al., 2011) study and NXT trial (Nørgaard 
et al., 2014) reported diagnostic accuracies of 84.3 and 86% respectively. There is also evidence 
that CT FFR could reduce the number of referrals put forward for invasive angiography by up to 
half (Lu et al., 2017). As a diagnostic tool however, the assumptions inputted into the CT FFR 
mathematical model are not individual for each patient, meaning inevitable errors. This is shown 
in some studies having less favourable, moderate diagnostic accuracy (Gaur et al., 2017). 
Hydrostatic effect is not one of the factors in CT FFR calculation. 
 
4.8.2 - Angio-FFR 
 
 
Angiogram derived FFR was developed as an alternative to invasive FFR, as it can be done 
without an invasive wire insertion or a hyperaemic stimulus. The recent FAST-FFR (Fearon et 
al., 2019) trial demonstrated angiogram derived FFR has high sensitivity (94%) and specificity 
(91%) as well as diagnostic accuracy (92%) when compared to standard FFR. Diagnostic 
accuracy was maintained in 'grey zone' values of 0.75 to 0.85 at 87%. 
Unlike CT FFR, invasive aortic pressure is available for angio FFR calculation. This combined 
with multiple angiographic images of the coronary tree and stenoses is factored into a 
mathematical algorithm which estimates resistances and flow, producing an FFR result. Studies 
have utilised slightly different methods with computational fluid dynamics, but all must use a set 
of boundary conditions to produce a result (Morris et al., 2017).  Beneficially, 96% of cases in 
the FAST-FFR study were appropriate for analysis, compared to only 67% in the PROMISE 
trial, which used CT FFR (Lu et al., 2017) 
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4.8.3 - Hydrostatic Effect in Non-invasive FFR 
 
 
As has been demonstrated, non-invasive FFR correlates well with invasive FFR (Koo et al., 
2011) (Nørgaard et al., 2014). These studies did not individually compare each artery. This 
would have been useful to assess for any potential mismatch. 
Lack of specific haemodynamic data is a notable flaw in non-invasive FFR calculation. 
However, the non-invasive nature of these measurements may also be beneficial, in that 
confounding factors which plague invasive FFR are irrelevant. Atrial pressure, LVEDP, response 
to hyperaemia and hydrostatic pressure are no longer a factor in angio or CT FFR. Anterior and 
posterior artery position should have negligible or no effect on measured FFR. 
Interestingly, CT FFR data from the ADVANCE registry (Kitabata et al., 2018) showed a trend 
towards lower FFR values in LAD lesions compared to RCA lesions. The authors did not give an 
explanation for this or show any lesion specific data (e.g. lesion length). Boundary conditions 
which are required compute CT FFR are based on physical laws. Flow for example is calculated 
using myocardial wall volume extracted from CTA as a variable. This potentially has an impact 
on computed flow per vessel, as the LAD is known to supply the largest volume of myocardium. 
No study has addressed hydrostatic effect in non-invasive measures of FFR and correlation with 
invasive FFR. No mathematical algorithm mentions hydrostatic pressure as an included variable 
in non-invasive FFR calculation. Many studies aim to show that CT FFR as diagnostically 
accurate as invasive FFR, where the wealth of data lies. However, with the assumptions and 
boundary limitations in non-invasive FFR, coupled against the confounding factors and patient 
specific issues in invasive FFR, discordance is likely to be forever present. It is still not clear 






4.9 - Arguments Against Hydrostatic Effect 
 
 
Some experts stipulate the change in FFR along the length of a vessel, in the absence of a focal 
stenosis, is due to diffuse coronary artery disease (Bruyne et al., 2001) . This potentially explains 
why the FFR may be 0.97 in the distal LAD, in what appears to be a relatively disease-free 
vessel. Whilst this is certainly a valid physiological explanation, it does not explain why the FFR 
changes in the opposite direction during position change to prone. The diffuse atherosclerosis is 
still present, but the distal Pd/Pa is now seen to be above 1.0. This is exactly the situation for 
case 11, where supine Pd/Pa was 0.97 in the LAD, and prone Pd/Pa was 1.02. 
Another interesting discussion point relates to the mass of myocardium supplied by a vessel. The 
suggested reason that the LAD has lower FFR values for the same stenosis severity than other 
vessels, relates to the mass of myocardium supplied. A larger myocardial mass means greater 
flow in the artery that supplies it, and in turn a larger gradient during maximal hyperaemia 
(Leone et al., 2013a). This does not detract from the change in FFR when a patient changes 
positions. 
In the same lettered response to Härle et al., from Johnson et al (Hydrostatic Forces: Don’t Let 
the Pressure Get to Your Head! - PubMed - NCBI, 2019) the authors suggest that a change in 
5mmHg for example, will have little effect on an FFR measurement which shows a 30mmHg 
transtenotic gradient. This is a valid response, however a significant proportion of stenoses have 
gradients closer to 20mmHg. A change of ± 5mmHg, is highly relevant. 
Intra thoracic movement of organs is the basic principle in prone positioning in ARDS, as the 
weight of organs is lifted off dorsal structures (Scholten et al., 2017). One could argue the weight 
of the heart when changing position is responsible for the pressure change within the coronary 
arteries. Whilst this may contribute, it would not explain the variation in magnitude of change 
between the arteries themselves. One may expect all arteries to change by a set magnitude with 




4.10 - Study Limitations 
 
 
All patients were male. Male sex is a predictor for increased height from distal to proximal 
coronary artery (Härle et al., 2017a). Height is also a predictive factor for coronary height 
variations, and as on average, male patients are taller than females, the height calculations are 
potentially larger. This could lead to an overestimation of the hydrostatic effect. 
The default wire position for all measurements was in the distal vessel. This may not be the point 
of measurement in every clinical case and exaggerate the hydrostatic effect.  
The Pa pressure was lower on average when taking supine measurements. Prone measurements 
were first, followed by supine measurements. The reason for this was predominantly patient 
safety, in that starting supine, followed by prone, would mean positioning the patient back to 
supine if the artery needed treatment. To minimise the number of turns, and the risks associated 
with this, the study protocol was designed to take prone measurements first. Supine Pa was 
5mmHg on average lower for Pd/Pa, and 6mmHg lower on average for FFR. The effect this has 
on delta change between positions is minimal, but noteworthy. 
Guide to wire measurements were taken during angiography in the left lateral position. In some 
cases, the left lateral angle was not exactly 90 degrees. This may cause a minute amount of error 
in the guide to wire height measurement. Furthermore, a useful addition in retrospect would be to 
repeat guide to wire measurement in the supine position, not only the prone position. The 
combination of both measurements may lead to a more accurate correlation with delta change in 
Pd/Pa and FFR. 
Stenosis assessment using QCA is has inaccuracies (Wunderlich et al., 1998). Calibration of the 
QCA system uses the size of a known calibre coronary catheter to measure distances on a still 
image. There is a potential for error in the measured distances, therefore. 
Right atrial pressure was excluded in the assessment of FFR in the study demographic for safety 
reasons. However, recent studies demonstrate that right atrial pressure is negligible with regards 
to FFR measurement (Toth et al., 2016). 
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Lastly the correction factor of 0.8mmHg/cm to convert vertical height into hydrostatic pressure is 
the closest value available for use at the present time. Pressure simulator results from Härle et al., 
2017a, show a conversion factor of 0.77mmHg/cm with 0.9% saline fluid instead of blood. 
Correcting for the density of blood, the value of 0.8mmHg/cm is more likely to represent the 
correct value. Further studies in vivo are needed to accurately define the conversion rate. 
The possible weight of the heart affecting intracoronary pressure has already been discussed. 
I designed, conducted and co-ordinated this study and performed all data collection and analysis. 
I was aware of the research hypothesis and was unblinded to the results. This may have 
introduced bias despite all precautions. I did have to guide placement of the physiology wire to 
keep positioning as constant as possible as well as ensure study protocol with regards to heparin 
and nitrates was adhered to. I did not have any intervention beyond this.  
 
4.11 - Future Research 
 
 
4.11.1 - Ideal Study Protocol 
 
 
In an ideal scenario and protocol, a more comprehensive assessment of hydrostatic effect would 
measure the following: 
 
1. Pd/Pa, iFR and FFR in all coronary arteries in every patient 
 
2. Prone, supine, left and right lateral patient position. 
 
3. Proximal, mid and distal measurement points in every artery 
 




5. Doppler and thermodilution flow measurements 
 
6. CTCA for all patients before invasive angiography to map their coronary circulation 
 
7. LAO angiogram in every position. 
 
This would of course be unethical and require extensive resources. It would however provide a 
robust and accurate data set however, to truly demonstrate the extent and magnitude of 
hydrostatic effect in vivo. 
 
4.11.2 - STEMI 
 
 
The initial research question still remains; does a change of patient position during an ST 
elevation myocardial infarction, alter flow to the affected heart muscle? 
From the study results, it appears a change in patient position does not affect flow in mild to 
moderately diseased arteries. The study demographic did not have an occluded or sub occluded 
vessel as is usually the case in ST elevation myocardial infarction.  The research team at the 
Essex Cardiothoracic Centre now have a better understanding of coronary physiology in non-
emergency patients, and have the background knowledge to trial subsequent theories in STEMI. 
Armed with the knowledge that flow does not change with position in a relatively normal artery, 
one can now attempt to ask the same question in acute myocardial infarction. In the acute setting 
of a myocardial infarction, the microcirculation is dysfunctional, and autoregulation is disturbed 
(Tamita et al., 2002). Changing pressure in this clinical context may therefore correlate into a 
change in flow if autoregulation cannot compensate. 
It is unclear to what magnitude pressure would increase flow. We expect a change in coronary 
pressure of up to 10mm Hg. In animal models with impaired autoregulation this equates to a 
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change of approximately 10 to 20ml/min of coronary blood flow (Goodwill et al., 2017). How 
this translates into clinical outcomes is unknown, and would be the focus of future studies. 
This next step would be to extend the current research into the acute group of patients. The 
current study has proved prone angiography is not only possible, but safe and with correct staff 
training and not overly time consuming. The risk of cardiac arrest in acute myocardial infarction 
is much higher than elective patients, and if the patient is prone, there will be added risk related 
to the time taken to manoeuvre back into the supine position to commence CPR. Figure 53 




Figure 53 - Suggested STEMI Pathway. Possible chain of events in STEMI patients of future 
GRAVITY studies. 
 
Recruitment based on evidence of current ST elevation 
myocardial infarction 
Inclusion and exclusion criteria 
satisfied 




For continuing care as 
per Essex CTC 
Treat culprit artery as per standard CTC care 
without delay 
 
At end of procedure - balloon 
occlude artery at point of original 
blockage 
Measure flow and pressure beyond 
balloon occlusion 










Measurements are taken from a physiology wire beyond a balloon which is occluding the vessel. 
This mimics occlusion of the vessel. Myocardial blood flow beyond this blockage is supplied by 
coronary collaterals as there is no antegrade flow. The pressure and flow measurements obtained 
will therefore be collateral flow and collateral pressure. The centre has experience in obtaining 
these measurements from previous studies (Mohdnazri et al., 2018). If flow can be increased 
with changes in position, ambulance or emergency staff could position patient prone for certain 
infarcts during transfer to a PCI centre, saving myocardium and reducing infarct size. Infarct size 
is a clear determinant of outcomes for patients suffering acute myocardial infarction (Stone et al., 
2016a). 
A prospective randomised trial of prone versus supine positioning versus control (standard care), 
and the assessment of infarct size (CMRI) and adverse cardiac events at 30 days and 1 year. 
 
4.11.3 - Chronic Total Occlusion 
 
 
Before studying acute myocardial infarction, and acute blockages of a coronary artery, the 
intermediate step may be to study patients with a chronic occlusion of an artery. In chronic total 
occlusion, the microcirculation is thought to be dysfunctional (Ladwiniec et al., 2016). Ethical 
approval for this has already been obtained, recruitment could commence at any time.  The 
counter argument is that if the final target group is STEMI patients, one should not involve a 
separate group of patients who are subjected to the small, but potential risks of the study protocol 
and instead go straight to acute infarct patients. 
 
4.11.4 - Vessel Mapping 
 
 
The current research suggests single thresholds for all coronary arteries is an oversimplification. 
However, a single adjustment factor per artery would also be only partially correct. 
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A more elegant solution would be specific correction factors for each segment of each artery. 
The vessel is 'mapped' to assess hydrostatic pressure effect at each point. In clinical practice, this 
may mean separate adjustments for proximal, mid and distal vessel. 
The most accurate way to do this, would be to study normal coronary arteries in live patients, 
with pressure-based measurements at multiple points in each artery. With enough data, one could 
create a hydrostatic map for each coronary artery. Studying non culprit arteries as part of the 
protocol was explored during the study period. Unfortunately, an ethical amendment was 
rejected by the local ethics committee. It was deemed that five extra pressure wire measurements 
instead of one was excessive for study purposes. Physiology measurements in unobstructed 
coronary arteries would be unethical. 
CT coronary angiography may provide an alternative solution. From an anatomical perspective, 
CTCA could still be useful in mapping hydrostatic effect via vertical height. This could be 
gathered from retrospective CT coronary angiograms, to build a database of height measurement 
for each coronary artery at multiple points. This translates into hydrostatic effect, and would map 
effect per portion of artery. Being non invasive, this bypasses many ethical issues, and having a 
full database of scans at the Essex Cardiothoracic Centre means this could be done locally and 
rapidly. 
CT scans would map multiple points in the coronary tree, and provide a correction factor for 
proximal, mid and distal vessel in all coronary arteries (Figure 54). The correction factor could 
either be applied directly to pressure wire software, or be available to angioplasty operators 




Figure 54 - Graduated Hydrostatic Correction - demonstration of LAD with proximal, mid and 
distal LAD correction factors 
 
 
4.12 - Novel Pressure Wires Immune to Hydrostatic Effect 
 
 
The concept of hydrostatic effect has impressed upon medical equipment developers. In the final 
few months of research, a medical devices company approached the institution with interest 
surrounding our CT coronary angiogram data.  
There appears to be a way in vivo to abolish hydrostatic effect by using a specific kind of 
physiology wire, which is undergoing preliminary trials. The concept involves measuring 
pressure distal to the stenosis using a physiology wire with a saline filled centre. The pressure is 
projected through the saline central lumen to an external pressure sensor sitting at aortic level 
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outside of the patient. This abolishes hydrostatic pressure, by ensuring the distal sensor is always 
at the same vertical level. The pressure in the distal vessel is now not compounded by hydrostatic 
effect. Figure 55 demonstrates this. 
 
Figure 55 - Hydrostatic Effect Immune Wires - Pd pressure is transferred through a saline 
centred wire and measured externally through a transducer at the same level as Pa. The height 
difference is therefore abolished 
 
This wire, if fully produced, could negate all hydrostatic effect, and give a pure stenosis pressure 
signal. This would make vessel mapping obsolete if incorporated into angiography laboratory 
set-up. 
It is hugely re-assuring to know that a concept which has considered largely irrelevant, is being 
investigated by other academics in the field, partly due to the literature this study has produced. 
There may indeed be future collaborations between industry and our institution, in developing 
novel, and clinically relevant medical equipment. 
 
4.13 - Final Thoughts 
 
 
The aim of this study was not to change clinical practice, or specifically alter the use of pressure-
based indices. It would be impossible to invalidate over twenty-five years of data with a 
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relatively small data set. The hope is to emphasise the importance of widely neglected 
phenomenon to clinicians who use pressure-based indices as a daily diagnostic tool. 
The study has certainly changed the way operators at the Essex Cardiothoracic Centre approach 
pressure wire studies. If this ethos could spread to the wider community, it should only aid the 
continuous learning process in delivering the best patient care. 
In my personal practice, I am mindful of the position of the physiology wire and the vessel I am 
assessing. I believe in a multi-faceted approach in the assessment of the patient and their 
coronary anatomy. Pressure based indices are a single piece of the whole, and whilst FFR is an 
excellent diagnostic aid, like any clinical tool, it has limitations. This research has certainly 
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Coronary artery disease is the second largest cause of premature death in the UK (Avoidable 
mortality in England and Wales - Office for National Statistics, 2018). By definition, it is a disease 
process which leads to a restriction or obstruction of blood flow to the myocardium. For the 
purpose of this thesis, this will be synonymous with atherosclerosis. Atherosclerosis is a 
pathological process involving coronary, cerebral, peripheral arteries and the aorta (Faxon et al., 
2004; Libby, Ridker and Hansson, 2011). The process can be divided into stages which lead to 
progressive deposition of cholesterol and fibrous tissue in the wall of the coronary arteries (Figure 
X).The stages are summarised below: 
1. Fatty streak - This process starts when low density lipoprotein (LDL) enters the vessel 
intima. This triggers an inflammatory process and leads to lipid-laden macrophages 
accumulation. Smooth muscle cell proliferation and extracellular matrix deposition leads 
to focal intimal thickening. Progressive smooth muscle cell proliferation expands the 
streak. Some of these smooth muscles cells undergo apoptosis, leading to further 
macrophage infiltration and progression to an atherosclerotic plaque (Davies et al., 1988) 
 
2. Atheroma and Fibroatheroma - Increased accumulation of macrophages, inflammatory 
cells and smooth muscle cells lead to continuing vessel thickening. Increasing amounts of 
lipid are bound within the atheroma, and an on-going cycle of cell death leads to necrotic 
debris and further inflammation (Insull, 2009). 
 
On-going inflammation and necrosis causes loss of the normal intimal structure, which is 
replaced by lipid rich necrotic cores. The plaque continues to grow into the adjacent media 
and adventitia of the vessel, causing distortion in vessel layers and occupying up to 50% 
of the vessel wall. To compensate for threatened lumen reduction, the arterial wall may 
enlarge its diameter. Finally fibrous tissue forms above the core, just under the endothelium 
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at the blood interface. This is known as a thin fibrous cap, and is susceptible to rupture, 
causing myocardial infarction and even sudden cardiac death (Virmani et al., 2000). 
 
3. Complex lesion formation - Many ruptures of thin fibrous caps are silent and re-heal by 
further fibrous tissue formation (Virmani et al., 2000). This can happen multiple times per 
lesion. Calcium deposition is seen at this stage, in a cumulative fashion as the disease 
progresses. The mass of the plaque alone may become enough to trigger symptoms in the 
patient (Insull, 2009). 
 
As can be seen, luminal area is progressively lost during disease progression, with symptoms rarely 
present until 80% vessel stenosis (Fearon, 2015). Even in the first decade of life, the initial stages 
of disease can be seen in the aorta. A post-mortem study of 2,876 men and women aged 15 to 34 
found fatty aortic streaks in all studied individuals (Strong et al., 1999). 
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Figure X, stages of atherosclerosis.  
(Stages of endothelial dysfunction in 
atherosclerosis,  (https://commons.wikimedia.org/wiki/File:Endo_dysfunction_Athero.PNG), 







Data exists to predict certain 'risk factors' in the development of atherosclerosis. The earliest study 
to identify such factors was the Framingham Heart Study published initially in 1957. The study 
enrolled 5,209 men and women aged 30-59 in the town of Framingham, Massachusetts, USA, and 
collected various demographic data, including blood samples, blood pressure, heart rate, 
electrocardiograms, and medical histories. The Framingham heart study outlined the main risk 
factors for coronary artery disease we still follow to this day, namely hypertension, 
hypercholesterolaemia, diabetes, smoking and family history (Dawber et al., 1959; Kannel et al., 
1961; Snowden et al., 1982). The disease process does not follow risk factors strictly, as those with 
none may still develop aggressive atherosclerosis, and vice versa. 
Additionally, patients who modify and control their risk factors after a diagnosis of coronary artery 
disease, have better prognosis and outcomes from treatment (Ford et al., 2007; Farkouh et al., 
2013; Hammal et al., 2014). 
 
Implications of Coronary Artery Disease 
 
Coronary artery disease is only superseded by cancer as the largest cause of premature death in the 
UK (Avoidable mortality in England and Wales - Office for National Statistics, 2018). The 
footprint of mortality is therefore enormous. 
The effect on morbidity is equally large. With the potential development of heart failure, persistent 
anginal symptoms, recurrent cardiovascular events and the need for bypass surgery or other 
invasive treatment (Madhavan et al., 2014).  
At a patient level, a quarter of patients report a significant decline in their quality of life after 
diagnosis (Sajobi et al., 2018). This could be attributable to anginal symptoms related to their 
coronary artery disease (Gandjour and Lauterbach, 1999) or heart failure (Nieminen et al., 2015). 
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It is more likely however, due to the complex physical, emotional and social interactions which 
constitute quality of life. Truly identifying the cause is problematic. 
 
Heart Disease in Today's World 
 
The impact of heart disease in the current health climate is huge. Statistics from the British Heart 
Foundation show that 26% of all deaths in the UK are due to heart disease (Heart statistics, 2018) 
with 2.3 million current sufferers of coronary artery disease. One hospital visit every three 
minutes is due to a myocardial infarction, leading to 180 deaths per day. 
Coronary artery disease is estimated to cost the National Health Service (NHS) just over seven 
billion pounds annually. Death rates have fallen over the past 5 decades, but an aging and 




Identifying and modifying the risk factors identified from the Framingham heart study is the 
cornerstone of preventing morbidity and mortality from coronary artery disease. Anti-hypertensive 
and lipid lowering agents are widely used, but advances in coronary prevention are still on-going. 
Newer lipid lowering drugs (PCSK9 Inhibitors) are expected to further lower the incidence of 
coronary artery disease (Steg and Ducrocq, 2016). Furthermore, genetic testing could provide an 
individually personalised plan for coronary prevention in the near future (Steg and Ducrocq, 2016). 
 
Secondary Prevention and Long Term Treatment 
 
Management of cardiovascular risk factors in patients with established atherosclerosis has been 
shown to improve outcomes (Ford et al., 2007; Farkouh et al., 2013; Hammal et al., 2014). Patients 
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who have suffered a cardiovascular event, and therefore require secondary prevention derive 
benefit when taking aspirin and statin therapy compared to those who do not. For aspirin, this was 
first demonstrated in the ISIS-2 trial published in 1998 (Baigent et al., 1998). Further meta-
analyses further contributed to this stance, showing low dose aspirin (75mg once daily) also has 
protective effects against further events (Antithrombotic Trialists’ Collaboration, 2002). Statin 
therapy also has compelling evidence regarding secondary prevention, with the first trial published 
in 1994 of over 4000 patients showing mortality reduction with statin therapy compared to placebo 
(Pedersen et al., 2004). Further meta-analyses showed reduction in mortality and further ischaemic 























The rate of death is higher than basic angiography alone, and also dependent on the clinical 
context. From large volume United States registry data sets, elective PCI mortality was 0.65% 
compared to 4.81% in STEMI patients. Overall mortality was 1.27% (Anderson et al., 2007). Of 





The reported rates of peri-procedural myocardial infarction are highly variable. They are linked 
with multiple factors including age, burden of atherosclerosis, lesion and procedure complexity 
and procedural complications such as dissection and vessel closure. Depending on the diagnostic 
criteria used, rates of peri-procedural myocardial infarction are on average 25%, but can range 
from 0-70% (Herrmann, 2005). Presentation is often clinically silent, but some studies have 
linked peri-procedural myocardial infarction with increased long term risks of cardiac mortality 
(Fuchs et al., 2001). There appears to be two major type of infarction, namely proximal (type I) 
distal (type II). In proximal type infarctions, local occlusion of a side branch causes infarction at 
that local site, whereas type II infarction is caused by distal embolisation of thrombus, which can 
be seen on subsequent cardiac magnetic resonance imaging (MRI) (Choi et al., 2004).  
 




Due to the nature of coronary intervention, the rate of stroke is higher when compared to 
diagnostic angiography. A large study of over twenty thousand patients demonstrated an 
incidence of 0.3% for cerebrovascular events (Dukkipati et al., 2004). Patients were also more 
likely to suffer an event if they suffered from diabetes, hypertension or previous strokes. The 
cause of ischaemic stroke during catheterisation is thought to be due to micro-embolism 
propagating into the cerebral circulation. 
 
Coronary Dissection and Perforation 
 
Coronary damage is rarely seen in diagnostic procedures, and is often caused by aggressive 
guide catheter selection or intubation. In PCI, this is still a possibility, but coronary dissection 
and perforation are more often due to instrumentation of the artery in question, either with 
coronary guidewires, or dilatations balloons and stents themselves. The reported incidence is 
around 2% after stent implantation (Biondi-Zoccai et al., 2006). Left untreated, they were 
associated with higher in hospital and 1 month rates of major adverse cardiac events (MACE-  
mortality, myocardial infarction or coronary revascularisation). 
Coronary artery perforation is a more serious complication, and often caused by guidewire 
perforation. Incidence in most studies is <1% but can range up to 3% (Nair and Roguin, 2006). 
The use of advanced guidewires, especially in treatment of chronic total occlusions (CTO), may 
lead to an increase in incidence. Studies have not shown an increase in the current interventional 
era (Kiernan et al., 2009). Treatment varies from conservative observation, to stenting of the area 
of perforation to seal the leak, and in extreme cases CABG. The chance of needing CABG 
following coronary perforation is approximately 0.3% (Nair and Roguin, 2006). Cardiac 
tamponade may ensue in minutes with large perforation, necessitating pericardiocentesis. 
Perforation is divided into three types (Al-Mukhaini et al., 2011); 
• Type 1 - Extra luminal perforation without extravasation into surrounding tissue 
• Type 2 - Perforation into pericardium or myocardium 
225 
 
• Type 3 - Extravasation through a frank perforation, sometimes into an adjacent coronary 
cavity 
 
 Coronary perforation and types. Type I - into the wall of the artery, type II - into surrounding 






Balloon angioplasty was plagued by acute vessel closure, leading to the implementation of stent 
technology. The early bare metal stents were then found to have a high rate of restenosis 
(Serruys et al., 1994; Fischman et al., 1994), leading to the implementation of drug eluting stents, 
which inhibited smooth muscle cell proliferation, and growth of the intima over the stent. 
Delayed endothelialisation led to concern regarding increased rates of stent thrombosis. Definite 
stent thrombosis is defined as angiographic or pathological confirmation of partial or total 
thrombotic occlusion within the peri-stent region (Cutlip et al., 2007). Timing is also divided 
into; 
1. Acute  - within 24 hours. 
2. Subacute - between 24 hours and 30 days. 
3. Late - 31 days to 1 year. 
4. Very late - over 1 year. 
Early studies using bare metal stents and different anticoagulation regimes often quoted stent 
thrombosis rates of around 20% (Serruys et al., 1991; Claessen et al., 2014). Thanks to dual 
antiplatelet therapy (DAPT) and adequate expansion of stents with high pressure balloons, rates 
of stent thrombosis up to 1 year range from 0.5 - 3% (Kedhi et al., 2010).  The incidence does 
not differ between bare metal and drug eluting stents (Mauri et al., 2009). Early stent thrombosis 
is linked to suboptimal procedural results, whereas late stent thrombosis is linked to delayed 
endothelial coverage and on-going vessel inflammation (Claessen et al., 2014). Mortality after 










Appendix C - Standard Angiography and Laboratory Set-up 
 
 
Standard angiography uses the supine position and commonly access is gained through the right 
radial artery or right femoral artery. Left sided arteries are also used but less commonly. A guide 
catheter is placed into the coronary artery ostium and iodinated contrast media injected to outline 
the coronary artery of interest under fluoroscopy. To take physiological measurements, a 
physiology wire is advanced into the required position, and measurements taken. Infusion of 
adenosine is required to produce a hyperaemic steady state. Routinely, pressure measurements 
are used to assess coronary artery stenoses and guide clinical treatment, due to ease of use. 
Velocity or 'flow' measurements, are used in clinical practice less routinely, but have important 
uses in research studies. Velocity measurements take longer to obtain and results can be operator 
dependent. Pressure studies are more robust and reliable, hence their more common clinical use. 
A standard angiography laboratory or 'lab' in the UK has several standard components. Firstly, 
there are core members of staff enlisted to ensure safety and efficiency of the procedure for the 
patients and all others involved. These are outlined below; 
1. Scrub Nurse - This nurse will assist the operator by donning surgical gowns and gloves. 
They will assist in preparing equipment, such as coronary catheters, coronary wires, 
medications, arterial access equipment, contrast injection equipment and maintaining all 
of this on a sterile trolley. They are trained in intra-arterial contrast injection, and will aid 
the operator when they are busy manipulating the catheter. Their role is vital, as although 
a single operator coronary angiogram is standard practice in other countries, it can add 
time and unneeded complexity to the procedure, as well as compromising safety. 
 
2. Runner Nurse - This nurse is not in sterile surgical vestments and will aid the scrub nurse 
and operator with obtaining needed equipment. They will hand equipment from its outer 
packing in a sterile way to the operator and scrub nurse. Medication preparation and 
administration through intravenous cannulae is part of their role.  Any needs the patient 
has (such as oxygen, oral care and comfort issues) will also be tended to by the running 
nurse. If emergency medication needs to be administered (such as for hypotension or an 
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allergic reaction), they will need to be swift and on hand to dispense this. They are also a 
key part the resuscitation team in the event of a cardiac arrest and are advanced life 
support (ALS) trained. 
 
3. Radiographer - The radiographers principle role is to manipulate the x-ray tube and table 
in order for the operator to acquire adequate pictures of the coronary artery. They will 
angulate the x-ray equipment and table based on prompts from the operator to achieve 
satisfactory acquisitions of the coronary vasculature. The radiographer is also in control 
of contrast medium use, and is bound to remind the operator if use is excessive, 
potentially risking renal injury in a patient. Furthermore, they are the advocate for 
radiation protection for the entire team and patient, trying to minimise radiation exposure. 
They must ensure radiation shielding equipment, from the lead skirt sitting underneath 
the table, to radiation glasses are being properly utilised. If a procedure exceeds preset 
radiation limits, they must document and report this. 
 
4. Cardiac Physiologist - the role of the physiologist is to monitor haemodynamics and 
electrocardiogram outputs continuously from the patient. They must alert the operator of 
any significant changes in blood pressure and heart rate, as well as the onset of any 
arrhythmias. They log the procedure electronically on the relevant lab system. They are 
also responsible for using software required by physiology equipment, such as pressure 
wires, to obtain further information, useful to the operator. This again applies to 
intravascular imaging, such as intravascular ultrasound and optical coherence 
tomography. If needed urgently, the cardiac physiologist is often called on to provide an 
urgent echocardiogram whilst the patient is still on the table. In similar fashion, in cases 
where an intra-aortic balloon pump is needed, the cardiac physiologist is responsible for 
setting up and using this hardware initially (perfusionists are on-site who have further 
expertise should there be any problems). 
 
5. Cardiologist - The cardiologist is the primary operator for the procedure. They are 
responsible for gaining arterial access and passing catheters towards the coronary artery 
origins. They must manipulate the catheter to engage into the coronary ostium and 
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acquire diagnostic pictures. In coronary intervention or physiology measurements, the 
appropriate wire must be passed into the coronary artery and 'steered' into the correct 
position. They are responsible for the overall safety of the patient, and responsible for 
dealing with complications should they arise. The cardiologist should lead the team and 
prompt necessary actions. The first operator is normally a cardiology consultant or senior 
cardiac registrar, with adequate previous experience (minimum of 300 previous cases). 
Decisions on treatment, medication administration and continuing care are made by the 
cardiologist. 
 
6. Research Fellow / Registrar - My role in the procedure was to brief the whole team on 
how study protocol differed from routine practice and potentially train or introduce new 
techniques.  Whilst the cardiologist still led the case, I had to guide the procedure to 
ensure not only the safety of all involved, but also the collection of scientifically 
adequate, robust and quality data. The use of a specific research physiology wire meant 
that I operated the required equipment (see below) rather than the cardiac physiologist. I 


















Appendix D - Turning Checklist and Description 
 
 
Illustration of order of events / checklist when turning a patient prone during angiography. 
 
Order of Events / Checklist 
 
Responsible Person 
Only sheath left in situ 
 
Cardiologist 






Two slide sheets on correct side 
 
Nurse / Radiographer / Physiologist 
Two members of staff on each side of the 
table 
 
Nurse / Radiographer /Physiologist / 
Researcher 
Turn prone (pull slide sheets) and keep 
patient central on fluoroscopy table 
 







Adjust ECG stickers if needed 
 
Physiologist 
Re-drape / resterilise 
 
Nurse/Cardiologist 
Continue with procedure 
 
Cardiologist 
The physical movement of a supine patient to prone and vice versa was something the institution 
had experience of in the intensive care unit. The expertise from the intensive care unit was 
passed down to the catheter laboratory staff and incorporated into the study. Patients were not 
sedated as on intensive care, the arterial sheath used during angiography is larger and less 
malleable than an arterial line, and the fluoroscopy table is also significantly narrower than a 
standard ICU bed. ECG monitoring and intravenous lines were another potential issue which we 
had to take into consideration. On turning, sterile drapes would need to be replaced. 
To prepare for the real situation, multiple 'dry runs' using volunteer members of staff were 
conducted, mimicking the turning procedure. On simulation of turning during these dry runs, 
arterial sheaths and venous cannulae were taped onto the skin, and ECG stickers attached as on a 
real patient. Two members of staff from each catheter laboratory discipline were invited (two 
nurses, two physiologists, two radiographers and two cardiologists) as well a senior ICU nurse. 
The patient was treated as a 'sedated' patient and prompted not to assist or move the left arm 
(holding the radial sheath). Two slide sheets are inserted under the patient and pulled in the 
correct direction to assist proning. Two members of staff are situated on each side of the table to 
ensure the patient cannot fall off the table and a central position is maintained.  
In real situations, patients would start prone and would be turned supine. Before turning, all 
coronary catheters, physiology wires were removed from the patient. Cannulae were 
disconnected and reconnected once the manoeuvre had finished. ECG leads were not removed 
but could be adjusted if displaced during repositioning. The only invasive device left in situ, was 
the radial sheath itself. This was covered with an inflatable band or clear dressing, to help keep it 
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in position during the turn. Displacement of the sheath was a possibility during turning, and the 
team had to be observant regarding this issue. 
Once two members of staff were on each side of the patient, the slide sheets were pulled to turn 
the patient over. The patient was positioned centrally on the table after turning. ECG stickers 
were checked to ensure adequate contact. Cannulae were reconnected and the procedure 
continued as in a normal supine patient via the left radial artery with the catheter and wire re-
inserted.  
It became clear after the first two patients, that most were able to turn themselves, with 
assistance and instructions regarding the arterial sheath. Slide sheets were no longer required, 
and often patients turned independently, without using the left arm to maintain the radial sheath 


















Appendix E - Image Acquisition During Angiography 
 
 
Difference in viewing angles to achieve the same visualisation when comparing supine to prone 




Supine X-ray view Prone X-ray view 
LAD 
 
AP Cranial AP Caudal 
LAD 
 
LAO Cranial RAO Caudal 
Cx 
 
AP Caudal AP Cranial 
Cx 
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Background: Fractional flow reserve (FFR) uses pressure-based measurements to assess the 
severity of a coronary stenosis. Distal pressure (Pd) is often at a different vertical height to that of 
the proximal pressure (Pa). The difference in pressure between Pd and Pa due to hydrostatic 
pressure, may impact FFR calculation. 
Methods: One hundred CT coronary angiographies were used to measure height differences 
between the coronary ostia and  points in the coronary tree. Mean heights were used to calculate 
the hydrostatic pressure effect in each artery, using a correction factor of 0.8mmHg/cm. This was 
tested in a simulation of intermediate coronary stenosis to give the “corrected FFR” (cFFR) and 
percentage of values, which crossed a threshold of 0.8. 
Results:The mean height from coronary ostium to distal LAD was +5.26cm, distal Cx -3.35cm, 
distal RCA-PLV -5.74cm and distal RCA-PDA +1.83cm.For the LAD, correction resulted in a 
mean change in FFR of +0.042, -0.027 in the Cx, -0.046 in the PLV and +0.015 in the PDA. Using 
200 random FFR values between 0.75 and 0.85, the resulting cFFR crossed the clinical treatment 
threshold of 0.8 in 43% of LAD, 27% of Cx, 47% of PLV and 15% of PDA cases. 
Conclusions: There are significant vertical height differences between the distal artery (Pd) and 
its point of normalisation (Pa). This is likely to have a modest effect on FFR calculation and the 
results in values crossing the treatment threshold. Operators should be mindful of this phenomenon 
when interpreting FFR values. 
 





Fractional flow reserve (FFR) is the gold standard for invasive assessment of flow limitation 
caused by a coronary stenosis and it has been shown to improve clinical outcomes in randomised 
clinical trials [1, 2, 3]. In practice, FFR is calculated as the ratio of the distal trans-stenotic pressure 
to the proximal coronary or aortic pressure during pharmacological hyperaemia. The hydrostatic 
consequences of the wire position are one of the recognised pitfalls when FFR measurements are 
performed. Coronary arteries lie in different vertical planes and height variations are part of normal 
anatomy. Thus, the pressure wire sensor measuring distal pressure (Pd) is seldom at the same level 
with the coronary ostium where aortic pressure (Pa) is measured and where the Pd and Pa were 
previously equalised. This effect is present in any pressure based measurement, including the 
resting indices such as instantaneous wave free ratio (iFR) (Davies et al., 2017). Despite strong 
evidence for its use, FFR remains underutilised (Tebaldi et al., 2018). Avoiding confounding 
factors when using pressure based indices is crucial in accurate stenosis assessment. 
 
In clinical practice hydrostatic effect produces FFR values higher than 1.00 in a non-diseased 
vessels, most commonly positioned posteriorly (Nijjer et al., 2016). A recent study documented 
coronary ostia and distal vessels height differences in an elderly patient cohort with aortic stenosis 
(Härle et al., 2017b). Furthermore, the investigators used an in vitro model to calculate the impact 
of their observed height difference in pressure derived physiological indices. The observed 
changes were small meaning that it is unlikely to cause a significant change of FFR value in clinical 
practice. However, when using a binary cut-off for flow limitation for a given coronary stenosis, 
even a change of 0.02 can change the classification of FFR from ischaemic to non-ischaemic (FFR 




In this study, we aimed to quantify the height differences between the distal coronary vessels and 
the corresponding coronary ostia in a supine position in a real life cohort of patients undergoing 
investigations for coronary artery disease. Based on these measurements, we tried to quantify the 




We conducted a retrospective analysis of 100 patients undergoing CT coronary angiograms from 
August 2016 to April 2017 for new onset chest pain suspected to be angina. Vertical coronary 
height measurements were recorded in all coronary arteries and then used to calculate the potential 
hydrostatic effect on that specific point in the artery.  The effect of the calculated pressure 
difference and hence effect on FFR was applied to a model of two hundred randomly generated 
FFR values. FFR was compared pre- and post-correction for hydrostatic force. 
 
Inclusion and Exclusion Criteria 
All patients were elective outpatients under investigation for angina. Patients with previous bypass 
grafting or valve surgery were excluded. Scans, which did not show the upper rim of the CT table 
could not be analysed (as this was the reference point for measurement). Coronary visualisations 
with poor contrast penetration, or significant artefact were excluded. Finally, left dominant 
coronary circulations were not included in analysis. 
 




CT coronary angiography was performed as per local criteria at our institution using a 64-slice CT 
scanner. A resting heart rate of less than 80 beats per minute was required. Intravenous metoprolol 
was administered for heart rate reduction if necessary.  
 
Coronary Height Analysis 
Using an electronic radiology reporting program (Agfa IMPAX™) and a measuring calliper, 
distance from the upper rim of the CT table to multiple points in the coronary tree were obtained. 
Arterial measurement points included; 
 
1. Left coronary ostium 
2. Right coronary ostium 
3. Ostial left anterior descending (LAD) 
4. Distal LAD - at its highest point 
5. Distal circumflex (Cx) - at its lowest point 
6. Right coronary artery bifurcation 
7. Distal posterior descending artery (PDA) - at its highest point 
8. Distal posterior left ventricular artery (PLV) - at its lowest point 
 
Measurements were in millimetres and taken at the furthest point of contrast penetration visible in 
the vessel. 
 




The difference in height between the coronary ostium and the measurement point in the artery is 
the calculated height difference. This was multiplied by 0.8 (according to Pascal's Law and 
adjusting for blood density) to give a positive or negative change in pressure - in mmHg. This is 
the theoretical effect on Pd. The denominator (Pa) is assumed to be 100 in the following calculation 
model.  The resulting value was factored into 200 random computer generated FFR values between 
0.75 and 0.85 to give a corrected FFR (cFFR) using Microsoft Excel™. Corrected FFR was 
compared with baseline FFR and the percentage of values that crossed the threshold of 0.8 (from 
positive to negative or vice versa) was calculated. 
 
Statistical Analysis 
Continuous variables are expressed as mean values plus or minus standard deviation. Categorical 
variables are described as numbers and percentages. Statistical significance of coronary height 




Patient demographics are summarised in table 1.  
All patients had a resting heart rate below 80 beats per minute before scanning. 
 




Figure 1 shows an example of coronary height measurement. The measuring calliper in green 
calculates height from the upper rim of the CT table to the corresponding point in the coronary 
artery. In this particular example the calliper is measuring from ostial left main stem.    
Results are displayed below of all measurement points within the coronary tree (Table 2, Figure 
2). Height measurement is taken from the upper rim of the CT table.  
Table 3 summarises data points from each coronary artery with regard to their respective coronary 
ostia. The height difference between the coronary specific coronary ostium (Pa) and the vessel 
containing the height measurement point (Pd), is the value used to calculate effect on FFR and 
hence, the cFFR. 
 
Hydrostatic effect and cFFR 
The corresponding hydrostatic effect of distal LAD, distal Cx, distal PDA and distal PLV were 
factored into the FFR equation to give the cFFR (Table 3). For anterior vessels, the FFR increased, 
for posterior vessels, it fell. Out of the 200randomly generated FFR values, 45.5% were below 0.8 
and 55.5% above. After correction and calculation of cFFR, these percentages changed 
substantially. Those that crossed from positive to negative, or vice versa were calculated. Table 4 
summarises the results. 
 
Clinical Case Example 
An in vivo example demonstrating the effect of wire position is presented of a 73-year old male 
with a lesion in the mid right coronary artery (RCA) (figure 3). The patient presented with typical 
stable angina. There is a background history of inflammatory bowel disease, but no typical cardiac 
risk factors. Ejection fraction was normal. A combined pressure and velocity wire (Combowire, 
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Volcano Corporation™, San Diego, California, USA) is passed through a 6F guiding catheter. The 
wire is passed beyond the lesion and FFR is measured firstly in the PDA (as distal as a clear 
velocity tracing allowed), followed by the PLV (distally as per PDA) and lastly placed 3 vessel 
diameters beyond the stenosis in the main mid RCA. 400 micrograms of intra-arterial nitrates were 
administered before FFR measurement. Intravenous adenosine at 140mcg/kg was used to induce 
a steady state of hyperaemia. There was no drift with any of the acquired measurements. Invasive 
measurements are presented in Table 5. 
 
For the same lesion, placement of the wire in the PDA or PLV altered FFR by 0.05. Placing the 
wire 3 vessel diameters beyond the stenosis, gives an FFR of 0.79.  The small flow variations 
measured on each occasion are not significantly different, and within normal variations expected 
during doppler measurements (Davies et al., 2006). 
 
Discussion 
In summary, our findings show that coronary anatomy results in statistically significant height 
variations between proximal (Pa) and distal vessel (Pd). There is a potential change in FFR of 
0.02-0.05, causing a number of 'grey-zone' FFR results to cross a binary cut-off point. 
In our cohort, the most superior points in a supine patient were the distal LAD, followed by 
distal PDA. The most inferior points were the distal Cx and distal PLV. All measurements were 
statistically significant when compared to the respective ostium, apart from the ostial LAD. Even 
though the mean height of PLV and Cx were identical with reference to the CT table, when 
compared to their respective ostium (Pa), the PLV had a larger height difference, owing to the 
more superior position of the RCA ostium. In turn, the hydrostatic pressure effect was more 
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pronounced in the PLV. More proximal points in a vessel, e.g ostial LAD or RCA bifurcation 
had a smaller height variation when compared to their respective coronary artery ostium. In 
general there is a gradual change in height from proximal to distal vessel. Note however, that the 
most distal point in the vessel does not always have the greatest height variation. An example of 
this is in a 'wrap around' LAD, where the vessel height falls after reaching the apex. This occurs 
in over half of patients in one study (Kobayashi et al., 2015b).  
CT coronary angiography can accurately map the course of coronary vessels and their vertical 
heights.  Subsequently, the height of the distal vessel (i.e the position of the pressure wire, or Pd) 
may be higher, or lower than its origin (Pa), depending on the course it takes. This may explain 
observed changes in groups of patients with 'moderate' coronary stenoses in which posterior 
vessels (those vertically lower when supine - Circumflex, Posterior left ventricular) have higher 
mean FFR values than anterior vessels (those that are vertically higher - left anterior descending, 
posterior descending) (Härle et al., 2017d). Resting Pd/Pa can also often be seen above 1.0. Studies 
have identified this phenomenon (Nijjer et al., 2016) and it is caused by the distal pressure sensor 
sitting vertically lower than the aortic pressure sensor (and original point of normalisation). For a 
resting index to be above one, disease in the vessel is usually mild. While often attributed to drift, 
physical principles can predict this concept. It is useful to note this phenomenon rather than assume 
the physiology wire is at fault. 
A recent study assessing coronary artery height variations using CT coronary angiograms has been 
conducted recently in a group composed predominantly of transcutaneous aortic valve 
implantation (TAVI) patients [5]. Hydrostatic pressure effects were then confirmed using an in 
vitro model. The anatomy of these patients with severe aortic stenosis may slightly alter the 
anatomy of the coronary arteries themselves due to changes in the aortic root. Our assessment of 
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coronary height variations in a more heterogeneous group of patients presenting with stable cardiac 
chest pain was thought to be a useful addition to current knowledge. In general, our patients were 
younger females in keeping with the low to intermediate risk group initially assessed with CT 
coronary angiography at the time. There were some differences in height measurements from CT 
scans between our study and Härle et al. Measurements from ostial left coronary artery to LAD 
and Cx were similar (5.3cm vs. 4.9 and 3.4 vs. 3.9 respectively). There were however more 
pronounced differences in the measurement of PLV and PDA from the right coronary ostium (5.7 
vs. 2.6 and 1.8 vs. 3.8). There are potential explanations. Observer variation between two studies 
may account for some of the change. Contrast penetration into the distal vessel can significantly 
alter the measurement point within the artery, leading to error in measurements in both studies. 
Finally, the patient cohort varies between the studies. One anticipates that coronary height 
measurements may vary between a predominantly older population with aortic stenosis, and a 
younger cohort without. 
Pressure based invasive physiology such as FFR, has been well validated over many years. 
However, pressure-based measurements are subject to the potential effects of hydrostatic 
pressure. If hydrostatic forces alter distal pressure recordings FFR will in turn change. The 
change may be small (0.02 - 0.05) but useful to know in FFR values circling the cut-off point 
(0.75-0.85) (Petraco et al., 2013). In theory, the addition of adenosine should not alter the 
physical hydrostatic pressure effect in a coronary vessel in vivo, as height, fluid density and 
gravitational effect have not changed. An important consideration is the hypotensive effect and 
hence reduction in Pa during adenosine infusion. Pa pressure may fall below 100mmHg during 
hyperaemia, meaning alterations in Pd have a larger effect on overall Pd/Pa. Hydrostatic effect is 
constant across resting and hyperaemic states. A change in Pd of 5mmHg is therefore of greater 
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relative importance in resting indices (where a transtenotic gradient of 10mmHg is considered 
abnormal) compared to hyperaemic indices (where 20mmHg is considered abnormal) 
Whilst the effect of hydrostatic pressure upon FFR is described, we believe that this novel data 
demonstrates that depending on the coronary artery in question and its anatomical course the 
physiological significance of a coronary stenosis can be both over or under-estimated. Treatment 
of intermediate coronary stenoses therefore must not be a binary decision, and the operator must 
exert clinical judgment when faced with grey zone physiology values. 
The exact position of the pressure sensor of the physiology wire is often not considered. 
Hydrostatic effect becomes more pronounced as the pressure sensor is positioned more distally. 
Avoiding an unnecessarily distal wire position will minimise the hydrostatic effect on obtained 
measurements by reducing the guide to pressure sensor distance. 
 
By changing patient position during angiography, (i.e turning onto one side), and leaving the wire 
in exactly the same position in the artery, FFR values have been shown to change (Härle et al., 
2018). Correcting for the presumed hydrostatic effect due to this position change (by using 
measured height difference between guide and wire), abolished the difference between the two 
FFR recordings, seemingly explaining the difference.  
Another important observation is the pressure change along the longitudinal length of a coronary 
artery, which has been attributed to diffuse atherosclerosis (Bruyne et al., 2001). The additive 
effect of hydrostatic pressure however cannot be excluded, as vertical height also gradually 
changes along the length of an artery. This along with other confounding factors, such chronic 
kidney disease (Tebaldi et al., 2016) may also impact stenosis assessment.  Finally, hydrostatic 
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pressure effects may also contribute to measurements that use mean distal pressure, such as the 
index of microvascular resistance (IMR) measured using thremodilution. 
In our clinical case example, wire placement altered FFR by 0.05 (PDA vs. PLV placement). Flow 
within the artery does not change in our case study as coronary autoregulation maintains flow over 
a wide pressure range when these mechanisms are intact (Ramanathan and Skinner, 2005) . Using 
our coronary CT data, the mean height difference between the PLV and PDA was 7.57cm, equating 
into a potential distal pressure difference (Pd) of 6.06mmHg. Therefore a change in FFR of up to 
0.06 is possible on average. Of course this is a mean change, and patient factors such as height, 
play a role in individual FFR measurements (Härle et al., 2017b). Although clinical decision-
making takes into account multiple factors and is not a binary process revolving around a cut-off 
point, one should recognise the potential effects of wire position and hydrostatic pressure. 
 
Study Limitations 
The study group consisted of low to intermediate risk patients, meaning the majority were younger 
females. This is not in keeping with a typical demographics of patients who require invasive 
treatment for coronary artery disease. 
The visualisation of the coronary artery in question was limited by contrast penetration into the 
distal vessel. Some vessels were not completely opacified, meaning a potential underestimation of 
height measurements. This seemed especially prominent in the PDA where contrast did not 
penetrate to the distal vessel in 15% of cases. Measurements for these patients were excluded. 
Height was measured at distal sections in the coronary artery, as this was the point of maximal 
height variation. In clinical practice the wire is often not positioned as far distal as these 
measurements were taken, meaning a potential overestimation of the hydrostatic effect. 
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With regards to the 200 random FFR results generated, it can be seen that 54.5% of FFR values 
generated were over 0.8. This was obviously a chance occurrence, but the lack of a more linear 
50/50 split of values will effect subsequent analysis. 
The hydrostatic effect on FFR in this study takes into account a Pa pressure of 100mmHg.Further 
data on alterations in Pa and the subsequent impact on FFR may have been a useful addition. 
The calculated hydrostatic effect is theoretical, and needs further investigation in vivo. Recent trials 
have upheld anticipated changes in pressure based measurements due to hydrostatic forces (Härle 
et al., 2018). 
 
Conclusion 
The anatomical path of coronary arteries results in a significant vertical height difference between 
the distal artery (Pd) and its point of normalisation (Pa). According to our hydrostatic pressure 
model, this is likely to have a modest effect on FFR calculation, which in turn could result in values 
crossing the treatment threshold. Operators should be mindful of this phenomenon when 
interpreting FFR values, particularly in the LAD and RCA-PLV. 
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Figure 1  
 
Vessel height measurement illustration on coronary CT 
The image demonstrates the measurement calliper from the left main stem ostium, to the upper 













Coronary height variation from their respective ostium 
Figure 2 demonstrates the height variation of the distal vessel from its respective ostium. ** 






























Distance  in mm from respective LCA/RCA Ostium




Mid right coronary artery stenosis 











































Mean height from Upper Rim of CT Table 
(mm) (Standard Deviation in mm) 
P Value compared 
to vessel ostium 





170.0    (± 19.6) N/A 
LAD Ostium 
 
167.9    (±19.6) 0.06 
Distal LAD 
 
222.5    (± 28.3) <0.0001 
Distal Cx 
 
136.4    (± 20.4) <0.0001 





193.8    (± 21.1) N/A 
RCA bifurcation 
 
175.6    (± 28.3) <0.0001 
Distal PDA 
 
212.1    (±30.7) <0.0001 
Distal PLV 
 





CT Height measurements 
The vertical height measurements are shown from the upper rim of the CT table. P values are 






Height from respective 
coronary ostium (mm) 
Height effect on distal 
pressure (Pd) - mmHg 
FFR Correction 
factor 
Height from Left Coronary 
Ostium 
 








+52.5 +4.2 +0.04 
Distal Cx 
 
-33.6 -2.7 -0.03 
Height from Right 
Coronary Ostium 
 
   
RCA bifurcation 
 
-18.2 -1.5 -0.02 
Distal PDA 
 
+18.3 +1.5 +0.02 




The height variations have been converted into pressure effect in mmHg. The impact on FFR 





(+change in Pd 
pressure) 
% FFR below 0.8 % FFR  above 0.8 % cFFR below 
0.8 




























92 8 46.5 







Effect on FFR measurements between 0.75 and 0.85 
The effect on 200 randomly generated FFR measurements is shown for each vessel point. % 













3 vessel diameters beyond 




Clinical case data 
The data from the clinical case described is shown in table 5. FFR measurement varied by 0.05 
between PLV and PDA. Velocity measurements did not vary significantly. This is due to the 
vertical height differences in both vessels and  in turn the hydrostatic effect.  
 
 
 
 
 
 
